WO2012170702A1 - Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci - Google Patents
Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci Download PDFInfo
- Publication number
- WO2012170702A1 WO2012170702A1 PCT/US2012/041375 US2012041375W WO2012170702A1 WO 2012170702 A1 WO2012170702 A1 WO 2012170702A1 US 2012041375 W US2012041375 W US 2012041375W WO 2012170702 A1 WO2012170702 A1 WO 2012170702A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- yloxy
- cyclohexyloxy
- pharmaceutical
- pharmaceutical agent
- compound according
- Prior art date
Links
- 0 *c(c(*)nc(*)c1*)c1O[C@](CC1)CC[C@@]1OC1CCN(*)CC1 Chemical compound *c(c(*)nc(*)c1*)c1O[C@](CC1)CC[C@@]1OC1CCN(*)CC1 0.000 description 3
- ZWPRRQZNBDYKLH-VIFPVBQESA-N N[C@@H](CC(N1Cc2nc(C(F)(F)F)nc(C(F)(F)F)c2CC1)=O)CN(CC(CC1)(F)F)C1=O Chemical compound N[C@@H](CC(N1Cc2nc(C(F)(F)F)nc(C(F)(F)F)c2CC1)=O)CN(CC(CC1)(F)F)C1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N N[C@@H](CC(N1Cc2nnc(C(F)(F)F)[n]2CC1)=O)Cc(cc(c(F)c1)F)c1F Chemical compound N[C@@H](CC(N1Cc2nnc(C(F)(F)F)[n]2CC1)=O)Cc(cc(c(F)c1)F)c1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to compounds of Formula (la) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof, that are useful as single
- an inhibitor of DPP-IV a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti- diabetic peptide analogue
- Diabetes mellitus is a serious disease afflicting over 100 million people worldwide. In the United States, there are more than 12 million diabetics, with 600,000 new cases diagnosed each year.
- Diabetes mellitus is a diagnostic term for a group of disorders characterized by abnormal glucose homeostasis resulting in elevated blood sugar.
- IDDM insulin-dependent diabetes mellitus
- NIDDM non-insulin-dependent diabetes mellitus
- the etiology of the different types of diabetes is not the same; however, everyone with diabetes has two things in common: overproduction of glucose by the liver and little or no ability to move glucose out of the blood into the cells where it becomes the body's primary fuel.
- Diabetes is a syndrome with interrelated metabolic, vascular, and neuropathic components.
- the metabolic syndrome generally characterized by hyperglycemia, comprises alterations in carbohydrate, fat and protein metabolism caused by absent or markedly reduced insulin secretion and/or ineffective insulin action.
- the vascular syndrome consists of abnormalities in the blood vessels leading to cardiovascular, retinal and renal complications. Abnormalities in the peripheral and autonomic nervous systems are also part of the diabetic syndrome. About 5% to 10% of the people who have diabetes have IDDM. These individuals don't produce insulin and therefore must inject insulin to keep their blood glucose levels normal.
- IDDM is characterized by low or undetectable levels of endogenous insulin production caused by destruction of the insulin-producing ⁇ cells of the pancreas, the characteristic that most readily distinguishes IDDM from NIDDM. IDDM, once termed juvenile-onset diabetes, strikes young and older adults alike.
- NIDDM type 2
- NIDDM is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to elevated blood glucose levels.
- endogenous insulin production in NIDDM there is always some endogenous insulin production in NIDDM; many NIDDM patients have normal or even elevated blood insulin levels, while other NIDDM patients have inadequate insulin production (Rotwein, R. et al. N. Engl. J. Med. 308, 65-71 (1983)).
- Most people diagnosed with NIDDM are age 30 or older, and half of all new cases are age 55 and older.
- NIDDM is more common among Native Americans, African- Americans, Latinos, and Hispanics.
- the onset can be insidious or even clinically unapparent, making diagnosis difficult.
- NIDDM neurodegenerative disease
- Kidney disease also called nephropathy
- Diabetes occurs when the kidney's "filter mechanism” is damaged and protein leaks into urine in excessive amounts and eventually the kidney fails. Diabetes is also a leading cause of damage to the retina at the back of the eye and increases risk of cataracts and glaucoma.
- diabetes is associated with nerve damage, especially in the legs and feet, which interferes with the ability to sense pain and contributes to serious infections. Taken together, diabetes complications are one of the nation's leading causes of death.
- Obesity and diabetes are among the most common human health problems in industrialized societies. In industrialized countries a third of the population is at least 20% overweight. In the United States, the percentage of obese people has increased from 25% at the end of the 1970's, to 33% at the beginning the 1990's. Obesity is one of the most important risk factors for NIDDM. Definitions of obesity differ, but in general, a subject weighing at least 20% more than the recommended weight for his/her height and build is considered obese. The risk of developing
- NIDDM is tripled in subjects 30% overweight, and three-quarters with NIDDM are overweight.
- Obesity which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals and human.
- Whether someone is classified as overweight or obese can be determined by a number of different methods, such as, on the basis of their body mass index (BMI) which is calculated by dividing body weight (kg) by height squared (m 2 ).
- BMI body mass index
- m 2 height squared
- Overweight is defined as a BMI in the range 25-30 kg/m 2
- obesity as a BMI greater than 30 kg/m 2 (see table below).
- body fat content greater than 25% and 30% in males and females, respectively.
- Coronary insufficiency, atheromatous disease, and cardiac insufficiency are at the forefront of the cardiovascular complication induced by obesity. It is estimated that if the entire population had an ideal weight, the risk of coronary insufficiency would decrease by 25% and the risk of cardiac insufficiency and of cerebral vascular accidents by 35%. The incidence of coronary diseases is doubled in subjects less than 50 years of age who are 30% overweight.
- Atherosclerosis is a complex disease characterized by inflammation, lipid accumulation, cell death and fibrosis. Atherosclerosis is characterized by cholesterol deposition and monocyte infiltration into the subendothelial space, resulting in foam cell formation. Thrombosis subsequent to atherosclerosis leads to myocardial infarction and stroke. Atherosclerosis is the leading cause of mortality in many countries, including the United States. (See, e.g., Ruggeri, Nat Med (2002) 8: 1227-1234; Arehart et al, Circ Res, Circ. Res. (2008) 102:986-993.)
- Osteoporosis is a disabling disease characterized by the loss of bone mass and microarchitectural deterioration of skeletal structure leading to compromised bone strength, which predisposes a patient to increased risk of fragility fractures. Osteoporosis affects more than 75 million people in Europe, Japan and the United States, and causes more than 2.3 million fractures in Europe and the United States alone. In the United States, osteoporosis affects at least 25% of all post-menopausal white women, and the proportion rises to 70% in women older than 80 years. One in three women older than 50 years will have an osteoporotic fracture that causes a considerable social and financial burden on society. The disease is not limited to women; older men also can be affected.
- IBD Inflammatory bowel disease
- Crohn's disease ulcerative colitis
- ulcerative proctitis U.S. medical costs of inflammatory bowel disease for 1990 have been estimated to be $1.4 to $1.8 billion. Lost productivity has been estimated to have added an additional $0.4 to $0.8 billion, making the estimated cost of inflammatory bowel disease $1.8 to $2.6 billion.
- Enteritis refers to inflammation of the intestine, especially the small intestine, a general condition that can have any of numerous different causes. Enterocolitis refers to inflammation of the small intestine and colon.
- CD Crohn's disease
- Ileitis is CD of the ileum which is the third part of the small intestine.
- Crohn's colitis is CD affecting part or all of the colon.
- Ulcerative colitis is an inflammatory disease of the large intestine, commonly called the colon. UC causes inflammation and ulceration of the inner lining of the colon and rectum. The inflammation of UC is usually most severe in the rectal area with severity diminishing (at a rate that varies from patient to patient) toward the cecum, where the large and small intestine join. Inflammation of the rectum is called proctitis. Inflammation of the sigmoid colon (located just above the rectum) is called sigmoiditis. Inflammation involving the entire colon is termed pancolitis. The inflammation causes the colon to empty frequently resulting in diarrhea. As the lining of the colon is destroyed ulcers form releasing mucus, pus and blood. Ulcerative proctitis is a form of UC that affects only the rectum.
- GPR119 is a G protein-coupled receptor (GPR119; e.g. , human GPR119, GenBank ®
- GPR119 activation leads to elevation of a level of intracellular cAMP, consistent with GPR119 being coupled to Gs.
- Agonists to GPR119 stimulate glucose-dependent insulin secretion in vitro and lower an elevated blood glucose level in vivo; see, e.g. , International Applications WO
- GPR119 has also been referred to as RUP3 (see, International Application WO 00/31258) and as Glucose-Dependent Insulinotropic Receptor GDIR (see, Jones, et. al. Expert Opin. Ther. Patents (2009), 19(10): 1339-1359).
- GPR119 agonists also stimulate the release of Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-Like Peptide- 1 (GLP-1), and at least one other L-cell peptide, Peptide YY (PYY) (Jones, et. al. Expert Opin. Ther. Patents (2009), 19(10): 1339-1359); for specific references related to GPR119 agonists and the release of:
- GIP Glucose-dependent Insulinotropic Polypeptide
- GLP-1 Glucagon-Like Peptide- 1
- PYY Peptide YY
- GLP-1 see Shah, Current Opinion in Drug Discovery & Development, (2009) 12:519-532; Jones, et al. , Ann. Rep. Med. Chem. , (2009) 44: 149-170; Schwartz et. al., Cell Metabolism, 2010, 11 :445-447; and WO 2006/076231 ; and
- GPR119 agonists enhance incretin release and therefore can be used in treatment of disorders related to the incretins, such as, GIP, GLP-1, and PYY.
- GIP and GLP-1 are substrates for the enzyme DPP-IV. Jones and co-workers (Jones, et ⁇ , ⁇ . Rep. Med.
- GIP Glucose -dependent insulinotropic polypeptide
- gastric inhibitory polypeptide is a peptide incretin hormone of 42 amino acids that is released from duodenal endocrine K cells after meal ingestion. The amount of GIP released is largely dependent on the amount of glucose consumed. GIP has been shown to stimulate glucose-dependent insulin secretion in pancreatic beta cells. GIP mediates its actions through a specific G protein-coupled receptor, namely GIPR.
- GIP contains an alanine at position 2, it is an excellent substrate for dipeptidyl peptidase-4 (DPP-IV), an enzyme regulating the degradation of GIP.
- DPP-IV dipeptidyl peptidase-4
- Full-length GIP(l-42) is rapidly converted to bioinactive GIP(3-42) within minutes of secretion from the gut K cell. Inhibition of DPP-IV has been shown to augment GIP bioactivity.
- GIP has been shown to promote bone formation.
- GIP has been shown to activate osteoblastic receptors, resulting in increases in collagen type I synthesis and alkaline phosphatase activity, both associated with bone formation.
- GIP has been shown to inhibit osteoclast activity and differentiation in vitro.
- GIP administration has been shown to prevent the bone loss due to ovariectomy.
- GIP receptor (GIPR) knockout mice evidence a decreased bone size, lower bone mass, altered bone microarchitecture and biochemical properties, and altered parameters for bone turnover, especially in bone formation.
- Patent No. 6,410,508 for the treatment of reduced bone mineralization by administration of GIP peptide.
- current GIP peptide agonists suffer from a lack of oral bioavailability, negatively impacting patient compliance.
- An attractive alternative approach is to develop an orally active composition for increasing an endogenous level of GIP activity.
- GLP-1 Glucagon-Like Peptide-1
- Glucagon-like peptide-1 (GLP-1) is an incretin hormone derived from the
- GLP-1 mediates its actions through a specific G protein-coupled receptor (GPCR), namely GLP-1R.
- GLP-1 is best characterized as a hormone that regulates glucose homeostasis.
- GLP-1 has been shown to stimulate glucose-dependent insulin secretion and to increase pancreatic beta cell mass.
- GLP-1 has also been shown to reduce the rate of gastric emptying and to promote satiety.
- the efficacy of GLP-1 peptide agonists in controlling blood glucose in Type 2 diabetics has been demonstrated in several clinical studies [see, e.g. , Nauck et al , Drug News Perspect (2003) 16:413-422], as has its efficacy in reducing body mass [Zander et al, Lancet (2002) 359:824- 830].
- GLP-1 receptor agonists are additionally useful in protecting against myocardial infarction and against cognitive and neurodegenerative disorders.
- GLP-1 has been shown to be cardioprotective in a rat model of myocardial infarction [Bose et al, Diabetes (2005) 54: 146- 151], and GLP-1 R has been shown in rodent models to be involved in learning and
- GLP-1 peptide agonists suffer from a lack of oral bioavailability, negatively impacting patient compliance. Efforts to develop orally bioavailable non-peptidergic, small- molecule agonists of GLP-1 R have so far been unsuccessful [Mentlein, Expert Opin Investig Drugs (2005) 14:57-64]. An attractive alternative approach is to develop an orally active composition for increasing an endogenous level of GLP-1 in the blood.
- Peptide YY is a 36 amino acid peptide originally isolated in 1980 from porcine intestine (Tatemoto et al, Nature (1980) 285:417-418). PYY is secreted from enteroendocrine L- cells within both the large and small intestine. It has been shown that in rat and human gut concentrations of immunoreactive PYY are low in duodenum and jejunum, high in ileum and colon, and highest in rectum (Lundberg et al, PNAS USA (1982) 79:4471-4475; Adrian et al, Gastroenterol.
- PYY 3 - 36 is generated from PYYi_ 36 by cleavage of the N-terminal Tyr and Pro residues by dipeptidyl peptidase IV.
- PYY 3 . 36 is the predominant form of PYY in human postprandial plasma (Grandt et al, Regul. Pept. (1994) 51 : 151-159).
- PYYi- 36 and PYY 3 . 36 have been reported to have comparable agonist activity at NPY Y2 receptor (Y2R), a G protein- coupled receptor (Parker et al, Br. J. Pharmacol. (2008) 153:420-431); however, PYY 3 . 36 has been reported to be a high-affinity Y2R selective agonist (Keire et al, Am. J. Physiol.
- Peripheral administration of PYY 3 . 36 has been reported to markedly reduce food intake and weight gain in rats, to decrease appetite and food intake in humans, and to decrease food intake in mice, but not in Y2R-null mice, which was said to suggest that the food intake effect requires the Y2R.
- infusion of PYY 3 . 36 was found to significantly decrease appetite and reduce food intake by 33% over 24 hours.
- Peripheral administration of PYY 3 . 36 has been reported to reduce food intake, body weight gain and glycemic indices in diverse rodent models of metabolic diseases of both sexes (Pittner et al, Int. J. Obes. Relat. Metab. Disord. (2004) 28:963-971). It has been reported that blockade of Y2R with the specific antagonist BIIE-246 attenuates the effect of peripherally administered endogenous and exogenous PYY 3 _ 36 for reducing food intake (Abbott et al, Brain Res (2005) 1043: 139-144).
- peripheral administration of a novel long- acting selective Y2R polyethylene gly col-conjugated peptide agonist reduces food intake and improves glucose metabolism (glucose disposal, plasma insulin and plasma glucose) in rodents (Ortiz et al, JPET (2007) 323:692-700; Lamb et al, J. Med. Chem. (2007) 50:2264-2268). It has been reported that PYY ablation in mice leads to the development of hyperinsulinemia and obesity (Boey et al, Diabetologia (2006) 49: 1360-1370). It has been reported that peripheral administration of a long-acting, potent and highly selective Y2R agonist inhibits food intake and promotes fat metabolism in mice (Balasubramaniam et al, Peptides (2007) 28:235-240).
- Y2R agonists such as PYY 1 36 and PYY 3 . 36 can confer protection against epileptic seizures, such as against kainate seizures (El Bahh et al, Eur. J.
- Y2R agonists such as PYY 1 36 and PYY 3 . 36 act as proabsorbtive (or anti-secretory) hormones, increasing upon intravenous administration the absorption of both water and sodium in various parts of the bowel (Bilchik et al, Gastroenterol. (1993) 105: 1441- 1448; Liu et al, J. Surg. Res. (1995) 58:6-11 ; Nightingale et al, Gut (1996) 39:267-272; Liu et al, Am Surg (1996) 62:232-236; Balasubramaniam et al, J. Med. Chem. (2000) 43:3420-3427). It has been reported that Y2R agonists such as PYY analogues inhibit secretion and promote absorption and growth in the intestinal epithelium (Balasubramaniam et al, J. Med. Chem.
- Y2R agonists such as PYY 1 36 and PYY 3 . 36 can confer protection against inflammatory bowel disease such as ulcerative colitis and Crohn's disease (WO 03/105763). It has been reported that PYY-deficient mice exhibit an osteopenic phenotype, i.e. that PYY can increase bone mass and/or can confer protection against loss of bone mass (e.g. , decreases loss of bone mass) (Wortley et al, Gastroenterol. (2007) 133: 1534-1543). It has been reported that PYY 3 . 36 can confer protection in rodent models of pancreatitis (Vona-Davis et al, Peptides (2007) 28:334-338).
- PYY and Y2R agonists such as PYY 3 . 36 can suppress tumor growth in the cases of, e.g. , pancreatic cancer such as pancreatic ductal adenocarcinoma, breast cancer such as breast infiltrative ductal adenocarcinoma, colon cancer such as colon
- Adiponectin is an adipokine with potent anti-inflammatory properties (Ouchi et al, Clin Chim Acta (2007) 380:24-30; Tilg et al, Nat. Rev. Immunol. (2006) 6:772-783).
- Adiponectin exerts anti-atherogenic effects by targeting vascular endothelial cells and macrophages and insulin-sensitizing effects, predominantly in muscle and liver (Kubota et al, J. Biol. Chem.
- adiponectin has been implicated in high density lipoprotein (HDL) assembly (Oku et al, FEBS Letters (2007) 581 :5029-5033).
- HDL high density lipoprotein
- Adiponectin has been found to ameliorate the abnormalities of metabolic syndrome, including insulin resistance, hyperglycemia, and dyslipidemia, in a mouse model of obesity-linked metabolic syndrome associated with decreased adiponectin levels (Hara et al, Diabetes Care (2006) 29: 1357-1362). Adiponectin has been reported to stimulate angiogenesis in response to tissue ischemia (Shibata et al, J. Biol. Chem. (2004) 279:28670-28674).
- Adiponectin has been reported to prevent cerebral ischemic injury through endothelial nitric oxide synthase-dependent mechanisms (Nishimura et al, Circulation (2008) 117:216-223). Adiponectin has been reported to confer protection against myocardial ischemia-reperfusion injury (Shibata et al, Nat Med (2005) 11 : 1096-1103; Tao et al, Circulation (2007) 115: 1408- 1416). Adiponectin has been reported to confer protection against myocardial ischemia- reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide (Gonon et al, Cardiovasc Res. (2008) 78: 116-122).
- Adiponectin has been reported to confer protection against the development of systolic dysfunction following myocardial infarction, through its abilities to suppress cardiac hypertrophy and interstitial fibrosis, and protect against myocyte and capillary loss (Shibata et al, J. Mol. Cell Cardiol. (2007) 42: 1065-1074). Adiponectin has been reported to confer protection against inflammatory lung disease; adiponectin-deficient mice exhibit an emphysema-like phenotype (Summer et al, Am J. Physiol. Lung Cell Mol. Physiol (March 7, 2008)).
- Adiponectin has been reported to confer protection against allergic airway inflammation and airway hyperresponsiveness such as may be associated with asthma (Shore et al, J. Allergy Clin. Immunol (2006) 118:389-395). Adiponectin has been suggested to confer protection against pulmonary arterial hypertension by virtue of its insulin-sensitizing effects (Hansmann et al, Circulation (2007) 115:1275-1284). Adiponectin has been reported to ameliorate obesity- related hypertension, with said amelioration of hypertension being associated in part with upregulated prostacyclin expression (Ohashi et al, Hypertension (2006) 47: 1108-1116).
- Adiponectin has been reported to decrease tumor necrosis factor (TNF)-a-induced expression of the adhesion molecules VCAM-1, E-selectin and ICAM-1 in human aortic endothelial cells (HAECs) (Ouchi et al, Circulation (1999) 100:2473-2476) and to inhibit production of TNF-a in macrophages (Yokota et al, Blood (2000) 96:1723-1732). Adiponectin has been reported to confer protection against restenosis after vascular intervention (Matsuda et al, J Biol Chem
- TNF-a-mediated inflammatory conditions encompass rheumatoid arthritis, inflammatory bowel disease such as Crohn's disease, ankylosing spondylitis, psoriasis, ischemic brain injury, cardiac allograft rejection, asthma, and the like (Bradley, J Pathol (2008) 214: 149-160). See, e.g.,
- One aspect of the present invention is directed to compounds, as described herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof, which bind to and modulate the activity of a GPCR, referred to herein as GPR119, and uses thereof.
- One aspect of the present invention encompasses, inter alia, certain cyclohexyl derivatives selected from compounds of Formula (la) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: C(0)OR 6 , C(0)R 6 , C(S)OR 6 , and CH 2 R 6 , wherein R 6 is selected from: Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 4 haloalkyl, and heterocyclyl, wherein the C 3 -C 7 cycloalkyl and heterocyclyl are each optionally substituted with one or more substituents selected independently from: Q-C4 alkyl, Q-C4 alkylamino, Q-C4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 alkylthio, amino, C 2 -C6 dialkylamino, and C 1 -C 4 haloalkyl; or
- R 1 is heteroaryl optionally substituted with one or more substituents selected independently from: C 1 -C 4 alkoxy, C 1 -C6 alkyl, C3-C7 cycloalkyl, C 1 -C 4 haloalkyl, and halogen, wherein the C3-C7 cycloalkyl is optionally substituted with one or more substituents selected independently from: C 1 -C 4 alkyl and C 1 -C 4 haloalkyl; and
- R 2 , R 3 , R 4 , and R 5 are selected independently from: H, C 1 -C 4 alkoxy, C 1 -C 4 alkyl, C 1 -C 4 alkylcarboxamide, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonamide, C 1 -C 4 alkylsulfonyl, C 1 -C 4 alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C3-C7 cycloalkyl, C 2 -C6
- dialkylcarboxamide C 1 -C 4 haloalkyl, halogen, heteroaryl, hydroxyl, and sulfonamide, wherein the C 1 -C 4 alkyl is optionally substituted with one or more substituents selected independently from: hydroxyl and oxo; or
- R 2 and R 3 together with the atoms to which they are each bonded form a heteroaryl optionally substituted with Ci-C 6 alkyl.
- compositions comprising a compound of the present invention.
- compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to methods for preparing a composition comprising the step of admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to methods for preparing a pharmaceutical composition comprising the step of admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to pharmaceutical products selected from: a pharmaceutical composition, a formulation, a unit dosage form, a combined preparation, a twin pack, and a kit; comprising a compound of the present invention.
- compositions comprising a compound of the present invention and a second pharmaceutical agent.
- One aspect of the present invention pertains to methods for preparing a composition comprising the step of admixing a compound of the present invention and a second
- compositions comprising a compound of the present invention, a second pharmaceutical agent, and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to pharmaceutical compositions comprising a compound of the present invention, a second pharmaceutical agent, and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to methods for preparing a composition
- methods for preparing a composition comprising the step of admixing a compound of the present invention, a second pharmaceutical agent, and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to compositions obtained by the methods of the present invention as described herein.
- One aspect of the present invention pertains to a pharmaceutical product selected from: a pharmaceutical composition, a formulation, a unit dosage form, a combined preparation, a twin pack, and a kit; comprising a compound of the present invention and a second
- One aspect of the present invention pertains to methods for modulating the activity of a GPRl 19 receptor, comprising administering to an individual in need thereof, a therapeutically effective amount of: a compound of the present invention; a composition of the present invention; or a pharmaceutical product of the present invention.
- One aspect of the present invention pertains to the use of a compound of the present invention; a composition of the present invention; or a pharmaceutical product of the present invention; in the manufacture of a medicament for modulating the activity of a GPRl 19 receptor in an individual.
- One aspect of the present invention pertains to a compound of the present invention; a composition of the present invention; or a pharmaceutical product of the present invention; for use in a method of treating the human or animal by therapy.
- One aspect of the present invention pertains to a compound of the present invention; a composition of the present invention; or a pharmaceutical product of the present invention; for use in a method of modulating the activity of a GPRl 19 receptor in an individual.
- One aspect of the present invention pertains to a pharmaceutical product selected from: a pharmaceutical composition, a formulation, a unit dosage form, a combined preparation, a twin pack, and a kit; comprising a compound of the present invention; for use in a method of treating the human or animal by therapy.
- One aspect of the present invention pertains to a pharmaceutical product selected from: a pharmaceutical composition, a formulation, a unit dosage form, a combined preparation, a twin pack, and a kit; comprising a compound of the present invention; for modulating the activity of a GPR119 receptor in an individual.
- One aspect of the present invention pertains to compounds, methods, compositions, uses of compounds, and pharmaceutical products, as described herein, for agonizing the GPR119 receptor.
- One aspect of the present invention pertains to compounds, methods, compositions, uses of compounds, and pharmaceutical products, as described herein, increasing the secretion of an incretin.
- One aspect of the present invention pertains to compounds, methods, compositions, uses of compounds, and pharmaceutical products, as described herein, increasing a blood incretin level.
- One aspect of the present invention pertains to compounds, methods, compositions, uses of compounds, and pharmaceutical products, as described herein, treating a disorder, wherein the disorder is selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; and obesity.
- One aspect of the present invention pertains to compounds, methods, compositions, uses of compounds, and pharmaceutical products, as described herein, each in combination with a second pharmaceutical agent.
- One aspect of the present invention pertains to compounds, methods, compositions, uses of compounds, and pharmaceutical products, as described herein, each in combination with a second pharmaceutical agent, wherein the second pharmaceutical agent is selected from: an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, and an anti-diabetic peptide analogue.
- the second pharmaceutical agent is selected from: an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, and an anti-diabetic peptide analogue.
- Figure 1 shows the in vivo effects of Compound 5 on glucose homeostasis in male
- FIG. 1 shows the in vivo effects of Compound 5 on glucose excursion in terms of percent glycemic inhibition (i.e., percent AUC reduction) in male 129SVE mice.
- Figure 3 shows the in vivo effects of Compound 5 on incretin hormone GIP release in male 129SVE mice.
- Figure 4 shows a general synthetic method for the preparation of (1 ⁇ ,4 ⁇ )-4-(1- methylpiperidin-4-yloxy)cyclohexanol (i.e., cis) and (lr,4r)-4-(l-methylpiperidin-4- yloxy)cyclohexanol (i.e., trans), see Example 1.1.
- Figure 5 shows a general synthetic method for the preparation of ( ⁇ s,4s)A-( ⁇ - methylpiperidin-4-yloxy)cyclohexanol (i.e., cis) and (lr,4r)-4-(l-methylpiperidin-4- yloxy)cyclohexanol (i.e., trans).
- Figure 6 shows a general synthetic method for the preparation of compounds of Formula (la) using a N-methyl piperidinyl intermediate.
- Figure 7 shows a general synthetic method for the preparation of compounds of Formula (la), wherein LG 1 is a leaving group, for example, F.
- FIG. 8 shows general synthetic methods for the preparation of certain compounds of
- R 1 is an optionally substituted oxadiazolyl and R a is H, Ci-C 6 alkoxy, Q- C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 6 haloalkyl, and halogen, wherein the C 3 -C 7 cycloalkyl is optionally substituted with one or more substituents selected independently from: C 1 -C4 alkyl and Ci-C 4 haloalkyl.
- FIG. 9 shows general synthetic methods for the preparation of certain compounds of
- R 1 is C(0)OR 6 or heteroaryl
- heteroaryl as shown in Figure 9 refers to a heteroaryl group optionally substituted with one or more substituents selected independently from: Ci-C 6 alkoxy, Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 6 haloalkyl, and halogen, wherein the C3-C7 cycloalkyl is optionally substituted with one or more substituents selected independently from: C 1 -C4 alkyl and C 1 -C4 haloalkyl; LG 2 is a leaving group, for example, C 6 F 5 O- ⁇ i.e.
- LG 2 is a leaving group, for example, a halogen, such as CI.
- Figure 10 shows the in vivo effects of Compound 29 on glucose homeostasis in male 129SVE mice (oral glucose tolerance test (oGTT)).
- Figure 11 shows the in vivo effects of Compound 29 on glucose excursion in terms of percent glycemic inhibition (i.e., percent AUC reduction) in male 129SVE mice.
- Figure 12 shows the in vivo effects of Compound 29 on incretin hormone GIP release in male 129SVE Mice.
- Figure 13 shows the PXRD for Compound 29 HC1 salt (nonsolvated).
- Figure 14 shows the PXRD for Compound 29 HC1 salt (dioxane solvate).
- Figure 15 shows the PXRD for Compound 29 HBr salt (monohydrate).
- Figure 16 shows the PXRD for Compound 29 HBr salt (nonsolvated).
- Figure 17 shows the PXRD for Compound 29 bisulfate salt (nonsolvated).
- Figure 18 shows the TGA for Compound 29 HC1 salt (nonsolvated).
- Figure 19 shows the TGA for Compound 29 HC1 salt (dioxane solvate).
- Figure 20 shows the TGA (dashed line) and DSC (solid line) for Compound 29 HBr salt (monohydrate).
- Figure 21 shows the TGA (dashed line) and DSC (solid line) for Compound 29 HBr salt (nonsolvated).
- FIG 22 shows the TGA (dashed line) and DSC (solid line) for Compound 29 bisulfate salt (nonsolvated).
- Figure 23 shows the PXRD for Compound 29 bisulfate salt (monohydrate).
- agonist refers to a moiety that interacts with and activates a G-protein-coupled receptor, for instance a GPR119-receptor, and can thereby initiate a physiological or pharmacological response characteristic of that receptor.
- a G-protein-coupled receptor for instance a GPR119-receptor
- an agonist may activate an intracellular response upon binding to a receptor, or enhance GTP binding to a membrane.
- antagonist refers to a moiety that competitively binds to the receptor at the same site as an agonist (for example, the endogenous ligand), but which does not activate the intracellular response initiated by the active form of the receptor and can thereby inhibit the intracellular responses by an agonist or partial agonist.
- An antagonist does not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
- GPR119 includes the human amino acid sequences found in GeneBank accession number AY288416, and naturally-occurring allelic variants thereof, and mammalian orthologs thereof.
- a preferred human GPR119 for use in screening and testing of the compounds of the invention is provided in the nucleotide sequence of Seq. ID.No: l and the corresponding amino acid sequence in Seq. ID.No:2 found in PCT Application No.
- the term "in need of treatment” and the term “in need thereof when referring to treatment are used interchangeably and refer to a judgment made by a caregiver (e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of a caregiver's expertise, but that includes the knowledge that the individual or animal is ill, or will become ill, as the result of a disease, condition or disorder that is treatable by the compounds of the invention. Accordingly, the compounds of the invention can be used in a protective or preventive manner; or compounds of the invention can be used to alleviate, inhibit or ameliorate the disease, condition or disorder.
- a caregiver e.g. physician, nurse, nurse practitioner, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals
- mice refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- inverse agonist refers to a moiety that binds to the endogenous form of the receptor or to the constitutively activated form of the receptor and which inhibits the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of an agonist or partial agonist, or decreases GTP binding to a membrane.
- the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50% and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist.
- modulate or modulating refers to an increase or decrease in the amount, quality, response or effect of a particular activity, function or molecule.
- composition refers to a compound, including but not limited to, salts, solvates, and hydrates of a compound of the present invention, in combination with at least one additional component.
- composition refers to a composition comprising at least one active ingredient, such as a compound as described herein; including but not limited to, salts, solvates, hydrates, and N-oxides of compounds of the present invention, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
- active ingredient such as a compound as described herein
- salts, solvates, hydrates, and N-oxides of compounds of the present invention whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
- terapéuticaally effective amount refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician or caregiver or by an individual, which includes one or more of the following:
- preventing the disease for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease;
- inhibiting the disease for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. , arresting further development of the pathology and/or
- ameliorating the disease for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e. , reversing the pathology and/or symptomatology).
- unit dosage form refers to a single dose form which is capable of being administered to a subject, and which can be readily handled and packaged, remaining as a physically and chemically stable unit comprising a compound of the present invention (i.e., compound used neat, such as in a dry powder inhaler (DPI) consisting of neat drug substance or for use in sublingual or buccal administration) or a pharmaceutically acceptable composition comprising a compound of the present invention such as in a pill, capsule, tablet, and the like.
- DPI dry powder inhaler
- amino refers to the group -NH 2 .
- C 1 -C4 alkoxy refers to a radical comprising a Ci-C alkyl group attached directly to an oxygen atom, wherein Ci-C alkyl has the same definition as found herein. Some embodiments contain 1 to 3 carbons. Some embodiments contain 1 or 2 carbons. Examples include, but are not limited to, methoxy, ethoxy, «-propoxy, isopropoxy, «-butoxy, i-butoxy, isobutoxy, and s-butoxy.
- Ci-C 6 alkyl refers to a straight or branched carbon radical containing 1 to 6 carbons. Some embodiments contain 1 to 5 carbons. Some embodiments contain 1 to 4 carbons. Some embodiments contain 1 to 3 carbons. Some embodiments contain 1 or 2 carbons.
- alkyl group examples include, but are not limited to, methyl, ethyl, w-propyl, isopropyl, n- butyl, s- butyl, isobutyl, i-butyl, pentyl, isopentyl, i-pentyl, neopentyl, 1-methylbutyl [i.e. , -CH(CH 3 )CH 2 CH 2 CH 3 ] , 2-methylbutyl [ . e. , -CH 2 CH(CH 3 )CH 2 CH 3 ] , and ra-hexyl.
- Ci-C 4 alkyl refers to a straight or branched carbon radical containing 1 to 4 carbons. Some embodiments contain 1 to 3 carbons. Some embodiments contain 1 or 2 carbons. Examples of an alkyl group include, but are not limited to, methyl, ethyl, w-propyl, isopropyl, n- butyl, s-butyl, isobutyl, and i-butyl.
- Ci-C 4 alkylamino refers to a radical comprising one Ci-C 4 alkyl group attached to an NH group, wherein Ci-C 4 alkyl has the same meaning as described herein. Some examples include, but are not limited to, methylamino, ethylamino, «-propylamino, isopropylamino, «-butylamino, s-butylamino, isobutylamino, and i-butylamino. Some embodiments are "Ci-C 2 alkylamino.”
- Ci-C alkylcarboxamide refers to a single Ci-C alkyl group attached to either the carbon or the nitrogen of an amide group, wherein Ci-C alkyl has the same definition as found herein.
- the C 1 -C4 alkylcarboxamide group can be represented by the following formulae:
- Examples include, but are not limited to, N-methylcarboxamide, N-ethylcarboxamide, N-n- propylcarboxamide, N-isopropylcarboxamide, N- «-butylcarboxamide, N-s-butylcarboxamide, N- isobutylcarboxamide, and N-i-butylcarboxamide.
- Ci-C alkylsulfinyl refers to a radical comprising a Ci-C alkyl group attached to the sulfur of a sulfinyl group (i.e., -S(O)-), wherein Ci-C alkyl has the same definition as described herein. Examples include, but are not limited to, methylsulfinyl, ethylsulfinyl, «-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, seobutylsulfinyl,
- Ci-C alkylsulfonyl refers to a radical comprising a Ci-C alkyl group attached to the sulfur of a sulfonyl group (i.e., -S(0) 2 -), wherein Ci-C 4 alkyl has the same definition as described herein. Examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, «-propylsulfonyl, isopropylsulfonyl, «-butylsulfonyl, seobutylsulfonyl, isobutylsulfonyl, and teri-butylsulfonyl.
- Ci-C 4 alkylthio refers to a radical comprising a Ci-C 4 alkyl group attached to a sulfur atom, wherein Ci-C 4 alkyl has the same definition as described herein. Examples include, but are not limited to, methylthio, ethylthio, «-propylthio, isopropylthio, «-butylthio, seobutylthio, isobutylthio, and teri-butylthio.
- C 2 -C 4 alkynyl refers to a radical containing 2 to 4 carbons and a carbon- carbon triple bond (-C ⁇ C-), some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons (-C ⁇ CH).
- Examples of a C 2 -C 4 alkynyl group include, but not limited to, ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, and 3-butynyl.
- C 3 -C 7 cycloalkyl refers to a saturated ring radical containing 3 to 7 carbons. Some embodiments contain 3 to 6 carbons. Some embodiments contain 3 to 5 carbons. Some embodiments contain 5 to 7 carbons. Some embodiments contain 3 to 4 carbons. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- carboxylate refers to the group -CONH 2 .
- carboxy refers to the group -C0 2 H; also referred to as a carboxylic acid group.
- cyano refers to the group -CN.
- C 2 -C 6 dialkylamino refers to a radical comprising an amino group substituted with two of the same or different Ci-C 3 alkyl groups, wherein Ci-C 3 alkyl has the same definition as found herein. Some examples include, but are not limited to, dimethylamino, methylethylamino, diethylamino, methylpropylamino, methylisopropylamino,
- ethylpropylamino ethylisopropylamino, dipropylamino, and propylisopropylamino.
- Some embodiments are C 2 -C 4 dialkylamino.
- C 2 -C 6 dialkylcarboxamide refers to a radical comprising an amide group wherein the nitrogen of the amide group is substituted with the same or different Ci-C 3 alkyl group, wherein C 1 -C3 alkyl has the same definition as found herein.
- the "C 2 -C6 dialkylcarboxamide” refers to a radical comprising an amide group wherein the nitrogen of the amide group is substituted with the same or different Ci-C 3 alkyl group, wherein C 1 -C3 alkyl has the same definition as found herein.
- C 1 -C3 alkyl has the same definition as found herein. Examples include, but are not limited to, N,N-dimethylcarboxamide, N,N-methylethylcarboxamide, and N,N- diethylcarboxamide.
- C 1 -C 4 alkylsulfonamide refers to one of the following groups shown below:
- C 1 -C 4 alkyl has the same definition as found herein.
- C 1 -C 4 haloalkyl refers to a radical comprising a C 1 -C 4 alkyl group substituted with one or more halogens, wherein C 1 -C 4 alkyl has the same definition as found herein.
- the C 1 -C 4 haloalkyl may be fully substituted in which case it can be represented by the formula C q L 2q+ i, wherein L is a halogen and "q" is 1 , 2, 3, or 4. When more than one halogen is present then they may be the same or different and selected from: fluorine, chlorine, bromine, and iodine. In some embodiments, haloalkyl contains 1 to 3 carbons.
- haloalkyl contains 1 or 2 carbons.
- haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 2- fluoropropan-2-yl, 1 ,1 -difluoropropyl, l ,3-difluoropropan-2-yl, (5)-l-fluoropropan-2-yl, (R)-l - fluoropropan-2-yl, l ,l , l-trifluoropropan-2-yl, and 1 ,1 ,1 , 3,3, 3-hexafluoropropan-2-yl.
- halogen refers to a fluoro, chloro, bromo, or iodo group.
- heteroaryl refers to a ring system containing 5 to 10 ring atoms, that may contain a single ring or two fused rings, and wherein at least one ring is aromatic and at least one ring atom of the aromatic ring is a heteroatom selected from, for example: O, S and N, wherein N is optionally substituted with H, C 1 -C 4 acyl, C 1 -C 4 alkyl, or O (i.e. , forming an N- oxide) and S is optionally substituted with one or two oxygens.
- the aromatic ring contains one heteroatom.
- the aromatic ring contains two heteroatoms.
- the aromatic ring contains three heteroatoms.
- 5-membered heteroaryl rings examples include, but are not limited to, furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, and thiadiazolyl.
- 6-membered heteroaryl rings examples include, but are not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl.
- heterocyclyl refers to a non-aromatic ring radical containing 3 to 8 ring atoms, wherein one, two or three ring atoms are heteroatoms selected from, for example: O, S, and N, wherein N is substituted with H, Ci-C 4 acyl or Ci-C 4 alkyl, and S is optionally substituted with one or two oxygens.
- heterocyclyl group examples include, but are not limited to, aziridinyl, azetidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, [1,3]- dioxolanyl, thiomorpholinyl, [l,4]oxazepanyl, oxetanyl, 1,1-dioxothiomorpholinyl, azepanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, l-oxo-hexahydro- ⁇ 4 -thiopyranyl, and 1 , 1 -dioxo-hexahydro- 1 ⁇ 6 -thiopyranyl.
- hydroxyl refers to the group -OH.
- oxo refers to a double bonded oxygen substituted on a carbon thus forming a carbonyl group.
- sulfonamide refers to the group S0 2 NH 2 .
- phenyl refers to the group -C 6 H 5 .
- One aspect of the present invention encompasses, inter alia, certain heterocyclyl derivatives selected from compounds of Formula (la) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxi
- R 1 , R 2 , R 3 , R 4 , and R 5 have the same definitions as described herein, supra and infra. It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the chemical groups represented by the variables ⁇ e.g.
- all subcombinations of the chemical groups listed in the embodiments describing such variables, as well as all subcombinations of uses and medical indications described herein, are also specifically embraced by the present invention just as if each and every subcombination of chemical groups and subcombination of uses and medical indications was individually and explicitly recited herein.
- some embodiments include every combination of one or more pharmaceutical agents, such as an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a
- some embodiments of the present invention include every combination of one or more embodiments pertaining to the chemical groups represented by the variables and generic chemical formulae as described herein or every combination of one or more compounds of Formula (la) together/in combination with every combination of one or more pharmaceutical agents, such as an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, and the like, either specifically disclosed herein or specifically disclosed in any reference recited herein just as if each and every combination was individually and explicitly recited.
- substituted indicates that at least one hydrogen atom of the chemical group is replaced by a non-hydrogen substituent or group, the non-hydrogen substituent or group can be monovalent or divalent. When the substituent or group is divalent, then it is understood that this group is further substituted with another substituent or group.
- a chemical group herein when a chemical group herein is "substituted" it may have up to the full valance of substitution; for example, a methyl group can be substituted by 1, 2, or 3 substituents, a methylene group can be substituted by 1 or 2 substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5 substituents, a naphthyl group can be substituted by 1, 2, 3, 4, 5, 6, or 7 substituents, and the like.
- substituted with one or more substituents refers to the substitution of a group with one substituent up to the total number of substituents physically allowed by the group.
- a group when a group is substituted with more than one group they can be identical or they can be different.
- Compounds of the invention can also include tautomeric forms, such as keto-enol tautomers and the like. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is understood that the various tautomeric forms are within the scope of the compounds of the present invention. It is understood and appreciated that compounds of Formula (la) and formulae related thereto may have one or more chiral centers and therefore can exist as enantiomers and/or diastereoisomers. The invention is understood to extend to and embrace all such enantiomers, diastereoisomers and mixtures thereof, including but not limited to racemates. It is understood that compounds of Formula (la) and formulae used throughout this disclosure represent all individual enantiomers and mixtures thereof, unless stated or shown otherwise.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- One aspect of the present invention pertains to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: C(0)OR 6 , C(0)R 6 , C(S)OR 6 , and CH 2 R 6 , wherein R 6 is selected from: C 1 -C6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 4 haloalkyl, and heterocyclyl, wherein the C 3 -C 7 cycloalkyl and heterocyclyl are each optionally substituted with one or more substituents selected independently from: Ci-C 4 alkyl, Ci-C 4 alkylamino, Ci-C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 alkylthio, amino, C 2 -C6 dialkylamino, and C 1 -C 4 haloalkyl; or R 1 is heteroaryl optionally substituted with one or more substituents selected independently from: C 1 -C 4 alkoxy, Ci-C 6 alkyl, C 3 -
- R 1 is selected from: C(0)OR 6 and CH 2 R 6 ; and R 6 is selected from: C3-C7 cycloalkyl, C 1 -C 4 haloalkyl, and heterocyclyl, wherein the C3-C7 cycloalkyl and heterocyclyl are each optionally substituted with one or more substituents selected
- R 1 is selected from: a five-member heteroaryl and a six-member heteroaryl, each optionally substituted with one or more substituents selected independently from: C 1 -C6 alkyl, C 1 -C4 haloalkyl, and halogen.
- R 1 is selected from: C(0)OR 6 and CH 2 R 6 ; and R 6 is selected from: C3-C7 cycloalkyl, C 1 -C 4 haloalkyl, and heterocyclyl, wherein the C3-C7 cycloalkyl and heterocyclyl are each optionally substituted with one or more substituents selected
- R 1 is selected from: a five-member heteroaryl and a six-member heteroaryl, each optionally substituted with one or more substituents selected independently from: Ci-C 6 alkyl and C 1 -C4 haloalkyl.
- R 1 is selected from: C(0)OR 6 and CH 2 R 6 ; and R 6 is selected from: cyclobutyl, cyclopropyl, (5)-l ,l , l-trifluoropropan-2-yl, (R)-l , l ,l -trifluoropropan-2-yl, and oxetanyl, wherein the cyclobutyl, cyclopropyl, and oxetanyl, are each optionally substituted with one or more substituents selected independently from: methyl and trifluoromethyl; or
- R 1 is selected from: 1 ,2,4-oxadiazolyl, and pyrimidinyl, each optionally substituted with one or more substituents selected independently from: isopropyl, 2-fluoropropan-2-yl, and trifluoromethyl.
- R 1 is selected from: (5)-(l , l ,l-trifluoropropan-2-yloxy)carbonyl, (R)-( 1 ,1 , 1 -trifluoropropan-2-yloxy)carbonyl, ( 1 -(trifluoromethyl)cyclobutoxy)carbonyl, (3- (trifluoromethyl)oxetan-3-yloxy)carbonyl, ( 1 -methylcyclopropoxy)carbonyl, ( 1 - (trifluoromethyl)cyclopropyl)methyl, 3-isopropyl-l ,2,4-oxadiazol-5-yl, 5 -(trifluoromethyl) - 1 ,2,4-oxadiazol-3-yl, 3-(trifluoromethyl)- 1 ,2,4-oxadiazol-5-yl, 3-(2-fluoropropan-2-yl)-l ,2,4- oxadiazol-5-yl, 5-(2-fluoropropan-2
- R 1 is C(0)OR 6 ; and R 6 is selected from: C 3 -C 7 cycloalkyl, C 1 -C4 haloalkyl, and heterocyclyl, wherein the C 3 -C 7 cycloalkyl and heterocyclyl are each optionally substituted with one or more substituents selected independently from: C 1 -C4 alkyl and Q-C4 haloalkyl.
- R 1 is C(0)OR 6 ; and R 6 is selected from: cyclobutyl, cyclopropyl, (S)-l , l ,l-trifluoropropan-2-yl, (R)-l ,l , l-trifluoropropan-2-yl, and oxetanyl, wherein the cyclobutyl, cyclopropyl, and oxetanyl, are each optionally substituted with one or more substituents selected independently from: methyl and trifluoromethyl.
- R 1 is selected from: (5)-(l , l ,l-trifluoropropan-2-yloxy)carbonyl, (R)-( 1 ,1 , 1 -trifluoropropan-2-yloxy)carbonyl, ( 1 -(trifluoromethyl)cyclobutoxy)carbonyl, (3- (trifluoromethyl)oxetan-3-yloxy)carbonyl, (l-methylcyclopropoxy)carbonyl, (1 ,1 ,1 ,3,3,3- hexafluoropropan-2-yloxy)carbonyl, isopropoxycarbonyl, and ( 1 ,1 , 1 -trifluoro-2-methylpropan- 2-yloxy)carbonyl.
- R 1 is CH 2 R 6 ; and R 6 is C3-C7 cycloalkyl optionally substituted with one or more C 1 -C4 haloalkyl substituents.
- R 1 is CH 2 R 6 ; and R 6 is cyclopropyl optionally substituted with one or more trifluoromethyl substituents.
- R 1 is: (l-(trifluoromethyl)cyclopropyl)methyl.
- R 1 is selected from: a five-member heteroaryl and a six-member heteroaryl, each optionally substituted with one or more substituents selected independently from: Ci-C 6 alkyl and Q-C4 haloalkyl.
- R 1 is selected from: 1 ,2,4-oxadiazolyl, and pyrimidinyl, each optionally substituted with one or more substituents selected independently from: isopropyl, 2- fluoropropan-2-yl, and trifluoromethyl.
- R 1 is selected from: 3-isopropyl-l ,2,4-oxadiazol-5-yl, 5- (trifluoromethyl)-l ,2,4-oxadiazol-3-yl, 3-(trifluoromethyl)-l ,2,4-oxadiazol-5-yl, 3-(2- fluoropropan-2-yl)-l ,2,4-oxadiazol-5-yl, 5-(2-fluoropropan-2-yl)-l ,2,4-oxadiazol-3-yl, 5- (trifluoromethyl)pyrimidin-2-yl, and 5-isopropyl-l ,2,4-oxadiazol-3-yl.
- R 1 is selected from: 3-isopropyl-l ,2,4-oxadiazol-5-yl, 5- (trifluoromethyl)-l ,2,4-oxadiazol-3-yl, 3-(trifluoromethyl)-l ,2,4-oxadiazol-5-yl, 3-(2- fluoropropan-2-yl)-l ,2,4-oxadiazol-5-yl, 5-(2-fluoropropan-2-yl)-l ,2,4-oxadiazol-3-yl, 5- (trifluoromethyl)pyrimidin-2-yl, 5-isopropyl-l ,2,4-oxadiazol-3-yl, 5-ethylpyrimidin-2-yl, and 5- chloropyrimidin-2-yl.
- R 1 is (5)-(l ,l , l-trifluoropropan-2-yloxy)carbonyl.
- R 1 is (R)-(l , l ,l-trifluoropropan-2-yloxy)carbonyl.
- R 1 is (l-(trifluoromethyl)cyclobutoxy)carbonyl.
- R 1 is (3-(trifluoromethyl)oxetan-3-yloxy)carbonyl.
- R 1 is (l-methylcyclopropoxy)carbonyl.
- R 1 is (l-(trifluoromethyl)cyclopropyl)methyl. In some embodiments, R 1 is 3-isopropyl-l,2,4-oxadiazol-5-yl.
- R 1 is 5-(trifluoromethyl)-l,2,4-oxadiazol-3-yl.
- R 1 is 3-(trifluoromethyl)-l,2,4-oxadiazol-5-yl.
- R 1 is 3-(2-fluoropropan-2-yl)-l ,2,4-oxadiazol-5-yl.
- R 1 is 5-(2-fluoropropan-2-yl)-l ,2,4-oxadiazol-3-yl.
- R 1 is 5-(trifluoromethyl)pyrimidin-2-yl.
- R 1 is 5-isopropyl-l,2,4-oxadiazol-3-yl.
- R 1 is 5-ethylpyrimidin-2-yl.
- R 1 is 5-chloropyrimidin-2-yl.
- R 1 is ( 1 , 1 , 1 ,3,3,3-hexafluoropropan-2-yloxy)carbonyl.
- R 1 is isopropoxycarbonyl.
- R 1 is ( 1 , 1 , 1 -trifluoro-2-methylpropan-2-yloxy)carbonyl.
- R 2 is selected from: H, C 1 -C4 alkoxy, Ci-C alkyl, Ci-C alkylcarboxamide, Ci-C alkylsulfinyl, Ci-C alkylsulfonamide, Ci-C alkylsulfonyl, Ci-C alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 6
- R 2 is selected from: H, C 1 -C4 alkoxy, C 1 -C4 alkyl, C 1 -C4 alkylsulfinyl, C 1 -C4 alkylsulfonyl, C 1 -C4 alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C3-C7 cycloalkyl, C 1 -C4 haloalkyl, halogen, heteroaryl, and sulfonamide.
- R 2 is selected from: H, methoxy, methyl, ethyl, methylsulfonyl, methylsuliinyl, methylthio, ethynyl, carboxamide, carboxy, cyano, cyclopropyl, trifluoromethyl, fluoro, iodo, chloro, lH-l,2,4-triazol-l-yl, and sulfonamide.
- R 2 is ⁇ .
- R 2 is methoxy
- R 2 is methyl
- R 2 is ethyl
- R 2 is methylsulfonyl
- R 2 is methylsulfonyl
- R 2 is methylthio
- R 2 is ethynyl
- R 2 is carboxamide
- R 2 is carboxy
- R 2 is cyano. In some embodiments, R 2 is cyclopropyl.
- R 2 is trifluoromethyl.
- R 2 is fluoro
- R 2 is iodo.
- R 2 is chloro
- R 2 is lH-l,2,4-triazol-l-yl.
- R 2 is sulfonamide
- R 3 is selected from: ⁇ , Ci-C 4 alkoxy, Ci-C 4 alkyl, Ci-C 4 alkylcarboxamide, Ci-C 4 alkylsulfinyl, Ci-C alkylsulfonamide, Ci-C alkylsulfonyl, Ci-C alkylthio, C 2 -C alkynyl, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C6
- R 3 is selected from: ⁇ , C 1 -C 4 alkoxy, C 1 -C 4 alkyl, C 1 -C 4 alkylcarboxamide, Q-C4 alkylsulfinyl, C 1 -C 4 alkylsulfonamide, C 1 -C 4 alkylsulfonyl, Q-C4 alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 6
- dialkylcarboxamide C 1 -C 4 haloalkyl, halogen, heteroaryl, hydroxyl, and sulfonamide, wherein the C 1 -C 4 alkyl is optionally substituted with one or more substituents selected independently from: hydroxyl and oxo.
- R 3 is selected from: ⁇ , Q-C4 alkyl, and halogen.
- R 3 is selected from: ⁇ and Q-C4 alkyl.
- R 3 is selected from: ⁇ and methyl.
- R 3 is ⁇ .
- R 3 is methyl
- R 3 is chloro
- R 2 and R 3 together with the atoms to which they are each bonded form a heteroaryl optionally substituted with C 1 -C6 alkyl.
- R 4 is selected from: ⁇ , Q-C4 alkoxy, Q-C4 alkyl, Q-C4 alkylcarboxamide, Q-C4 alkylsulfinyl, Q-C4 alkylsulfonamide, Q-C4 alkylsulfonyl, Q-C4 alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 6
- dialkylcarboxamide C 1 -C 4 haloalkyl, halogen, heteroaryl, hydroxyl, and sulfonamide, wherein the C 1 -C 4 alkyl is optionally substituted with one or more substituents selected independently from: hydroxyl and oxo.
- R 4 is selected from: H, Q-C4 alkyl, and halogen.
- R 4 is selected from: H and halogen.
- R 4 is selected from: H and fluoro.
- R 4 is H.
- R 4 is fluoro
- R 5 is selected from: H, C 1 -C 4 alkoxy, C 1 -C 4 alkyl, C 1 -C 4 alkylcarboxamide, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonamide, C 1 -C 4 alkylsulfonyl, C 1 -C 4 alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C3-C7 cycloalkyl, C 2 -C6
- dialkylcarboxamide C 1 -C 4 haloalkyl, halogen, heteroaryl, hydroxyl, and sulfonamide, wherein the C 1 -C 4 alkyl is optionally substituted with one or more substituents selected independently from: hydroxyl and oxo.
- R 5 is selected from: H and Q-C4 alkyl.
- R 5 is H.
- R 2 is selected from: H, Q-C 4 alkoxy, Q-C 4 alkyl, Q-C 4 alkylcarboxamide, Q-C 4 alkylsulfinyl, Q-C 4 alkylsulfonamide, C 1 -C 4 alkylsulfonyl, C 1 -C 4 alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C 3 -C 7 cycloalkyl, C 2 -C 6
- R 3 is selected from: H and C 1 -C 4 alkyl; or
- R 2 and R 3 together with the atoms to which they are each bonded form a heteroaryl optionally substituted with C 1 -C6 alkyl;
- R 4 is selected from: H, C 1 -C 4 alkyl, and halogen
- R 5 is selected from: H and C 1 -C 4 alkyl.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: C(0)OR 6 and CH 2 R 6 ; and R 6 is selected from: C 3 -C 7 cycloalkyl, C C 4 haloalkyl, and heterocyclyl, wherein the C 3 -C 7 cycloalkyl and heterocyclyl are each optionally substituted with one or more substituents selected independently from: C 1 -C 4 alkyl and Q-C4 haloalkyl; or
- R 1 is selected from: a five-member heteroaryl and a six-member heteroaryl, each optionally substituted with one or more substituents selected independently from: C 1 -C6 alkyl and C 1 -C 4 haloalkyl;
- R 2 is selected from: H, C 1 -C 4 alkoxy, C 1 -C 4 alkyl, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 alkylthio, C 2 -C 4 alkynyl, carboxamide, carboxy, cyano, C3-C7 cycloalkyl, C 1 -C 4 haloalkyl, halogen, heteroaryl, and sulfonamide;
- R 3 is selected from: H and C 1 -C 4 alkyl
- R 4 is selected from: H and halogen.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: C(0)OR 6 and CH 2 R 6 ; and R 6 is selected from: cyclobutyl, cyclopropyl, (S)-l , l ,l-trifluoropropan-2-yl, (R)-l , l ,l -trifluoropropan-2-yl, and oxetanyl, wherein the cyclobutyl, cyclopropyl, and oxetanyl, are each optionally substituted with one or more substituents selected independently from: methyl and trifluoromethyl; or
- R 1 is selected from: 1 ,2,4-oxadiazolyl, and pyrimidinyl, each optionally substituted with one or more substituents selected independently from: isopropyl, 2-fluoropropan-2-yl, and trifluoromethyl;
- R 2 is selected from: H, methoxy, methyl, ethyl, methylsulfonyl, methylsulfinyl, methylthio, ethynyl, carboxamide, carboxy, cyano, cyclopropyl, trifluoromethyl, fluoro, iodo, chloro, lH-l ,2,4-triazol-l-yl, and sulfonamide;
- R 3 is selected from: ⁇ and methyl
- R 4 is selected from: ⁇ and fluoro.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: (5)-(l ,l , l-trifluoropropan-2-yloxy)carbonyl, (R)-( 1 , 1 ,1 - trifluoropropan-2-yloxy)carbonyl, ( 1 -(trifluoromethyl)cyclobutoxy)carbonyl, (3- (trifluoromethyl)oxetan-3-yloxy)carbonyl, ( 1 -methylcyclopropoxy)carbonyl, ( 1 - (trifluoromethyl)cyclopropyl)methyl, 3-isopropyl-l ,2,4-oxadiazol-5-yl, 5 -(trifluoromethyl) - 1 ,2,4-oxadiazol-3-yl, 3-(trifluoromethyl)- 1 ,2,4-oxadiazol-5-yl, 3-(2-fluoropropan-2-yl)-l ,2,4- oxadiazol-5-yl, 5-(2-fluoropropan-2
- R 2 is selected from: H, methoxy, methyl, ethyl, methylsulfonyl, methylsulfinyl, methylthio, ethynyl, carboxamide, carboxy, cyano, cyclopropyl, trifluoromethyl, fluoro, iodo, chloro, lH-l ,2,4-triazol-l-yl, and sulfonamide;
- R 3 is selected from: ⁇ and methyl
- R 4 is selected from: ⁇ and fluoro.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: (5)-(l ,l , l-trifluoropropan-2-yloxy)carbonyl, (R)-( 1 , 1 ,1 - trifluoropropan-2-yloxy)carbonyl, (l-(trifluoromethyl)cyclobutoxy)carbonyl, (3- (trifluoromethyl)oxetan-3-yloxy)carbonyl, ( 1 -methylcyclopropoxy)carbonyl, ( 1 - (trifluoromethyl)cyclopropyl)methyl, 3-isopropyl-l ,2,4-oxadiazol-5-yl, 5 -(trifluoromethyl) - 1 ,2,4-oxadiazol-3-yl, 3-(trifluoromethyl)- 1 ,2,4-oxadiazol-5-yl, 3-(2-fluoropropan-2-yl)-l ,2,4- oxadiazol-5-yl, 5-(2-fluoropropan-2-
- R 2 is selected from: ⁇ , methoxy, methyl, ethyl, methylsulfonyl, methylsulfinyl, methylthio, ethynyl, carboxamide, carboxy, cyano, cyclopropyl, trifluoromethyl, fluoro, iodo, chloro, lH-l ,2,4-triazol-l-yl, and sulfonamide;
- R 3 is selected from: H and methyl;
- R 4 is selected from: H and fluoro.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: a five-member heteroaryl and a six-member heteroaryl, each optionally substituted with one or more substituents selected independently from: C 1 -C6 alkyl and C 1 -C 4 haloalkyl;
- R 2 is selected from: C 1 -C 4 alkoxy, carboxamide, carboxy, cyano, C 1 -C 4 haloalkyl, halogen, heteroaryl, and sulfonamide;
- R 3 is selected from: H and C 1 -C 4 alkyl
- R 4 is selected from: H and halogen.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: 1 ,2,4-oxadiazolyl, and pyrimidinyl, each optionally substituted with one or more substituents selected independently from: isopropyl, 2-fluoropropan-2-yl, and trifluoromethyl;
- R 2 is selected from: methoxy, carboxamide, carboxy, cyano, trifluoromethyl, fluoro, chloro, lH-l,2,4-triazol-l-yl, and sulfonamide;
- R 3 is selected from: ⁇ and methyl
- R 4 is selected from: ⁇ and fluoro.
- One aspect of the present invention pertains to compounds of Formula (Ic) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is selected from: 3-isopropyl-l,2,4-oxadiazol-5-yl, 5-(trifluoromethyl)-l,2,4- oxadiazol-3-yl, 3-(trifluoromethyl)-l,2,4-oxadiazol-5-yl, 3-(2-fluoropropan-2-yl)-l,2,4- oxadiazol-5-yl, 5-(2-fluoropropan-2-yl)-l ,2,4-oxadiazol-3-yl, 5-(trifluoromethyl)pyrimidin-2-yl, and 5-isopropyl-l,2,4-oxadiazol-3-yl;
- R 2 is selected from: methoxy, carboxamide, carboxy, cyano, trifluoromethyl, fluoro, chloro, lH-l,2,4-triazol-l-yl, and sulfonamide;
- R 3 is selected from: ⁇ and methyl
- R 4 is selected from: ⁇ and fluoro.
- One aspect of the present invention pertains to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is C(0)OR 6 ;
- R is selected from: ⁇ , C 1 -C4 alkyl, Ci-C alkylsulfinyl, Ci-C alkylsulfonyl, Ci-C alkylthio, C 2 -C 4 alkynyl, cyano, C 3 -C 7 cycloalkyl, and halogen; and
- R 6 is selected from: C 3 -C 7 cycloalkyl, Ci-C haloalkyl, and heterocyclyl, wherein the C3-C7 cycloalkyl and heterocyclyl are each optionally substituted with one or more substituents selected independently from: C 1 -C4 alkyl and C 1 -C4 haloalkyl.
- One aspect of the present invention pertains to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is C(0)OR 6 ;
- R is selected from: ⁇ , methyl, ethyl, methylsulfonyl, methylsulfinyl, methylthio, ethynyl, cyano, cyclopropyl, and iodo; and R 6 is selected from: cyclobutyl, cyclopropyl, (S)-l , l ,l-trifluoropropan-2-yl, (R)- 1 ,1 , 1 - trifluoropropan-2-yl, and oxetanyl, wherein the cyclobutyl, cyclopropyl, and oxetanyl, are each optionally substituted with one or more substituents selected independently from: methyl and trifluoromethyl.
- One aspect of the present invention pertains to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates, h drates, and N-oxides thereof:
- R 1 is selected from: (5)-(l ,l , l-trifluoropropan-2-yloxy)carbonyl, (R)-( 1 , 1 ,1 - trifluoropropan-2-yloxy)carbonyl, ( 1 -(trifluoromethyl)cyclobutoxy)carbonyl, (3- (trifluoromethyl)oxetan-3-yloxy)carbonyl, and (l-methylcyclopropoxy)carbonyl; and
- R 2 is selected from: H, methyl, ethyl, methylsulfonyl, methylsulfinyl, methylthio, ethynyl, cyano, cyclopropyl, and iodo.
- One aspect of the present invention pertains to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is CH 2 R 6 ;
- R is cyano
- R 6 is C 3 -C7 cycloalkyl optionally substituted with one or more Q-C4 haloalkyl substituents.
- One aspect of the present invention pertains to compounds of Formula (Ie) and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof:
- R 1 is CH 2 R 6 ;
- R 2 is cyano
- R 6 is cyclopropyl optionally substituted with one or more trifluoromethyl substituents.
- Some embodiments of the present invention include every combination of one or more compounds and pharmaceutically acceptable salts, solvates, hydrates, and N-oxides thereof selected from the following group shown in Table A.
- individual compounds and chemical genera of the present invention encompass all pharmaceutically acceptable salts, solvates, hydrates, and N- oxides thereof.
- the compounds of Formula (la) of the present invention may be prepared according to relevant published literature procedures that are used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter in the working Examples.
- Protection and deprotection may be carried out by procedures generally known in the art (see, for example, Greene, T. W. and Wuts, P. G. M., Protecting Groups in Organic Synthesis, 3 rd Edition, 1999 [Wiley]).
- the present invention embraces, each isomer, each diastereoisomer, each enantiomer and mixtures thereof of each compound and generic formulae disclosed herein just as if they were each individually disclosed with the specific stereochemical designation for each chiral carbon. Separation of the individual isomers and enantiomers (such as, by chiral HPLC, recrystallization of diastereoisomeric mixtures and the like) or selective synthesis (such as, by enantiomeric selective syntheses and the like) of the individual isomers can be accomplished by application of various methods which are well known to practitioners in the art.
- compositions Compositions, Methods, Indications, Pharmaceutical Products, Combinations, and Uses of Compounds of the Present Invention.
- compositions comprising a compound of the present invention.
- One aspect of the present invention pertains to pharmaceutical products selected from: a pharmaceutical composition, a formulation, a unit dosage form, and a kit; each comprising a compound of the present invention.
- One aspect of the present invention pertains to pharmaceutical compositions comprising a compound of the present invention, and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to methods for preparing a pharmaceutical composition comprising the step of admixing a compound of the present invention, and a pharmaceutically acceptable carrier; some embodiments pertain to pharmaceutical compositions obtained by any of the methods described herein.
- One aspect of the present invention pertains to compositions comprising a compound of the present invention, and a second pharmaceutical agent.
- a pharmaceutical agent and “a second pharmaceutical agent”
- these terms in some aspects be further limited to a pharmaceutical agent that is not a compound of Formula (I) or a compounds related thereto.
- a pharmaceutical agent and “a second pharmaceutical agent” may refer to a pharmaceutical agent that is not detectable or has an EC 50 that is greater than a value selected from: 50 ⁇ , 10 ⁇ , 1 ⁇ , and 0.1 ⁇ in a GPR119 receptor activity assay as described in Example 4.
- One aspect of the present invention pertains to methods for preparing a composition comprising the step of admixing a compound of the present invention, and a second pharmaceutical agent; some embodiments pertain to compositions obtained by any of the methods described herein.
- One aspect of the present invention pertains to pharmaceutical products selected from: a pharmaceutical composition, a formulation, a unit dosage form, a combined preparation, a twin pack, and a kit; comprising a compound of the present invention, and a second pharmaceutical agent.
- One aspect of the present invention pertains to
- compositions comprising a compound of the present invention, a second pharmaceutical agent, and a pharmaceutically acceptable carrier.
- One aspect of the present invention pertains to methods for preparing a pharmaceutical composition comprising the step of admixing a compound of the present invention, a second pharmaceutical agent, and a pharmaceutically acceptable carrier; some embodiments pertain to pharmaceutical compositions obtained by any of the methods described herein.
- One aspect of the present invention pertains to methods selected from one or more of the following: 1) for modulating the activity of a GPR119 receptor; 2) for agonizing a GPR119 receptor; 3) for increasing the secretion of an incretin in an individual; 4) increasing a blood incretin level in an individual; and 5) for treating/treatment of a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; and obesity; in an individual; comprising: A) administering to an individual in need thereof or B) prescribing to an individual in need thereof, a therapeutically effective amount of: a compound of the present invention; a composition of the present invention; a pharmaceutical product of the present invention; or a pharmaceutical composition of the present invention; each optionally in combination with a therapeutically effective amount of a second pharmaceutical agent.
- Some embodiments pertain to methods comprising administering to an individual in need thereof a therapeutically effective amount of: a compound of the present invention; a composition of the present invention; a pharmaceutical product of the present invention; or a pharmaceutical composition of the present invention. Some embodiments pertain to methods for prescribing to an individual in need thereof, a therapeutically effective amount of: a compound of the present invention; a composition of the present invention; a pharmaceutical product of the present invention; or a pharmaceutical composition of the present invention.
- One aspect of the present invention pertains to the use of a compound of the present invention, optionally in combination with a second pharmaceutical agent, in the manufacture of a medicament, selected from one or more of the following: 1) for modulating the activity of a GPR119 receptor in an individual; 2) for agonizing a GPR119 receptor; 3) for increasing the secretion of an incretin in an individual; 4) increasing a blood incretin level in an individual; and 5) for treating/treatment of a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; and obesity.
- a compound of the present invention optionally in combination with a second pharmaceutical agent, in the manufacture of a medicament, selected from one or more of the following: 1) for modulating the activity of a GPR119 receptor in an individual; 2) for agonizing a GPR
- One aspect of the present invention pertains to a compound of the present invention; a composition of the present invention; a pharmaceutical product of the present invention; or a pharmaceutical composition of the present invention; optionally in combination with a second pharmaceutical agent, for use in a method of treatment of the human or animal body by therapy.
- One aspect of the present invention pertains to one or more of the following: methods of the present invention, compounds of the present invention; compositions of the present invention; pharmaceutical products of the present invention; and pharmaceutical compositions of the present invention; optionally in combination with a second pharmaceutical agent, for use in a method selected from one or more of the following: 1) for modulating the activity of a GPR119 receptor; 2) for agonizing a GPR119 receptor; 3) for increasing the secretion of an incretin in an individual; 4) increasing a blood incretin level in an individual; and 5) for treating/treatment of a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic- related disorder; and obesity.
- a second pharmaceutical agent for use in a method selected from one or more of the following: 1) for modulating the activity of a GPR119 receptor; 2)
- One aspect of the present invention pertains to a pharmaceutical agent in combination with a compound of the present invention; a composition of the present invention; a pharmaceutical product of the present invention; or a pharmaceutical composition of the present invention; for use in a method of treatment of the human or animal body by therapy.
- One aspect of the present invention pertains to a pharmaceutical agent in combination with a compound of the present invention; a composition of the present invention; a pharmaceutical product of the present invention; or a pharmaceutical composition of the present invention; for use in a method selected from one or more of the following: 1) for modulating the activity of a GPR119 receptor; 2) for agonizing a GPR119 receptor; 3) for increasing the secretion of an incretin in an individual; 4) increasing a blood incretin level in an individual; and 5) for treating/treatment of a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; and obesity.
- Some embodiments pertain to methods, uses, compounds, and pharmaceutical agents, each as described herein, for modulating the activity of a GPR119 receptor. Some embodiments pertain to methods, uses, compounds, and pharmaceutical agents, each as described herein, for agonizing a GPR119 receptor. Some embodiments pertain to methods, uses, compounds, and pharmaceutical agents, each as described herein, for increasing the secretion of an incretin in an individual. Some embodiments pertain to methods, uses, compounds, and pharmaceutical agents, each as described herein, for increasing a blood incretin level in an individual.
- Some embodiments pertain to methods, uses, compounds, and pharmaceutical agents, each as described herein, for treatment of a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; and obesity; in an individual.
- a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; and obesity; in an individual.
- the disorder is a GPR119-receptor-related disorder. In some embodiments, the disorder is a condition ameliorated by increasing secretion of an incretin. In some embodiments, the disorder is a condition ameliorated by increasing a blood incretin level. In some embodiments, the disorder is a condition characterized by low bone mass. In some embodiments, the disorder is a neurological disorder. In some embodiments, the disorder is a metabolic -related disorder. In some embodiments, the disorder is obesity. In some embodiments, the disorder is type 2 diabetes. In some embodiments, the disorder is hyperglycemia. In some embodiments, the disorder is hyperlipidemia. In some embodiments, the disorder is
- the disorder is type 1 diabetes. In some embodiments, the disorder is dyslipidemia. In some embodiments, the disorder is syndrome X.
- the pharmaceutical product comprises a pharmaceutical composition. In some embodiments, the pharmaceutical product comprises a formulation. In some embodiments, the pharmaceutical product comprises a unit dosage form. In some embodiments, the pharmaceutical product comprises a kit. In some embodiments, the pharmaceutical product comprises a combined preparation. In some embodiments, the pharmaceutical product comprises a twin pack.
- the compound and pharmaceutical agent or the second pharmaceutical agent are administered simultaneously, separately, or sequentially. In some embodiments, the compound and the pharmaceutical agent or the second pharmaceutical agent are administered simultaneously. In some embodiments, the compound and the pharmaceutical agent or the second pharmaceutical agent are administered separately. In some embodiments, the compound and the pharmaceutical agent or the second pharmaceutical agent are
- the incretin is GLP-1. In some embodiments, the incretin is GIP.
- the incretin is PYY.
- a DPP-IV inhibitor a biguanide
- an alpha-glucosidase inhibitor an insulin analogue
- a sulfonylurea an SGLT2 inhibitor
- meglitinide a thiazolidinedione
- anti- diabetic peptide analogue analogue
- One aspect of the present invention pertains to compositions, methods, pharmaceutical products, pharmaceutical compositions, uses; compounds, and pharmaceutical agents, each as described herein, wherein: 1) the compound and the pharmaceutical agent or the second pharmaceutical agent are provided in amounts which give a synergistic effect in treating the disorder; 2) the amount of the compound alone is substantially therapeutically ineffective at treating the disorder; and/or 3) the amount of the pharmaceutical agent alone or the second pharmaceutical agent alone is substantially therapeutically ineffective at treating the disorder.
- One aspect of the present invention relates to methods for preparing pharmaceutical products: mixing said compound with a first pharmaceutically acceptable carrier to prepare a compound unit dosage form; mixing said second pharmaceutical agent with a second pharmaceutically acceptable carrier to prepare a second pharmaceutical agent unit dosage form; and combining said compound unit dosage form and said second pharmaceutical agent unit dosage form in a combined unit dosage form for simultaneous, separate, or sequential use.
- the first pharmaceutically acceptable carrier is different from the second pharmaceutically acceptable carrier. In some embodiments, the different
- pharmaceutically acceptable carriers are suitable for administration by the same route.
- the different pharmaceutically acceptable carriers are suitable for administration by different routes.
- the first pharmaceutically acceptable carrier is substantially the same as the second pharmaceutically acceptable carrier.
- the substantially the same pharmaceutically acceptable carriers are suitable for oral
- a compound as described herein or a pharmaceutical composition thereof can be utilized for modulating the activity of the GPR119- receptor and therefore related diseases, conditions and/or disorders related thereto such as those described herein.
- modulating the activity includes the treatment of a GPR119- receptor-related disorder.
- a GPR119-receptor-related disorder is a condition ameliorated by increasing a blood incretin level.
- a GPR119- receptor-related disorder is a condition characterized by low bone mass.
- a GPR119-receptor-related disorder is a neurological disorder.
- a GPR119-receptor-related disorder is a metabolic-related disorder.
- a GPR119-receptor-related disorder is obesity.
- Some embodiments of the present invention include every combination of one or more conditions characterized by low bone mass selected from: osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget' s disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
- the disorder is selected from: stroke and Parkinson's disease.
- Some embodiments of the present invention include every combination of one or more metabolic -related disorders selected from: type 1 diabetes, type 2 diabetes mellitus, and conditions associated therewith, such as, but not limited to, coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g.
- necrosis and apoptosis dyslipidemia, post-prandial lipemia, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, osteoporosis, hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, insulin resistance, impaired glucose metabolism, erectile dysfunction, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance.
- ITT impaired glucose tolerance
- Some embodiments of the present invention include every combination of one or more metabolic -related disorders selected from: diabetes, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, impaired glucose tolerance, insulin resistance, hyperglycemia,
- hyperlipidemia hypertriglyceridemia, hypercholesterolemia, dyslipidemia, atherosclerosis, stroke, syndrome X, hypertension, pancreatic beta-cell insufficiency, enteroendocrine cell insufficiency, glucosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, peripheral neuropathy, diabetic coronary artery disease, diabetic cerebrovascular disease, diabetic peripheral vascular disease, diabetic retinopathy, metabolic syndrome, a condition related to diabetes, myocardial infarction, learning impairment, memory impairment, a neurodegenerative disorder, a condition ameliorated by increasing a blood GLP-1 level in an individual with a neurodegenerative disorder, excitotoxic brain damage caused by severe epileptic seizures, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion- associated disease, stroke, motor-neuron disease, traumatic brain injury, spinal cord injury, and obesity.
- the disorder is type 2 diabetes. In some embodiments, the disorder is hyperglycemia. In some embodiments, the disorder is hyperlipidemia. In some embodiments, the disorder is hypertriglyceridemia. In some embodiments, the disorder is type 1 diabetes. In some embodiments, the disorder is dyslipidemia. In some embodiments, the disorder is syndrome X. In some embodiments, the disorder is obesity.
- One aspect of the present invention pertains to methods for weight management, comprising administering to an individual in need thereof, a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of a pharmaceutical agent; wherein the compound and the pharmaceutical agent are as described herein.
- the weight management comprises weight loss. In some embodiments, the weight management comprises maintenance of weight loss. In some embodiments, the weight management further comprises a reduced-calorie diet. In some embodiments, the weight management further comprises a program of regular exercise. In some embodiments, the weight management further comprises both a reduced-calorie diet and a program of regular exercise.
- the individual in need of weight management is a patient with an initial body mass of index > 40 kg/m2; > 39 kg/m2; > 38 kg/m2; > 37 kg/m2; > 36 kg/m2; > 35 kg/m2; > 34 kg/m2; > 33 kg/m2; > 32 kg/m2; > 31 kg/m2; > 30 kg/m2; > 29 kg/m2; > 28 kg/m2; > 27 kg/m2; > 26 kg/m2; > 25 kg/m2; > 24 kg/m2; > 23 kg/m2; > 22 kg/m2; > 21 kg/m2; or > 20 kg/m2; and the patient optionally has at least one or at least two weight related comorbid condition(s).
- the comorbid condition(s) when present are selected from:
- hypertension hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, and sleep apnea.
- Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, forming the resulting mixture into a desired shape.
- excipients such as binding agents, fillers, acceptable wetting agents, tabletting lubricants and disintegrants may be used in tablets and capsules for oral
- Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions and syrups.
- the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives and flavorings and colorants may be added to the liquid preparations.
- Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.
- a compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically- acceptable carriers, outside those mentioned herein, are known in the art; for example, see
- a compound of the invention may, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.
- Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in an efficient manner with minimal degradation of the drug.
- transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner.
- the compounds of the invention may thus be placed into the form of pharmaceutical formulations and unit dosages thereof and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
- Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid.
- the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
- Examples of such dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate.
- the active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.
- active ingredient defined in the context of a “pharmaceutical composition” refers to a component of a pharmaceutical composition that provides the primary pharmacological effect, as opposed to an "inactive ingredient” which would generally be recognized as providing no pharmaceutical benefit.
- the dose when using the compounds of the present invention can vary within wide limits and as is customary and is known to the physician, it is to be tailored to the individual conditions in each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis conducted or on whether further active compounds are administered in addition to the compounds of the present invention.
- Representative doses of the present invention include, but not limited to, about 0.001 mg to about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to about 1000 mg, 0.001 mg to about 500 mg, 0.001 mg to about 250 mg, about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg and about 0.001 mg to about 25 mg.
- Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or 4 doses. Depending on the individual and as deemed appropriate from the patient's physician or caregiver it may be necessary to deviate upward or downward from the doses described herein.
- the amount of active ingredient, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician.
- a model system typically an animal model
- these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors.
- compositions of this invention are selected in accordance with a variety factors as cited above.
- the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
- the daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4 part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
- the compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt, solvate, or hydrate of a compound of the invention.
- a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible granules.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desire shape and size.
- the powders and tablets may contain varying percentage amounts of the active compound.
- a representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active compound; however, an artisan would know when amounts outside of this range are necessary.
- Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter and the like.
- the term "preparation” refers to the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included.
- Tablets, powders, capsules, pills, cachets and lozenges can be used as solid forms suitable for oral administration.
- a low melting wax such as an admixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogenous mixture is then poured into convenient sized molds, allowed to cool and thereby to solidify.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Liquid form preparations include solutions, suspensions and emulsions, for example, water or water-propylene glycol solutions.
- parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
- injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
- parenteral administration e.g. by injection, for example bolus injection or continuous infusion
- the pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
- a suitable vehicle e.g. sterile, pyrogen-free water
- Aqueous formulations suitable for oral use can be prepared by dissolving or suspending the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents, as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
- viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like.
- the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
- Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
- the formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
- Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant.
- aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant.
- the compounds of the present invention or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler.
- Pharmaceutical forms for administration of the compounds of the present invention as an aerosol can be prepared by processes well known to the person skilled in the art.
- solutions or dispersions of the compounds of the present invention in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others and, if appropriate, customary propellants, for example include carbon dioxide, CFCs, such as, dichlorodifluoromethane, trichlorofluorome thane, or dichlorotetrafluoroe thane; and the like.
- the aerosol may conveniently also contain a surfactant such as lecithin.
- the dose of drug may be controlled by provision of a metered valve.
- the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
- formulations adapted to give sustained release of the active ingredient may be employed.
- the active ingredients may be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
- the powder carrier will form a gel in the nasal cavity.
- the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
- the pharmaceutical preparations are preferably in unit dosage forms.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
- the compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
- Representative acids include, but are not limited to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic,
- Certain compounds of the present invention which contain a carboxylic acid functional group may optionally exist as pharmaceutically acceptable salts containing non-toxic, pharmaceutically acceptable metal cations and cations derived from organic bases.
- Representative metals include, but are not limited to, aluminium, calcium, lithium, magnesium, potassium, sodium, zinc and the like. In some embodiments the pharmaceutically acceptable metal is sodium.
- organic bases include, but are not limited to, benzathine (N ⁇ N 2 -dibenzylethane-l,2-diamine), chloroprocaine (2- (diethylamino)ethyl 4-(chloroamino)benzoate), choline, diethanolamine, ethylenediamine, meglumine ((2R,3R,4R,5S)-6-(methylamino)hexane-l,2,3,4,5-pentaol), procaine (2-
- the acid addition salts may be obtained as the direct products of compound synthesis.
- the free base may be dissolved in a suitable solvent containing the appropriate acid and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
- the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
- Compounds of the present invention can be converted to "pro-drugs.”
- the term “prodrugs” refers to compounds that have been modified with specific chemical groups known in the art and when administered into an individual these groups undergo biotransformation to give the parent compound. Pro-drugs can thus be viewed as compounds of the invention containing one or more specialized non-toxic protective groups used in a transient manner to alter or to eliminate a property of the compound.
- the "pro-drug” approach is utilized to facilitate oral absorption.
- a thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems Vol. 14 of the A.C.S. Symposium Series; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
- Some embodiments of the present invention include a method of producing a pharmaceutical composition for "combination-therapy" comprising admixing at least one compound according to any of the compound embodiments disclosed herein, together with at least one known pharmaceutical agent as described herein and a pharmaceutically acceptable carrier.
- GPRl 19 receptor modulators are utilized as active ingredients in pharmaceutical compositions, these are not intended for use in humans only, but in non- human mammals as well.
- active agents such as GPRl 19 receptor modulators
- livestock animals e.g., horses, cows, etc.
- the dosage forms described herein may comprise, as the active component, either a compound described herein or a pharmaceutically acceptable salt or as a pharmaceutically acceptable solvate or hydrate thereof.
- various hydrates and solvates of the compounds described herein and their salts will find use as intermediates in the manufacture of pharmaceutical compositions. Typical procedures for making and identifying suitable hydrates and solvates, outside those mentioned herein, are well known to those in the art; see for example, pages 202-209 of KJ. Guillory, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," in: Polymorphism in Pharmaceutical Solids, ed. Harry G. England, Vol.
- one aspect of the present invention pertains to methods of administering hydrates and solvates of compounds described herein and/or their pharmaceutical acceptable salts, that can be isolated and characterized by methods known in the art, such as, thermogravimetric analysis (TGA), TGA-mass spectroscopy, TGA-Infrared spectroscopy, powder X-ray diffraction (XRPD), Karl Fisher titration, high resolution X-ray diffraction, and the like.
- TGA thermogravimetric analysis
- TGA-mass spectroscopy TGA-Infrared spectroscopy
- powder X-ray diffraction (XRPD) powder X-ray diffraction
- Karl Fisher titration high resolution X-ray diffraction
- a compound of the invention can be administered as the sole active pharmaceutical agent (i.e. , mono-therapy), or it can be used in combination with one or more pharmaceutical agents (i.e. , combination-therapy), such as pharmaceutical agents, such as, known anti-diabetic agents, either administered together or separately for the treatment of the diseases, conditions, and disorders described herein. Therefore, another aspect of the present invention includes methods of treatment of a metabolic related disorder, including a weight-related disorder, such as obesity, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of Formula (la) and pharmaceutically acceptable salts, solvates and hydrates thereof, in combination with one or more pharmaceutical agents, such as anti-diabetic agents, as described herein.
- a metabolic related disorder including a weight-related disorder, such as obesity
- the combination can be used by mixing the respective active components, a compound of Formula (la) and a pharmaceutical agent, either together or independently optionally with a physiologically acceptable carrier, excipient, binder, diluent, etc. , as described herein, and administering the mixture or mixtures either orally or non- orally as a pharmaceutical composition(s).
- a compound of Formula (la) is administered as a combination therapy with another active compound the compound of Formula (la) and the pharmaceutical agent can be formulated as separate pharmaceutical compositions given at the same time or at different times; or the compound of Formula (la) and the pharmaceutical agent can be formulated together as a single unit dosage.
- Suitable pharmaceutical agents that can be used in combination with the compounds of the present invention include anti-obesity agents such as apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors; MCR-4 agonists, cholescystokinin-A
- anti-obesity agents such as apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors
- apo-B/MTP apolipoprotein-B secretion/microsomal triglyceride transfer protein
- MCR-4 agonists cholescystokinin-A
- CCK-A serotonin and norepinephrine reuptake inhibitors
- serotonin and norepinephrine reuptake inhibitors for example, sibutramine
- sympathomimetic agents for example, ⁇ 3 adrenergic receptor agonists
- dopamine agonists for example, bromocriptine
- melanocyte-stimulating hormone receptor analogues cannabinoid 1 receptor antagonists [for example, SR141716: N-(piperidin-l-yl)-5-(4-chlorophenyl)-l-(2,4- dichlorophenyl)-4-methyl-lH-pyrazole-3-carboxamide]; melanin concentrating hormone antagonists; leptin (the OB protein); leptin analogues; leptin receptor agonists; galanin antagonists; lipase inhibitors (such as tetrahydrolipstatin, i.e.
- anorectic agents such as a bombesin agonist
- neuropeptide -Y antagonists such as a bombesin agonist
- thyromimetic agents such as a bombesin agonist
- dehydroepiandrosterone or an analogue thereof such as glucocorticoid receptor agonists or antagonists
- orexin receptor antagonists such as urocortin binding protein antagonists
- ciliary neutrotrophic factors such as AxokineTM available from Regeneron
- GPP human agouti-related proteins
- H3R histamine 3 receptor
- neuromedin U receptor agonists for example, phentermine, mazindol and the like
- noradrenergic anorectic agents for example, phentermine, mazindol and the like
- appetite suppressants for example, bupropion
- anti-obesity agents including the agents set forth infra, are well known, or will be readily apparent in light of the instant disclosure, to one of ordinary skill in the art.
- the anti-obesity agents are selected from the group consisting of orlistat, sibutramine, bromocriptine, ephedrine, leptin, and pseudoephedrine.
- compounds of the present invention and combination therapies are administered in conjunction with exercise and/or a calorie -controlled diet.
- combination-therapy of the compounds of the present invention with anti-obesity agents, anorectic agents, appetite suppressant and related agents is not limited to those listed above, but includes in principle any combination with any pharmaceutical agent or pharmaceutical composition useful for the treatment of overweight and obese individuals.
- combination-therapy of the compounds of the present invention with other pharmaceutical agents is not limited to those listed herein, supra or infra, but includes in principle any combination with any pharmaceutical agent or pharmaceutical composition useful for the treatment of diseases, conditions or disorders that are linked to metabolic related disorders.
- Some embodiments of the present invention include methods of treatment of a disease, disorder, condition or complication thereof as described herein, comprising administering to an individual in need of such treatment a therapeutically effective amount or dose of a compound of Formula (la) in combination with at least one pharmaceutical agent selected from the group consisting of: sulfonylureas (for example, tolbutamide (Orinase); acetohexamide (Dymelor); tolazamide (Tolinase); chlorpropamide (Diabinese); glipizide (Glucotrol); glyburide (Diabeta, Micronase, Glynase); glimepiride (Amaryl); gliclazide (Diamicron); and sulfonylureas known in the art); meglitinides (for example, repaglinide (Prandin), nateglinide (Starlix), mitiglinide, and other meglitinides known in the art); biguanides (for example,
- PPAR- ⁇ ) agonists for example, rosiglitazone (Avandia), pioglitazone (Actos), troglitazone (Rezulin), rivoglitazone, ciglitazone, and thiazolidinediones known in the art); insulin and insulin analogues; anti-diabetic peptide analogues (for example, exenatide, liraglutide, taspoglutide, and anti-diabetic peptides analogues know in the art); HMG- CoA reductase inhibitors (for example, rosuvastatin, pravastatin and its sodium salt, simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, rosuvastatin, pitavastatin, pravastatin, and other HMG-CoA reductase inhibitors known in the art); cholesterol-lowering drugs (for example, cholesterol
- antiplatelet agents for example, aspirin and adenosine diphosphate receptor antagonists that include: clopidogrel, ticlopidine and the like
- angiotensin-converting enzyme inhibitors for example, captopril, enalapril, alacepril, delapril; ramipril, lisinopril, imidapril, benazepril, ceronapril, cilazapril, enalaprilat, fosinopril, moveltopril, perindopril, quinapril, spirapril, temocapril, trandolapril, and other angiotensin converting enzyme inhibitors known in the art); angiotensin II receptor antagonists [for example, losartan (and the potassium salt form), and other angiotensin II receptor antagonists known in the art; adip
- Suitable pharmaceutical agents that can be used in conjunction with compounds of the present invention include, but are not limited to: amylin agonists (for example, pramlintide); insulin secretagogues (for example, GLP-1 agonists, exendin-4, and insulinotropin (NN2211)); acyl CoA cholesterol acetyltransferase inhibitors (for example, ezetimibe, eflucimibe, and other acyl CoA cholesterol acetyltransferase inhibitors known in the art); cholesterol absorption inhibitors (for example, ezetimibe, pamaqueside and other cholesterol absorption inhibitors known in the art); cholesterol ester transfer protein inhibitors (for example, CP-529414, JTT- 705, CETi-1, and other cholesterol ester transfer protein inhibitors known in the art);
- amylin agonists for example, pramlintide
- insulin secretagogues for example, GLP-1 agonists, exendin-4, and insulinotropin (NN22
- microsomal triglyceride transfer protein inhibitors for example, implitapide, and other microsomal triglyceride transfer protein inhibitors known in the art
- cholesterol modulators for example, NO-1886, and other cholesterol modulators known in the art
- bile acid modulators for example, GT 103 -279 and other bile acid modulators known in the art
- insulin signaling pathway modulators inhibitors of protein tyrosine phosphatases (PTPases); non-small molecule mimetics and inhibitors of glutamine-fructose-6-phosphate amidotransf erase (GFAT);
- G6Pase glucose-6- phosphatase
- F-l ,6-BPase fructose-l ,6-bisphosphatase
- GP glycogen phosphorylase
- glucagon receptor antagonists inhibitors of phosphoenolpyruvate carboxykinase (PEPCK); pyruvate dehydrogenase kinase (PDHK) inhibitors; insulin sensitivity enhancers; insulin secretion enhancers; inhibitors of gastric emptying; ⁇ -adrenergic antagonists; retinoid X receptor (RXR) agonists; and dipeptidyl peptidase-4 (DPP-IV) inhibitors; and the like.
- G6Pase glucose-6- phosphatase
- F-l ,6-BPase fructose-l ,6-bisphosphatase
- GP glycogen phosphorylase
- PEPCK phosphoenolpyruvate carboxykinas
- Some aspects of the present invention include compounds of Formula (la) that can be employed in any of the methods, pharmaceutical products, uses, compounds, and
- the two distinct pharmaceutical agents are selected from any of the pharmaceutical agents, or classes of pharmaceutical agents described herein.
- the two distinct pharmaceutical agents are selected from: an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, and an anti-diabetic peptide analogue.
- the two distinct pharmaceutical agents include every combination selected from pharmaceutical agents of the following group: an inhibitor of DPP-IV, a biguanide, an alpha- glucosidase inhibitor, a sulfonylurea, and an SGLT2 inhibitor.
- the two distinct pharmaceutical agents include: an inhibitor of DPP-IV and a biguanide.
- the two distinct pharmaceutical agents include: 3(R)-amino-l-[3- (trifluoromethyl)-5,6,7,8-tetrahydro[l ,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l -one (Januvia®) and metformin).
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds of the following group and pharmaceutically acceptable salts, solvates, and hydrates thereof: an inhibitor of DPP-IV selected from: 3(R)-amino-l -[3- (trifluoromethyl)-5,6,7,8-tetrahydro[l ,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l -one; l-[2-(3-hydroxyadamant-l-ylamino)acetyl]pyrrolidine-2(5)- carbonitrile; (15,35,55)-2-[2(5)-amino-2-(3-hydroxyadamantan-l-yl)acetyl]-2- azabicyclo[3.1.0]hexane-3-carbonitrile; 2-[6-[3(R)-aminopiperidin-l-yl]-3-methyl-2,4-diox
- a-glucosidase inhibitor selected from: acarbose ((2R,3R,4R,5R)-4-((2R,3R,4R,55,6R)-5-((2R,3R,45,55,6R)-3,4-dihydroxy-6-methyl-5- ((15,4R,55,65)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enylamino)tetrahydro-2H-pyran-
- acarbose ((2R,3R,4R,5R)-4-((2R,3R,4R,55,6R)-5-((2R,3R,45,55,6R)-3,4-dihydroxy-6-methyl-5- ((15,4R,55,65)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enylamino)tetrahydro-2H-pyran-
- an insulin analogue selected from: ⁇ insulin (also known as Humulin ⁇ , Novolin N, NPH Lletin II, and insulin isophane); insulin lispro (28B-L-lysine-29B-L-proline -insulin, wherein insulin is human insulin); insulin aspart (28B-L-aspartic acid-insulin, wherein insulin is
- glibenclamide also known as glyburide (Diabeta, Micronase, Glynase, 5-chloro-N-(4-(N-
- glimepiride Amaryl, 3- ethyl-4-methyl-N-(4-(N-((lr,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo- 2,5-dihydro-lH-pyrrole-l-carboxamide
- gliclazide Diamicron, N-
- an SGLT2 inhibitor selected from: dapagliflozin ((2S,3R,4R,5S,6R)-2-(4-chloro-3-(4- ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3 ,4,5 -triol) ; remogliflozin (ethyl ((2R,35,45,5R,65)-3,4,5-trihydroxy-6-(4-(4-isopropoxybenzyl)-l-isopropyl-5-methyl-lH- pyrazol-3-yloxy)tetrahydro-2H-pyran-2-yl)methyl carbonate); ASP1941, canagliflozin
- a thiazolidinedione selected from: rosiglitazone (Avandia, 5-(4-(2-(methyl(pyridin-2- yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione); pioglitazone (Actos, 5-(4-(2-(5-ethylpyridin-2- yl)ethoxy)benzyl)thiazolidine-2,4-dione); troglitazone (Rezulin, 5-(4-((6-hydroxy-2
- the two distinct pharmaceutical agents include every combination selected from pharmaceutical agents of the following group: sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin, phenformin, metformin, buformin, acarbose, miglitol, voglibose, tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glibenclamide, glimepiride, gliclazide, dapagliflozin, remigliflozin, and sergliflozin.
- pharmaceutical agents of the following group sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin, phenformin, metformin, buformin, acarbose, miglitol, voglibose, tolbutamide, acetohexamide,
- Dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5) exhibits catalytic activity against a broad range of peptide substrates that includes peptide hormones, neuropeptides, and chemokines.
- GIP insulinotropic polypeptide
- PYY Peptide YY
- PYY is a gut peptide that has been implicated in modulating satiety (Chaudhri et al, Annu Rev Physiol (2008) 70:239- 255). PYY is released into the circulation as PYYi_ 36 and PYY 3 _ 36 (Eberlein et al, Peptides (1989) 10:797-803).
- PYY 3 -36 is generated from PYYi_ 36 by cleavage of the N-terminal Tyr and Pro residues by DPP-IV. Both pharmacological and genetic attenuation of DPP-IV activity is associated with enhanced incretin action, increased insulin, and lower blood glucose in vivo. Genetic attenuation of DPP-IV activity has been shown to provide resistance to obesity and to improve insulin sensitivity.
- Inhibitors of DPP-IV have shown to be useful as therapeutics, for example, oral administration of vildagliptin (l-[2-(3-hydroxyadamant-l- ylamino)acetyl]pyrrolidine-2(5)-carbonitrile) or sitagliptin (3(R)-amino-l-[3-(trifluoromethyl)- 5,6,7, 8-tetrahydro[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l -one) to human patients suffering with type 2 diabetes has been found to reduce fasting glucose and postprandial glucose excursion in association with significantly reduced HbA lc levels.
- DPP-IV inhibitors for the treatment of type 2 diabetes, reference is made to the following publications: (1) H.-U. Demuth, et al , "Type 2 diabetes-therapy with DPP-IV inhibitors," Biochim. Biophys. Acta, 1751 : 33-44 (2005), and (2) K. Augustyns, et al , "Inhibitors of proline-specific dipeptidyl peptidases: DPP-IV inhibitors as a novel approach for the treatment of type 2 diabetes", Expert Opin. Ther. Patents, 15: 1387-1407 (2005).
- suitable pharmaceutical agents include inhibitors of DPP-IV that can be used in conjunction with compounds of the present invention either dosed separately or together.
- Inhibitors of DPP-IV are well-known in the art or can be readily identified and their in vitro biological activity determined using any number of methods available, for example, O'Brien, M., Daily, B., Schurria, M., "Assay for DPPIV activity using a homogeneous, luminescent method," Cell Notes, Issue 11, 2005; see also the DPPIV-GloTM Protease Assay Technical Bulletin #TB339.
- DPP-IV inhibitors are described in Villhauer et al. , J. Med. Chem. (2003) 46:2774-2789, for LAF237; Ahren et al., J. Clin. Endocrinol. Metab. (2004) 89:2078-2084;
- DPP-IV inhibitors include, but are not limited to, dipeptide derivatives or dipeptide mimetics such as alanine-pyrrolidide, isoleucine-thiazolidide, and the pseudosubstrate N-valyl prolyl, O-benzoyl hydroxylamine, as described, for example, in U.S. Pat. No. 6,303,661.
- Some embodiments of the present invention include every combination of one or more DPP-IV inhibitors selected from the DPP-IV inhibitors found in U.S. Pat. Nos. 8,071,583, 8,030,315, 7,834,012, 7,671,076, 7,652,021, 7,411,093, 7,348,346, 7,262,207, 7,238,724, 7,235,538, 7,205,409, 7,192,952, 6,869,947, 6,867,205, 6,861,440, 6,849,622, 6,812,350, 6,803,357, 6,800,650, 6,727,261, 6,716,843, 6,710,040, 6,706,742, 6,645,995, 6,617,340, 6,699,871, 6,573,287, 6,432,969, 6,395,767, 6,380,398, 6,303,661, 6,242,422, 6,166,063, 6,100,234, and 6,040,145.
- DPP-IV inhibitors selected from the DPP-IV inhibitors found in U.S. Pat. Nos. 2012082635, 2010323988, 2010160328, 2010120790, 2010093808, 2009149504, 2008275086, 2008176838, 2008119464, 2008064728, 2008027035, 2008015146, 2008009512, 2007265301, 2007265261, 2007238753, 2007197522, 2007142436, 2007100561, 2007049596, 2007015269, 2006276487, 2006264433, 2006135512, 2005215784, 2005215603, 2005209249, 2005148606, 2005131019, 2005059724, 2005059716, 2005043292, 2005038020, 2005032804, 2005004205, 2004259903, 2004259902, 2004259883, 2004259843, 2004254226, 2004242898, 2004229926, 2004180925, 2004176406, 2004138214, 2004121964, 2004116328, 2004110817, 2004106656, 2004
- Some embodiments of the present invention include every combination of one or more DPP-IV inhibitors selected from the DPP-IV inhibitors found in International Patent Application Publication Nos. WO 12/060590, WO 12/017391, WO 11/147207, WO 11/079778, WO 11/037793, WO 11/028455, WO 11/026781, WO 10/146597, WO 10/086411, WO 09/113423, WO 09/037719, WO 09/009751, WO 09/003681, WO 08/144730, WO 08/141021, WO 08/040995, WO 08/040974, WO 08/028662, WO 08/027273, WO 08/017670, WO 07/128761, WO 07/071738, WO 07/071576, WO 07/027651, WO 06/134613, WO 06/104356, WO
- DPP-IV inhibitors selected from the DPP-IV inhibitors found in Patent Publication Nos. EP 2292589, EP 2277509, EP 2175727, EP 2119717, EP 2061474, EP 2057160, EP 2023902, EP 2019099, EP 1966215, EP 1966193, EP 1912706, EP 1905759, EP 1888571, EP 1852108, EP 1851216, EP 1791536, EP 1778682, EP 1758863, EP 1756740, EP 1702916, EP 1682540, EP 1664031, EP 1638968, EP 1633970, EP 1623983, EP 1604989, EP 1604980, EP 1604662, EP 1593671, EP 1561752, EP 1541148, EP 1541143, EP 1517907, EP 1513808, EP 1492777, EP 1490335, EP 1489088, EP 1487807, EP 1480961, EP 1476435, EP 1476429, EP 1469873, EP 146
- the DPP-IV inhibitor has an IC 50 of less than about 10 ⁇ , less than about 1 ⁇ , less than about 100 nM, less than about 75 nM, less than about 50 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, or less than about 1 nM.
- the DPP-IV inhibitor has an IC 50 of less than about 50 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, or less than about 1 nM.
- the DPP-IV inhibitor is a selective DPP-IV inhibitor, wherein the selective DPP-IV inhibitor has a selectivity for human plasma DPP-IV over one or more of PPCE, DPP-II, DPP-8 and DPP-9 of at least about 10-fold. In some embodiments, the DPP-IV inhibitor is a selective DPP-IV inhibitor, wherein the selective DPP-IV inhibitor has a selectivity for human plasma DPP-IV over one or more of PPCE, DPP-II, DPP-8 and DPP-9 of at least about 100-fold.
- the DPP-IV inhibitor is a selective DPP-IV inhibitor, wherein the selective DPP-IV inhibitor has a selectivity for human plasma DPP-IV over one or more of PPCE, DPP-II, DPP-8 and DPP-9 of at least about 10-fold. In some embodiments, the DPP-IV inhibitor is a selective DPP-IV inhibitor, wherein the selective DPP-IV inhibitor has a selectivity for human plasma DPP-IV over one or more of PPCE, DPP-II, DPP-8 and DPP-9 of at least about 1000-fold.
- the DPP-IV inhibitor is orally active.
- the DPP-IV inhibitor is an inhibitor of human DPP-IV.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds of the following group and pharmaceutically acceptable salts, solvates, and hydrates thereof: 3(R)-amino-l -[3-(trifluoromethyl)-5,6,7,8- tetrahydro[l ,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one; l-[2-(3- hydroxyadamant-l-ylamino)acetyl]pyrrolidine-2(5)-carbonitrile; (15,35,55)-2-[2(5)-amino-2-(3- hydroxyadamantan- 1 -yl)acetyl] -2-azabicyclo [3.1.0]hexane-3-carbonitrile ; 2- [6- [3(R)- aminopiperidin-l-yl-
- Sitagliptin phosphate (Januvia®, MK-0431 , dihydrogenphosphate salt of 3(R)-amino-l - [3-(trifluoromethyl)-5,6,7,8-tetrahydro[l ,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l -one) is marketed by Merck & Co. for once -daily oral treatment of type 2 diabetes. Januvia was first launched in Mexico followed by commercialization in the U.S. In 2007, the product was approved by the European Medicines Evaluation Agency (EMEA) and is currently available in the U.K., Germany and Spain.
- EMEA European Medicines Evaluation Agency
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2003/004498 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from 3(R)-amino-l-[3-(trifluoromethyl)-5, 6,7,8- tetrahydro[l ,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the DPP-IV inhibitor is 3(R)-amino-l -[3-(trifluoromethyl)-5, 6,7,8- tetrahydro[l ,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one phosphate:
- the DPP-IV inhibitor is crystalline 3(R)-amino-l -[3-(trifluoromethyl)-5,6,7,8-tetrahydro[l ,2,4]triazolo[4,3-a]pyrazin- 7-yl] -4-(2,4,5-trifluorophenyl)butan- 1 -one phosphate monohydrate.
- Januvia® is also available in combination with a Biguanide and sold as Janumet®.
- Janumet® is a combination of Januvia® and metformin.
- Some aspects of the present invention include compounds of Formula (la) that can be used in any of the methods, pharmaceutical products, uses, compounds, and pharmaceutical agents, as described herein, in combination with two distinct pharmaceutical agents.
- a compound of the present invention is used in combination with Januvia® and a Biguanide.
- a compound of the present invention is used in combination with Janumet® (i.e., Januvia®, 3(R)-amino-l-[3- (trifluoromethyl)-5,6,7,8-tetrahydro[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one, and metformin).
- Janumet® i.e., Januvia®, 3(R)-amino-l-[3- (trifluoromethyl)-5,6,7,8-tetrahydro[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one, and metformin).
- Vildagliptin (Galvus®, LAF-237, l-[2-(3-hydroxyadamant-l- ylamino)acetyl]pyrrolidine-2(5)-carbonitrile) is another DPP-IV inhibitor and was first commercialized in Brazil and Mexico by Novartis for oral, once-daily treatment of type 2 diabetes.
- a marketing authorization application (MAA) was approved in the E.U. for this indication and launch took place in the U.K. in March, 2008.
- An approvable letter has been received for the regulatory application filed in the U.S. Vildagliptin was approved in Japan in 2010.
- the compound, l-[2-(3-hydroxyadamant-l-ylamino)acetyl]pyrrolidine-2(5)-carbonitrile, is disclosed in international patent publication WO2000/034241. Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2000/034241 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from l-[2-(3- hydroxyadamant- 1 -ylamino)acetyl]pyrrolidine-2(5)-carbonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the DPP-IV inhibitor is l-[2-(3-hydroxyadamant-l-ylamino)acetyl]pyrrolidine 2(5)-carbonitrile HCI:
- Saxagliptin (OnglyzaTM, BMS-477118, (15,35,55)-2-[2(5)-amino-2-(3- hydroxyadamantan-l-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile) is another DPP-IV inhibitor, which was launched in 2009 by AstraZeneca and Bristol-Myers Squibb in the U.S. for the treatment of type 2 diabetes. In 2009, the product was approved in the E.U. for the treatment of type 2 diabetes independently or in combination with metformin. Phase 3 clinical studies are ongoing in Japan for the treatment of type 2 diabetes.
- the DPP-IV inhibitor is selected from (15,35,55)-2-[2(5)-amino-2-(3- hydroxyadamantan-l-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the compound, 2-[6-[3(R)-aminopiperidin-l-yl]-3-methyl-2,4-dioxo-l , 2,3,4- tetrahydropyrimidin-l-ylmethyl]benzonitrile, and pharmaceutically acceptable salts thereof are disclosed in international patent publication WO 2005/095381.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO 2005/095381 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from 2-[6-[3(R)- aminopiperidin-l-yl]-3-methyl-2,4-dioxo-l ,2,3,4-tetrahydropyrimidin-l -ylmethyl]benzonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the DPP-IV inhibitor is 2-[6-[3(R)-aminopiperidin-l- yl]-3-methyl-2,4-dioxo- -tetrahydropyrimidin-l-ylmethyl]benzonitrile benzoate:
- Linagliptin (BI-1356, Tradjenta®, 8-[3(R)-aminopiperidin-l -yl]-7-(2-butynyl)-3- methyl-l-(4-methylquinazolin-2-ylmethyl)xanthine) is an inhibitor of DPP-IV approved by the FDA in May 2011 as an adjunct to diet and excerise to improve glycemic control in adults with type 2 diabetes.
- the compound, 8-[3(R)-aminopiperidin-l-yl]-7-(2-butynyl)-3-methyl-l -(4- methylquinazolin-2-ylmethyl)xanthine is disclosed in international patent publication
- WO2004/018468 Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2004/018468 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from 8-[3(R)-aminopiperidin-l-yl]-7-(2-butynyl)-3-methyl-l-(4- methylquinazolin-2-ylmethyl)xanthine, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the DPP-IV inhibitor is a crystalline form of 8-[3(R)- aminopiperidin-l-yl]-7-(2-butynyl)-3-methyl-l -(4-methylquinazolin-2-ylmethyl)xanthine.
- Dutogliptin (PHX-1149, l-[N-[3(R)-pyrrolidinyl]glycyl]pyrrolidin-2(R)-yl boronic acid) is a DPP-IV inhibitor in phase 3 clinical trials by Phenomix and Forest for the oral, once-daily treatment of type 2 diabetes.
- the compound, l-[N-[3(R)-pyrrolidinyl]glycyl] pyrrolidin-2(R)-yl boronic acid, and pharmaceutically acceptable salts thereof are disclosed in international patent publication WO2005/047297.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2005/047297 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from l-[N-[3(R)-pyrrolidinyl]glycyl]pyrrolidin-2(R)-yl boronic acid, and pharmaceutically acceptable salts, solvates, and h drates thereof:
- the DPP-IV inhibitor is l-[N- -pyrrolidinyl]glycyl]pyrrolidin-2(R)-yl boronic acid tartrate:
- Melogliptin (GRC-8200, 4(5)-fluoro-l-[2-[(lR,35)-3-(lH-l ,2,4-triazol-l - ylmethyl)cyclopentylamino]acetyl]pyrrolidine-2(5)-carbonitrile) is a DPP-IV inhibitor currently undergoing phase 2 clinical trials by Glenmark Pharmaceuticals and Merck KGaA for the treatment of type 2 diabetes.
- the compound, 4(5)-fluoro-l -[2-[(lR,35)-3-(lH-l ,2,4-triazol-l - ylmethyl)cyclopentylamino]acetyl]pyrrolidine-2(5)-carbonitrile, is disclosed in international patent publication WO2006/040625.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2006/040625 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from 4(5)-fluoro-l-[2-[(lR,35)-3-(lH-l,2,4-triazol-l- ylmethyl)cyclopentylamino] acetyl]pyrrolidine-2(5)-carbonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Carmegliptin (R-1579, 1-[(2S,3S,1 lbS)-2-amino-9,10-dimethoxy-2,3,4,6,7,l lb- hexahydro-lH-pyrido[2,l-a]isoquinolin-3-yl]-4(5)-(fluoromethyl)pyrrolidin-2-one) is a DPP-IV inhibitor.
- the compound, l-[(25,35,l lb5)-2-amino-9,10-dimethoxy-2,3,4,6,7,l lb-hexahydro- lH-pyrido[2,l-a]isoquinolin-3-yl]-4(5)-(fluoromethyl)pyrrolidin-2-one, is disclosed in international patent publication WO2005/000848. Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2005/000848 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from l-[(2S,3S,l lbS)-2-amino-9,10-dimethoxy- 2,3,4,6,7,11 b-hexahydro- 1 H-pyrido [2, 1 -a] isoquinolin-3-yl] -4(5)-(fluoromethyl)pyrrolidin-2- one, and pharmaceutically ac s thereof:
- ethylamino]acetylpyrrolidine a DPP-IV inhibitor in US patent publication US 2007/0112059.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in US 2007/0112059 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from (25,45)-2-cyano-4-fluoro-l-[(2-hydroxy-l,l- dimethyl)ethylamino]acetylpyrrolidine, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Sanofi-Aventis disclosed a series of substituted bicyclic 8-pyrrolidineoxanthine derivatives as DPP-IV inhibitors in US publication US 2007/0167468. Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in US publication US 2007/0167468 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from 8-(cw-hexahydro-pyrrolo[3,2-b]pyrrol-l-yl)-3-methyl-7-(3-methyl-but-2-enyl)-l -(2-oxo-2- phenylethyl)-3,7-dihydro-purine-2,6-dione, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Pfizer disclosed a series of 3-amino-pyrrolidine-4-lactam derivatives as DPP-IV inhibitors in international patent publication WO2007/148185.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2007/148185 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is l-((35,45)-4-amino-l-(4-(3,3-difluoropyrrolidin-l -yl)- l ,3,5-triazin-2-yl)pyrrolidin-3-yl)-5,5difluoropiperidin-2-one.
- the DPP- IV inhibitor is selected from l-((35,45)-4-amino-l -(4-(3,3-difluoropyrrolidin-l -yl)-l ,3,5-triazin- 2-yl)pyrrolidin-3-yl)-5,5difluoropiperidin-2-one, and pharmaceutically acceptable salts, solvates, and hydrates thereof
- Syrrx disclosed a series of substituted pyrimidine-2,4(lH,3H)-dione derivatives as DPP- IV inhibitors in international patent publication WO2005/095381.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2005/095381 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (R)-2-((6-(3-aminopiperidin-l-yl)-3-methyl-2,4-dioxo- 3,4-dihydropyrimidin-l(2H)-yl)methyl)-4-fluorobenzonitrile.
- the DPP- IV inhibitor is selected from (R)-2-((6-(3-aminopiperidin-l -yl)-3-methyl-2,4-dioxo-3,4- dihydropyrimidin-l(2H)-yl)methyl)-4-fluorobenzonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- One embodiment of the present invention pertains to any one or more crystalline forms of (R)-2-((6-(3-aminopiperidin-l-yl)-3-methyl-2,4- dioxo-3,4-dihydropyrimidin-l(2H)-yl)methyl)-4-fluorobenzonitrile succinic acid salt as described in international patent publication WO2008/067465.
- the DPP- IV inhibitor is crystalline (R)-2-((6-(3-aminopiperidin-l -yl)-3-methyl-2,4-dioxo-3,4- dihydropyrimidin-l(2H)- salt:
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2006/116157 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is 5- ⁇ (5)-2-[2-((5)-2-cyano-pyrrolidin-l -yl)-2-oxo- ethylamino] -propyl ⁇ -5-( 1 H-tetrazol-5 -yl) 10,11 -dihydro-5H-dibenzo [a,d]cycloheptene-2,8- dicarboxylic acid bis-dimethylamide.
- the DPP-IV inhibitor is selected from 5- ⁇ (5)-2-[2-((5)-2-cyano-pyrrolidin-l -yl)-2-oxo-ethylamino]-propyl ⁇ -5-(lH-tetrazol-5- yl) 10,l l-dihydro-5H-dibenzo[a,d]cycloheptene-2,8-dicarboxylic acid bis-dimethylamide, and pharmaceutically acceptable
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2002/0014271 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is ((25,45)-4-(4-(3-methyl-l -phenyl-lH-pyrazol-5- yl)piperazin-l -yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone.
- the DPP- IV inhibitor is selected from ((25,45)-4-(4-(3-methyl-l-phenyl-lH-pyrazol-5-yl)piperazin-l - yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- One embodiment of the present invention pertains to any one or more crystalline forms of ((25,45)-4-(4-(3-methyl-l - phenyl-1 H-pyrazol-5 -yl)piperazin-l -yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone salt as described in international patent publication WO2006/088129 and US publication
- the DPP-IV inhibitor is crystalline ((25,45)-4-(4-(3- methyl-l-phenyl-lH-pyrazol-5-yl)piperazin-l -yl)pyrrolidin-2-yl)(thiazolidin-3-yl)methanone 2.5 hydrobromide salt:
- the DPP-IV inhibitor is crystalline ((25,45) -4-(4-(3-methyl-l -phenyl-lH-pyrazol-5-yl)piperazin-l -yl)pyrrolidin-2-yl)(thiazolidin-3- yl)methanone di-hydrobromide salt.
- Kyorin disclosed a series of pyrrolidinecarbonitrile derivatives as DPP-IV inhibitors in international patent publication WO2008/114857 and US publication US 2008/0146818. Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2008/114857 and US publication US 2008/0146818, and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (25,45)-l -[2-[(4-ethoxycarbonylbicyclo[2.2.2]oct-l -yl)amino]acetyl]-4-fluoropyrrolidine-2- carbonitrile.
- the DPP-IV inhibitor is selected from (25,45)-l -[2-[(4- ethoxycarbonylbicyclo[2.2.2]oct-l-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2006/068163 and US publication US 2009/0192129 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is 6-[(3R)-3-amino-piperidin-l-yl]-5-(2-chloro-5-fluoro-benzyl)-l ,3-dimethyl- l ,5dihydro-pyrrolo[3,2-d]pyrimidine-2,4-dione.
- the DPP-IV inhibitor is selected from 6-[(3R)-3-amino-piperidin-l -yl]-5-(2-chloro-5-fluoro-benzyl)-l ,3-dimethyl- l ,5dihydro-pyrrolo[3,2-d]pyrimidine-2,4-dione, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the DPP-IV inhibitor is crystalline 6-[(3R)-3-amino-piperidin-l-yl]-5-(2-chloro-5- fluoro-benzyl)-l ,3-dimethyl-l ,5dihydro-pyrrolo[3,2-d]pyrimidine-2,4-dione monohydrochloride hemihydrate:
- the DPP-IV inhibitor is selected from 2-( ⁇ 6-[(3R)-3-amino-3- methylpiperidin- 1 -yl] - 1 ,3 -dimethyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-5H-pyrrolo [3 ,2-d]pyrimidin-5 - yl ⁇ methyl)-4-fluorobenzonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Hoffmann-La Roche disclosed a series of N-substituted pyrrolidine derivatives as DPP- IV inhibitors in international patent publication WO 03/037327.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO 03/037327 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (25)-l - ⁇ [2-(5-methyl-2-phenyl-oxazol-4-yl)- ethylamino] -acetyl ⁇ -pyrrolidine-2-carbonitrile.
- the DPP-IV inhibitor is selected from (25)-l- ⁇ [2-(5-methyl-2-phenyl-oxazol-4-yl)-ethylamino] -acetyl ⁇ -pyrrolidine -2- carbonitrile, and pharmaceu ates thereof:
- the DPP-IV inhibitor is (25)-l- ⁇ [2-(5- methyl-2-phenyl-oxazol-4-yl)-ethylamino] -acetyl ⁇ -pyrrolidine-2 -carbonitrile methansulfonic acid salt (i.e. , mesylat
- the DPP-IV inhibitor is selected from (25)- 1- ⁇ [1, 1 -dimethyl-3 -(4-pyridin-3 -yl-imidazol- 1 -yl)-propylamino] -acetyl ⁇ -pyrrolidine -2- carbonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the DPP-IV inhibitor is (2S)-l- ⁇ [l,l-dimethyl-3-(4-pyridin-3-yl- imidazol- 1 -yl) nic acid:
- the DPP-IV inhibitor is (25)- 1- ⁇ [1,1 -dimethyl-3 -(4-pyridin-3 -yl-imidazol- 1 -yl)-propylamino] -acetyl ⁇ -pyrrolidine -2- carbonitrile fumaric acid salt (i.e. , fumarate):
- Pfizer disclosed a series of proline derivatives as DPP-IV inhibitors in international patent publication WO2005/116014.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2005/116014 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (3,3-difluoropyrrolidin- 1 -yl)-((25,45)-4-(4-(pyrimidin-2-yl)piperazin- 1 -yl)pyrrolidin-2- yl)methanone.
- the DPP-IV inhibitor is selected from (3,3- difluoropyrrolidin- 1 -yl)-((25,45)-4-(4-(pyrimidin-2-yl)piperazin- 1 -yl)pyrrolidin-2- yl)methanone, and pharmac ates thereof:
- GlaxoSmithKline disclosed a series of fluoropyrrolidine derivatives as DPP-IV inhibitors in international patent publication WO 03/002531.
- Some embodiments of the present invention include every combination of one or more compounds selected from the DPP-IV inhibitors disclosed in WO 03/037327 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (25,45)-l-[(25)-2-amino-3,3-bis(4- fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile (Denagliptin).
- Denagliptin is (25,45)-l-[(25)-2-amino-3,3-bis(4- fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile
- the DPP-IV inhibitor is selected from (2S,4S)-l-[(2S)-2-amino-3,3-bis(4- fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- One salt disclosed is (25,45)-l-[(25)-2- amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile /?-toluenesulfonic acid salt (also referred to as (25,45)-4-fluoro-l-[4-fluoro- -(4-fluorophenyl)-L-phenylalanyl]-2- pyrrolidinecarbonitrile /?-toluenesulfonic acid salt, or Denagliptin tosylate).
- the DPP-IV inhibitor is (25,45)-l-[(25)-2-amino-3,3-bis(4- fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile /?-toluenesulfonic acid salt:
- Abbott disclosed a series of substituted pyrrolidinyl derivatives as DPP-IV inhibitors in international patent publication WO 2004/026822.
- Some embodiments of the present invention include every combination of one or more compounds selected from the DPP-IV inhibitors disclosed in WO 2004/026822 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (25,5R)-5-ethynyl-l- ⁇ N-(4-methyl-l-(4-carboxy-pyridin-2- yl)piperidin-4-yl)glycyl ⁇ pyrrolidine-2-carbonitrile.
- the DPP-IV inhibitor is selected from (25,5R)-5-ethynyl-l- ⁇ N-(4-methyl-l-(4-carboxy-pyridin-2-yl)piperidin-4- yl)glycyl ⁇ pyrrolidine-2-carbonitrile, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Abbott has further disclosed a series of substituted cyclohexanyl/cyclohexenyl derivatives as DPP-IV inhibitors in international patent publication WO 2007/027651.
- Some embodiments of the present invention include every combination of one or more compounds selected from the DPP-IV inhibitors disclosed in WO 2007/027651 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (15,6R)-3- ⁇ [3- (trifluoromethyl)-5,6-dihydro[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]carbonyl ⁇ -6-(2,4,5- trifluorophenyl)cyclohex-3-en-l -amine.
- the DPP-IV inhibitor is selected from (15,6R)-3- ⁇ [3-(trifluoromethyl)-5,6-dihydro[l ,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]carbonyl ⁇ -6-(2,4,5-trifluorophenyl)cyclohex-3-en-l -amine, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Gemigliptin (LC15-0444, l-[(25)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8- dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one) is another DPP-IV inhibitor under development for the treatment of type 2 diabetes.
- the compound, 1- [(25)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4- oxobutyl]-5,5-difluoropiperidin-2-one, and pharmaceutically acceptable salts thereof are disclosed in international patent publication WO2006/104356.
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2006/104356 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the DPP-IV inhibitor is selected from l -[(25)-2-amino- 4-[2,4-bis(trifluoromethyl)-5 , 8-dihydropyrido [3 ,4-d]pyrimidin-7(6H)-yl] -4-oxobutyl] -5 ,5 - difluoropiperidin-2-one, and ates, and hydrates thereof:
- the DPP-IV inhibitor is 1.5 hydrate L-tartrate salt of l-[(25)-2-amino-4- [2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl]-5,5- difluoropiperidin-2-one :
- the DPP-IV inhibitor is crystalline 1.5 hydrate L-tartrate salt of l-[(25)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8- dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one.
- the DPP-IV inhibitor is crystalline 0.5 hydrate L-tartrate salt of l-[(25)-2-amino- 4-[2,4-bis(trifluoromethyl)-5 , 8-dihydropyrido [3 ,4-d]pyrimidin-7(6H)-yl] -4-oxobutyl] -5 ,5 - difluoropiperidin-2-one.
- the DPP-IV inhibitor is crystalline anhydrous 1- [(25)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4- oxobutyl] -5 ,5 -difluoropiperidin-2-one.
- the biguanides are a class of drugs that stimulate anaerobic glycolysis, increase the sensitivity to insulin in the peripheral tissues, inhibit glucose absorption from the intestine, suppress of hepatic gluconeogenesis, and inhibit fatty acid oxidation.
- biguanides include phenformin ((phenylethyl)biguanide), metformin (dime thy lbiguanide), buformin
- the pharmaceutical agent or the second pharmaceutical agent is a biguanide selected from the following biguanides:
- the pharmaceutical agent or the second pharmaceutical agent is a biguanide selected from (phenylethyl)biguanide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof: In some embodiments, the pharmaceutical agent or the second pharmaceutical agent is a biguanide selected from dimethylbiguanide (chemical structure shown below) and
- the pharmaceutical agent or the second pharmaceutical agent is a biguanide selected from butylbiguanide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof; the chemical structure is as follows:
- the pharmaceutical agent or the second pharmaceutical agent is a biguanide selected from l -(j?-chlorophenyl)-5-isopropylbiguanide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof; the chemical structure is as follows:
- the pharmaceutical agent or the second pharmaceutical agent is a biguanide selected from the following biguanides: metformin, phenformin, buformin, and proguanil.
- the pharmaceutical agent or the second pharmaceutical agent is metformin.
- the pharmaceutical agent or the second pharmaceutical agent is phenformin.
- the pharmaceutical agent or the second pharmaceutical agent is buformin.
- the pharmaceutical agent or the second pharmaceutical agent is proguanil.
- a-Glucosidase inhibitors belong to the class of drugs which competitively inhibit digestive enzymes such as a-amylase, maltase, a-dextrinase, sucrase, etc. in the pancreas and or small intestine.
- the reversible inhibition by a-glucosidase inhibitors retard, diminish or otherwise reduce blood glucose levels by delaying the digestion of starch and sugars.
- a-glucosidase inhibitors include acarbose ((2R,3R,4R,5R)-4- ((2R,3R,4R,55,6R)-5-((2R,3R,45,55,6R)-3,4-dihydroxy-6-methyl-5-((15,4R,55,65)-4,5,6- trihydroxy-3 -(hydroxymethyl)cyclohex-2-enylamino)tetrahydro-2H-pyran-2-yloxy)-3 ,4- dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-2,3,5,6-tetrahydroxyhexanal), miglitol ((2R R,4R,55)-l -(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol), voglibose ((15,25,3R,45,55)-5-(l ,3-dihydroxy
- the pharmaceutical agent or the second pharmaceutical agent is a ⁇ -glucosidase inhibitor selected from the following ⁇ -glucosidase inhibitors:
- the pharmaceutical agent or the second pharmaceutical agent is a ⁇ -glucosidase inhibitor selected from (2R,3R,4R,5R)-4-((2R,3R,4R,55,6R)-5-((2R,3R,45,55,6R)- 3,4-dihydroxy-6-methyl-5-((15,4R,55,65)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2- enylamino)tetrahydro-2H-pyran-2-yloxy)-3,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H- pyran-2-yloxy)-2,3,5,6-tetrahydroxyhexanal (chemical structure shown below) and
- the pharmaceutical agent or the second pharmaceutical agent is a ⁇ -glucosidase inhibitor selected from (2R,3R,4R,55)-l-(2-hydroxyethyl)-2- (hydroxymethyl)piperidine-3,4,5-triol (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hy
- the pharmaceutical agent or the second pharmaceutical agent is a ⁇ -glucosidase inhibitor selected from (15,25,3R,45,55)-5-(l ,3-dihydroxypropan-2-ylamino)-l- (hydroxymethyl)cyclohexane-l ,2,3,4-tetraol (chemical structure shown below) and
- the pharmaceutical agent or the second pharmaceutical agent is an alpha-glucosidase inhibitor selected from: acarbose, miglitol, and voglibose.
- the pharmaceutical agent or the second pharmaceutical agent is acarbose.
- the pharmaceutical agent or the second pharmaceutical agent is miglitol.
- the pharmaceutical agent or the second pharmaceutical agent is voglibose.
- insulin analogue refers to the naturally occurring human hormone and insulin receptor ligands (i.e., synthetic insulin analogues). Insulin receptor ligands are structurally different from the natural human hormone, but have substantially the same activity as human insulin in terms of glycemic control.
- an insulin analogue examples include, NPH insulin (also known as Humulin N, Novolin N, NPH Lletin II, and insulin isophane), insulin lispro (28B-L -lysine -29B-L-proline -insulin, wherein insulin is human insulin), insulin aspart (28B-L-aspartic acid-insulin, wherein insulin is human insulin), insulin glulisine (3B-L -lysine - 29B-L-glutamic acid-insulin, wherein insulin is human insulin), and insulin analogues known in the art.
- NPH insulin also known as Humulin N, Novolin N, NPH Lletin II, and insulin isophane
- insulin lispro 28B-L -lysine -29B-L-proline -insulin, wherein insulin is human insulin
- insulin aspart 28B-L-aspartic acid-insulin, wherein insulin is human insulin
- insulin glulisine 3B-L -lys
- NPH insulin is marketed by Eli Lilly and Company under the name Humulin N, and is considered as an intermediate-acting insulin analogue given to help control the blood sugar level of those with diabetes.
- Insulin lispro is marketed by Eli Lilly and Company under the name
- Insulin aspart is marketed by Novo Nordisk and sold as NovoRapid. Insulin aspart is considered a fast acting insulin analogue.
- Insulin glulisine was developed by Sanofi-Aventis and is sold under the trade name Apidra. Insulin glulisine is considered a rapid acting insulin analogue but shorter duration of action compared to human insulin.
- the pharmaceutical agent or the second pharmaceutical agent is an insulin analogue selected from NPH insulin and pharmaceutically acceptable salts, solvates, and hydrates thereof. In some embodiments, the pharmaceutical agent or the second
- the pharmaceutical agent is an insulin analogue selected from insulin lispro and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the pharmaceutical agent or the second pharmaceutical agent is an insulin analogue selected from insulin aspart and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the pharmaceutical agent or the second pharmaceutical agent is an insulin analogue selected from insulin glulisine and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the sulfonylureas are drugs which promote secretion of insulin from pancreatic beta cells by transmitting signals of insulin secretion via receptors in the cell membranes.
- Examples of a sulfonylurea include tolbutamide (Orinase, N-(butylcarbamoyl)-4- methylbenzenesulfonamide); acetohexamide (Dymelor, 4-acetyl-N-
- glibenclamide also known as glyburide (Diabeta, Micronase, Glynase, 5-chloro-N-(4-(N- (cyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-methoxybenzamide); glimepiride (Amaryl, 3- ethyl-4-methyl-N-(4-(N-((l r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo- 2,5-dihydro-lH-pyrrole-l-carboxamide); gliclazide (Diamicron, N- (hexahydrocyclopenta[c]pyrrol-2(lH)-ylcarb
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from sulfonylureas:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from N-(butylcarbamoyl)-4-methylbenzenesulfonamide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from N-(azepan-l-ylcarbamoyl)-4-methylbenzenesulfonamide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from 4-chloro-N-(propylcarbamoyl)benzenesulfonamide (chemical structure shown below) and ph vates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical ag sulfonylurea selected from N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5- methylpyrazine-2-carboxamide (chemical structure shown below) and pharmaceutically acceptable salts, solva
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from 5-chloro-N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-2- methoxybenzamide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from 3-ethyl-4-methyl-N-(4-(N-((lr,4r)-4- methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro- lH-pyrrole- 1 - carboxamide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from N-(hexahydrocyclopenta[c]pyrrol-2(lH)-ylcarbamoyl)-4- methylbenzenesulfonamide (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from the following sulfonylureas and pharmaceutically acceptable salts, solvates, and hydrates thereof: glipizide, glimepiride, and glibenclamide.
- the pharmaceutical agent or the second pharmaceutical agent is tolbutamide.
- the pharmaceutical agent or the second pharmaceutical agent is acetohexamide.
- the pharmaceutical agent or the second pharmaceutical agent is tolazamide.
- the pharmaceutical agent or the second pharmaceutical agent is chlorpropamide.
- the pharmaceutical agent or the second pharmaceutical agent is glipizide.
- the pharmaceutical agent or the second pharmaceutical agent is glyburide.
- the pharmaceutical agent is glimepiride.
- the pharmaceutical agent or the second pharmaceutical agent is gliclazide.
- Sodium-glucose transporter-2 (SGLT2) inhibitors belong to the class of drugs which inhibit the protein SGLT2 and the reabsorption of glucose in the kidney. The inhibition by SGLT2 inhibitors retard, diminish, or otherwise reduce the amount of glucose that is reabsorbed and therefore is eliminated in the urine.
- SGLT2 inhibitors include dapagliflozin ((25,3R,4R,55,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Bristol-Myers Squibb and AstraZeneca), remogliflozin (ethyl ((2R,35,45,5R,65)-3,4,5-trihydroxy-6-(4-(4-isopropoxybenzyl)-l -isopropyl- 5-methyl-lH-pyrazol-3-yloxy)tetrahydro-2H-pyran-2-yl)methyl carbonate, GlaxoSmithKline), ASP1941 (Kotobuki/Astellas), canagliflozin ((25,3R,4R,55,6R)-2-(3-((5-(4- fluorophenyl)thi
- the pharmaceutical agent or the second pharmaceutical agent is an SGLT2 inhibitor selected from the following SGLT2 inhibitors:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from (25,3R,4R,55,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from ethyl ((2R,35,45,5R,65)-3,4,5-trihydroxy-6-(4-(4-isopropoxybenzyl)- 1 -isopropyl-5-methyl- lH-pyrazol-3-yloxy)tetrahydro-2H-pyran-2-yl)methyl carbonate
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from ethyl ((2R,35,45,5R,65)-3,4,5-trihydroxy-6-(2-(4- methoxybenzyl)phenoxy)tetrahydro-2H-pyran-2-yl)methyl carbonate (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is an SGLT2 inhibitor selected from: dapagliflozin, remigliflozin, and sergliflozin. In some embodiments, the pharmaceutical agent or the second pharmaceutical agent is dapagliflozin. In some embodiments, the pharmaceutical agent or the second pharmaceutical agent is remigliflozin. In some embodiments, the pharmaceutical agent or the second pharmaceutical agent is sergliflozin.
- Astellas and Kotobuki disclosed a series of SGLT2 inhibitors in international patent publication WO2004/080990. Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2004/080990 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is
- the SGLT2 inhibitor is selected from (2R,35,45,5R,65)- 2-(hydroxymethyl)-6-(2-(4-methoxybenzyl)thiophen-3-yloxy)tetrahydro-2H-pyran-3,4,5-triol, and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2005/012326 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- One such compound is (25,3R,4R,55,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
- the SGLT2 inhibitor is selected from (25,3R,4R,55,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4- methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, and pharmaceutically acceptable salts, solvates,
- Boehringer Ingelheim disclosed a series of SGLT2 inhibitors in international patent publication WO2005/092877. Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2005/092877 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- Chugai disclosed a series of SGLT2 inhibitors in international patent publication WO2006/080421. Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2006/080421 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- Lexicon disclosed a series of SGLT2 inhibitors in international patent publication
- WO2008/109591 Some embodiments of the present invention include every combination of one or more compounds selected from compounds disclosed in WO2008/109591 and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- meglitinides promote secretion of insulin by binding to the pancreatic beta cells in a similar manner as sulfonylureas but at an alternative binding site.
- meglitinides include Novo Nordisk's repaglinide (Prandin, (5)-2-ethoxy-4-(2-(3-methyl-l -(2-(piperidin-l - yl)phenyl)butylamino)-2-oxoethyl)benzoic acid), nateglinide (Starlix, (R)-2-((l r,4R)-4- isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid), mitiglinide ((5)-2-benzyl-4- ((3aR,7a5)-lH-isoindol-2(3H,3aH,4H,5H,6H,7H,7aH)-yl)-4-oxobutanoic acid), and the like
- the pharmaceutical agent or the second pharmaceutical agent is a meglitinide selected from the following meglitinides: (5)-2-ethoxy-4-(2-(3-methyl-l-(2- (piperidin-l-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid; (R)-2-((lr,4R)-4- isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid; (S)-2-benzyl-4-((3aR,7aS)-lH- isoindol-2(3H,3aH,4H,5H,6H,7H,7aH)-yl)-4-oxobutanoic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- meglitinides selected from the following meglitinides: (5)-2-ethoxy-4-(2-(3-methyl-l-(2- (piperidin-l
- the pharmaceutical agent or the second pharmaceutical agent is (5)-2-ethoxy-4-(2-(3 -methyl- 1 -(2-(piperidin- 1 -yl)phenyl)butylamino)-2-oxoethyl)benzoic acid (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from (R)-2-((lr,4R)-4-isopropylcyclohexanecarboxamido)-3- phenylpropanoic acid (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a sulfonylurea selected from (S)-2-benzyl-4-((3aR,7aS)-lH-isoindol-
- the pharmaceutical agent or the second pharmaceutical agent is a meglitinide selected from the following meglitinides: repaglinide, nateglinide, mitiglinide, and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the pharmaceutical agent or the second pharmaceutical agent is a meglitinide selected from repaglinide and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the pharmaceutical agent or the second pharmaceutical agent is a meglitinide selected from nateglinide and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the pharmaceutical agent or the second pharmaceutical agent is a meglitinide selected from mitiglinide and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- Thiazolidinediones belong to the class of drugs more commonly known as TZDs. These drugs act by binding to the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARy) activate transcription of a number of specific genes leading to a decrease in insulin resistance.
- TZDs nuclear receptor peroxisome proliferator-activated receptor gamma
- thiazolidinediones examples include rosiglitazone (Avandia, 5-(4-(2- (methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione), pioglitazone (Actos, 5-(4-(2- (5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione), troglitazone (Rezulin, 5-(4-((6- hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione),
- rivoglitazone (5-(4-((6-methoxy-l-methyl-lH-benzo[d]imidazol-2- yl)methoxy)benzyl)thiazolidine-2,4-dione), ciglitazone(5-(4-(( 1 - methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione), and thiazolidinediones known in the art.
- the pharmaceutical agent or the second pharmaceutical agent is a meglitinide selected from: 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4- dione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-(4-((6-methoxy-lH- benzo[d]imidazol-2-yl)methoxy)benzyl)thiazolidine-2,4-dione; 5-(4-((l- methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the pharmaceutical agent or the second pharmaceutical agent is 5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione (chemical structure shown below) and ph ates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is 5-(4-((6-methoxy- 1 -methyl- 1 H-benzo [d] imidazol-2-yl)methoxy)benzyl)thiazolidine-2,4-dione (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is 5-(4-((l-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione (chemical structure shown below) and pharmaceutically acceptable salts, solvates, and hydrates thereof:
- the pharmaceutical agent or the second pharmaceutical agent is a thiazolidinedione selected from rosiglitazone and pharmaceutically acceptable salts, solvates, and hydrates thereof. In some embodiments, the pharmaceutical agent or the second pharmaceutical agent is a thiazolidinedione selected from pioglitazone and pharmaceutically acceptable salts, solvates, and hydrates thereof. In some embodiments, the pharmaceutical agent or the second pharmaceutical agent is a thiazolidinedione selected from troglitazone and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- the pharmaceutical agent or the second pharmaceutical agent is a thiazolidinedione selected from rivoglitazone and pharmaceutically acceptable salts, solvates, and hydrates thereof. In some embodiments, the pharmaceutical agent or the second pharmaceutical agent is a
- thiazolidinedione selected from ciglitazone and pharmaceutically acceptable salts, solvates, and hydrates thereof.
- Anti-diabetic peptide analogues are peptides that promote secretion of insulin by acting as an incretin mimetic, such as, GLP-1 and GIP.
- examples of an anti-diabetic peptide analog include, exenatide, liraglutide, taspoglutide, and anti-diabetic peptides analogues know in the art.
- the pharmaceutical agent or the second pharmaceutical agent is an anti-diabetic peptide analogue selected from: exenatide; liraglutide; and taspoglutide.
- the pharmaceutical agent or the second pharmaceutical agent is exenatide.
- the pharmaceutical agent or the second pharmaceutical agent is liraglutide.
- the pharmaceutical agent or the second pharmaceutical agent is taspoglutide.
- the pharmaceutical agent or the second pharmaceutical agent is L-histidylglycyl-L-a-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a- aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a- glutamyl -L-alanyl-L-valyl-L-arginyl-L-leucyl -L-phenylalanyl-L -isoleucyl-L-a-glutamyl-L- tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl
- the pharmaceutical agent or the second pharmaceutical agent is L-histidyl-L-alanyl-L-a-glutamylglycyl-L-threonyl -L-phenylalanyl-L -threonyl-L-seryl-L-a- aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-a-glutamylglycyl-L-glutaminyl-L-alanyl- L-alanyl-N6- [N-( 1 -oxohexadecyl)-L-a-glutamyl] -L-lysyl-L-a-glutamyl-L-phenylalanyl-L- isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylg
- the pharmaceutical agent or the second pharmaceutical agent is
- Another object of the present invention relates to radio-labeled compounds of the present invention that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating GPR119 receptors in tissue samples, including human and for identifying GPR119 receptor ligands by inhibition binding of a radio-labeled compound. It is a further object of this invention to develop novel GPR119 receptor assays of which comprise such radio-labeled compounds.
- the present disclosure includes all isotopes of atoms occurring in the present compounds, intermediates, salts and crystalline forms thereof.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- One aspect of the present invention includes every combination of one or more atoms in the present compounds, intermediates, salts, and crystalline forms thereof that is replaced with an atom having the same atomic number but a different mass number.
- One such example is the replacement of an atom that is the most naturally abundant isotope, such as l H or 12 C, found in one the present compounds,
- Isotopic-labeling of the present compounds, intermediates, salts, and crystalline forms thereof can be accomplished using any one of a variety of different synthetic methods know to those of ordinary skill in the art and they are readily credited with understanding the synthetic methods and available reagents needed to conduct such isotopic- labeling.
- isotopes of hydrogen include 2 H (deuterium) and 3 H (tritium).
- Isotopes of carbon include n C, 13 C, and 14 C.
- Isotopes of nitrogen include 13 N and 15 N.
- Isotopes of oxygen include 15 O, 17 O, and 18 C.
- An isotope of fluorine includes 18 F.
- An isotope of sulfur includes 35 S.
- An isotope of chlorine includes 36 C1.
- Isotopes of bromine include 75 Br, 76 Br, 77 Br, and 82 Br.
- Isotopes of iodine include 123 I, 124 I, 125 I, and 131 I.
- compositions such as, those prepared during synthesis, preformulation, and the like, and pharmaceutical compositions, such as, those prepared with the intent of using in a mammal for the treatment of one or more of the disorders described herein, comprising one or more of the present compounds, intermediates, salts, and crystalline forms thereof, wherein the naturally occurring distribution of the isotopes in the composition is perturbed.
- compositions and pharmaceutical compositions comprising compounds as described herein wherein the compound is enriched at one or more positions with an isotope other than the most naturally abundant isotope.
- isotopically-labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays.
- the radionuclide 3 H and/or 14 C isotopes are useful in these studies.
- substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Drawings and Examples infra, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art. These synthetic methods, for example, incorporating activity levels of tritium into target molecules, are as follows:
- Tritium Gas Exposure Labeling This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst.
- Synthetic methods for incorporating activity levels of 125 I into target molecules include:
- Aryl and heteroaryl bromide exchange with 125 I This method is generally a two step process.
- the first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, a Pd catalyzed reaction [i.e. Pd(Ph 3 P) 4 ] or through an aryl or heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g.,
- a radiolabeled GPR119 receptor compound of Formula (la) can be used in a screening assay to identify/evaluate compounds.
- a newly synthesized or identified compound i.e., test compound
- test compound can be evaluated for its ability to reduce binding of the "radiolabeled compound of Formula (la)" to a GPR119 receptor. Accordingly, the ability of a test compound to compete with the "radiolabeled compound of Formula (la)" for the binding to a GPR119 receptor directly correlates to its binding affinity.
- Certain labeled compounds of the present invention bind to certain GPR119 receptors.
- the labeled compound has an IC 50 less than about 500 ⁇ , in another embodiment the labeled compound has an IC 50 less than about 100 ⁇ , in yet another embodiment the labeled compound has an IC 50 less than about 10 ⁇ , in yet another embodiment the labeled compound has an IC 50 less than about 1 ⁇ and in still yet another embodiment the labeled compound has an IC 50 less than about 0.1 ⁇ .
- Example 1 Syntheses of Compounds of the Present Invention.
- TLC Thin-layer chromatography
- PK6F silica gel 60 A 1 mm plates Whatman
- column chromatography i.e., CC
- BiotageTM or Flash Chromatatography was carried out using BiotageTM or Flash Chromatatography on silica gel, such as, Kieselgel 60, 0.063-0.200 mm (Merck) unless otherwise indicated.
- Evaporation was done under reduced pressure on a Biichi rotary evaporator.
- LCMS spec HPLC-pumps: LC-10AD VP, Shimadzu Inc.; HPLC system controller: SCL-IOA VP, Shimadzu Inc; UV-Detector: SPD-10A VP, Shimadzu Inc; Autosampler: CTC HTS, PAL, Leap Scientific; Mass spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex; Software: Analyst 1.2.
- Example 1.1 Preparation of (ls,4s)-4-(l-Methylpiperidin-4-yloxy)cyclohexanol and (lr,4r)-4-(l-Methylpiperidin-4-yloxy)cyclohexanol.
- Step A Preparation of 4-(l,4-Dioxaspiro[4.5]decan-8-yloxy)pyridine.
- Step B Preparation of 4-(Pyridin-4-yloxy)cyclohexanone.
- 4-(l,4-dioxaspiro[4.5]decan-8-yloxy)pyridine 169.5 g, 720 mmol
- water 1,500 mL
- 6 M HCl solution in water (240 mL, 1,441 mmol).
- the reaction mixture was stirred at 50 °C overnight.
- LCMS showed 95% conversion to the product and 5% starting material.
- the reaction mixture was cooled to 24 °C, and most of the organic solvent was removed under reduced pressure at 30 °C to give the aqueous solution (1,150 mL) to which water (650 mL) was added.
- the solution was adjusted to pH 6 by addition of solid potassium phosphate tribasic (194 g, 914 mmol) at room temperature portionwise while stirring over 10 min to give a turbid mixture.
- the mixture was then adjusted to pH 7-8 by addition of solid dibasic potassium phosphate (159 g, 914 mmol) at room temperature portionwise while stirring over about 10 min.
- the resulting mixture was stirred for 20 min at room temperature then extracted with 12% IPA-DCM (3 x 900 mL, 1 x 450 mL).
- Step C Preparation of (ls,4s)-4-(Pyridin-4-yloxy)cyclohexanol and (lr,4r)-4-
- the solid was filtered to give the cis product ( ⁇ 87 g, at least 96% cis via HPLC).
- the filtrate was extracted with IPA/DCM (1 :3), dried over anhydrous Na 2 S0 4 , filtered and concentrated to give a mixture of cisltrans.
- This mixture containing cisltrans products was also triturated with acetone to provide a precipitate.
- the precipitate was collected to give the trans enriched product (70-80% pure), which was then triturated with acetone to give the pure trans product ( ⁇ 25 g). After isolating the cis and trans products, the remaining cisltrans mixture weighed
- Step D Preparation of 4-((lr,4r)-4-Hydroxycyclohexyloxy)-l-methylpyridinium iodide.
- Step E Preparation of (lr,4r)-4-(l-Methyl-l,2,3,6-tetrahydropyridin-4- yloxy)cyclohexanol.
- Step F Preparation of (lr,4r)-4-(l-Methylpiperidin-4-yloxy)cyclohexanol.
- Example 1.2 Preparation of 4-((lr,4r)-4-(l-(3-Isopropyl-l,2,4-oxadiazol-5-yl)piperidin-4- yloxy)cyclohexyloxy)nicotinonitrile (Compound 2).
- Step A Preparation of 4-((lr,4r)-4-Hydroxycyclohexyloxy)piperidine-l- carbonitrile
- Step B Preparation of (lr,4r)-4-(l-(3-Isopropyl-l,2,4-oxadiazol-5-yl)piperidin-4- yloxy)cyclohexanol.
- Step C Preparation of 4-((lr,4r)-4-(l-(3-Isopropyl-l,2,4-oxadiazol-5-yl)piperidin- 4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 2).
- Example 1.3 Preparation of 5-(4-((lr,4r)-4-(3-Fluoropyridin-4- yloxy)cyclohexyloxy)piperidin-l-yl)-3-isopropyl-l,2,4-oxadiazole (Compound 3).
- Example 1.4 Preparation of 3-Isopropyl-5-(4-((lr,4r)-4-(3-(trifluoromethyl)pyridin-4- yloxy)cyclohexyloxy)piperidin-l-yl)-l,2,4-oxadiazole (Compound 4).
- Step A Preparation of 4-((lr,4r)-4-(l-Methylpiperidin-4- yloxy)cyclohexyloxy)nicotinonitrile.
- Step B Preparation of 4-((lr,4r)-4-(Piperidin-4- yloxy)cyclohexyloxy)nicotinonitrile.
- Step C Preparation of (S)-l,l,l-Trifluoropropan-2-yl 4-((lr,4r)-4-(3-cyanopyridin- 4-yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 5).
- Example 1.7 Preparation of 4-((lr,4r)-4-(l-(3-(Trifluoromethyl)-l,2,4-oxadiazol-5- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 8).
- Step A Preparation of (lr,4r)-4-(l-(3-(Trifluoromethyl)-l,2,4-oxadiazol-5- yl)piperidin-4-yloxy)cyclohexanol.
- 4-((lr,4r)-4-hydroxycyclohexyloxy)piperidine-l-carbonitrile (0.2 g, 0.892 mmol) and 2,2,2-trifluoro-N-hydroxyacetimidamide (0.206 g, 1.605 mmol) in THF (4 mL) was added 0.5 M zinc(II) chloride solution in THF (3.567 mL, 1.783 mmol).
- Step B Preparation of 4-((lr,4r)-4-(l-(3-(Trifluoromethyl)-l,2,4-oxadiazol-5- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 8).
- Example 1.8 Preparation of 4-((lr,4r)-4-(l-(3-(2-Fluoropropan-2-yl)-l,2,4-oxadiazol-5- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 9).
- Step A Preparation of (lr,4r)-4-(l-(3-(2-Fluoropropan-2-yl)-l,2,4-oxadiazol-5- yl)piperidin-4-yloxy)cyclohexanol.
- Step B Preparation of 4-((lr,4r)-4-(l-(3-(2-Fluoropropan-2-yl)-l,2,4-oxadiazol-5- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 9).
- Step A Preparation of l-(Trifluoromethyl)cyclobutyl lH-imidazole-l-carboxylate.
- Step A Preparation of Perfluorophenyl 3-(Trifluoromethyl)oxetan-3-yl carbonate.
- Step B Preparation of 3-(Trifluoromethyl)oxetan-3-yl 4-((lr,4r)-4-(3- cyanopyridin-4-yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 12).
- Step A Preparation of 3-Methyl-4-((lr,4r)-4-(l-methylpiperidin-4- yloxy)cyclohexyloxy)pyridine.
- Step B Preparation of 3-Methyl-4-((lr,4r)-4-(piperidin-4- yloxy)cyclohexyloxy)pyridine.
- Step C Preparation of (fl)-l,l,l-Trifluoropropan-2-yl 4-((lr,4r)-4-(3- methylpyridin-4-yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 14).
- Example 1.12 Preparation of (fl)-l,l,l-Trifluoropropan-2-yl 4-((lr,4r)-4-(3- cyclopropylpyridin-4-yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 18).
- Example 1.13 Preparation of 5-(4-((lr,4r)-4-(3,5-Difluoropyridin-4- yloxy)cyclohexyloxy)piperidin-l-yl)-3-isopropyl-l,2,4-oxadiazole (Compound 19).
- Example 1.14 Preparation of 4-((lr,4r)-4-(l-(3-Isopropyl-l,2,4-oxadiazol-5-yl)piperidin-4- yloxy)cyclohexyloxy)nicotinamide (Compound 22).
- Example 1.15 Preparation of 4-((lr,4r)-4-(l-(3-Isopropyl-l,2,4-oxadiazol-5-yl)piperidin-4- yloxy)cyclohexyloxy)nicotinic acid as the TFA Salt (Compound 23).
- Example 1.16 Preparation of 3-Isopropyl-5-(4-((lr,4r)-4-(3-methoxypyridin-4- yloxy)cyclohexyloxy)piperidin-l-yl)-l,2,4-oxadiazole (Compound 25).
- Step A Preparation of 4-Chloro-3-methoxypyridine.
- 4-chloropyridin-3-ol 200 mg, 1.544 mmol
- triphenylphosphine 0.810 g, 3.088 mmol
- MeOH 0.810 g, 3.088 mmol
- MeOH 0.810 g, 3.088 mmol
- MeOH 0.610 mL, 3.088 mmol
- the reaction was stirred at room temperature for 1 h.
- the mixture was concentrated under reduced pressure and the residue was triturated with EtOAc to precipitate triphenylphosphine oxide.
- Step B Preparation of 3-Isopropyl-5-(4-((lr,4r)-4-(3-methoxypyridin-4- yloxy)cyclohexyloxy)piperidin-l-yl)-l,2,4-oxadiazole (Compound 25).
- Example 1.17 Preparation of 5-(4-((lr,4r)-4-(3-Fluoro-5-(lH-l,2,4-triazol-l-yl)pyridin-4- yloxy)cyclohexyloxy)piperidin-l-yl)-3-isopropyl-l,2,4-oxadiazole (Compound 27).
- Example 1.18 Preparation of 1-Methylcyclopropyl 4-((lr,4r)-4-(3-Cyanopyridin-4- yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 29).
- Step A Preparation of 2,5-Dioxopyrrolidin-l-yl 1-Methylcyclopropyl carbonate.
- MeCN MeCN
- triethylamine 11.60 mL, 83 mmol
- N,N'-disuccinimidyl carbonate 10.66 g, 41.6 mmol.
- the mixture was stirred at room temperature for 2.5 days.
- the mixture was washed with saturated NaHC0 3 (aq) and brine, dried over anhydrous Na 2 S0 4 , and concentrated under reduced pressure.
- Step B Preparation of 1-Methylcyclopropyl 4-((lr,4r)-4-(3-Cyanopyridin-4- yloxy)cyclohexyloxy)piperidine-l-carboxylate(Compound 29).
- Example 1.19 Preparation of 4-((lr,4r)-4-(l-(5-(Trifluoromethyl)-l,2,4-oxadiazol-3- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 7).
- Step A Preparation of 4-((lr,4r)-4-Hydroxycyclohexyloxy)piperidine-l- carbonitrile.
- Step B Preparation of N'-Hydroxy-4-((lr,4r)-4-hydroxycyclohexyloxy)piperidine-
- Step C Preparation of (lr,4r)-4-(l-(5-(Trifluoromethyl)-l,2,4-oxadiazol-3- yl)piperidin-4-yloxy)cyclohexanol.
- Step D Preparation of 4-((lr,4r)-4-(l-(5-(Trifluoromethyl)-l,2,4-oxadiazol-3- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 7).
- Example 1.20 Preparation of 5-(4-((lr,4r)-4-(3-Chloropyridin-4- yloxy)cyclohexyloxy)piperidin-l-yl)-3-isopropyl-l,2,4-oxadiazole (Compound 20).
- Example 1.22 Preparation of 4-((lr,4r)-4-(l-(5-(2-Fluoropropan-2-yl)-l,2,4-oxadiazol-3- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 10).
- Step A Preparation of (lr,4r)-4-(l-(5-(2-Fluoropropan-2-yl)-l,2,4-oxadiazol-3- yl)piperidin-4-yloxy)cyclohexanol.
- Step B Preparation of 4-((lr,4r)-4-(l-(5-(2-Fluoropropan-2-yl)-l,2,4-oxadiazol-3- yl)piperidin-4-yloxy)cyclohexyloxy)nicotinonitrile (Compound 10).
- Example 1.23 Preparation of CR)-l,l,l-Trifluoropropan-2-yl 4-((lr,4r)-4-(3-iodopyridin-4- yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 13).
- Step A Preparation of 3-Iodo-4-((lr,4r)-4-(l-methylpiperidin-4- yloxy)cyclohexyloxy)pyridine.
- Step B Preparation of 3-Iodo-4-((lr,4r)-4-(piperidin-4- yloxy)cyclohexyloxy)pyridine.
- Step C Preparation of CR)-l,l,l-Trifluoropropan-2-yl 4-((lr,4r)-4-(3-iodopyridin- 4-yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 13).
- Example 1.24 Preparation of (fl)-l,l,l-Trifluoropropan-2-yl 4-((lr,4r)-4-(3- ethynylpyridin-4-yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 15).
- Ethynyltrimethylsilane (20.0 ⁇ , 0.148 mmol) was added and the flask was wrapped in aluminum foil and allowed to stir for 2 d at room temperature. Water was added and the aqueous layer was extracted with DCM. The combined extracts were dried (sodium sulfate) and then passed through a plug of silica gel (rinsing with 10% MeOH in DCM).
- Example 1.25 Preparation of CR)-l,l,l-Trifluoropropan-2-yl 4-((lr,4r)-4-(3-ethylpyridin- 4-yloxy)cyclohexyloxy)piperidine-l-carboxylate (Compound 17).
Abstract
La présente invention concerne des composés de Formule (Ia) et des sels, solvates, hydrates et N-oxydes pharmaceutiquement acceptables de ceux-ci, qui sont utiles en tant qu'agents pharmaceutiques uniques ou en combinaison avec un ou plusieurs agents pharmaceutiques supplémentaires, tels qu'un inhibiteur de DPP-IV, un biguanide, un inhibiteur d'alpha-glucosidase, un analogue de l'insuline, une sulfonylurée, un inhibiteur de SGLT2, un méglitinide, une thiazolidinedione ou un analogue d'un peptide antidiabétique, dans le traitement de, par exemple, un trouble choisi parmi : un trouble associé au récepteur GPR119 ; un état amélioré par l'augmentation de la sécrétion d'une incrétine ; un état amélioré par l'augmentation du taux d'incrétine sanguin ; un état caractérisé par une faible masse osseuse ; un trouble neurologique ; un trouble associé au métabolisme ; un diabète de type 2 ; l'obésité et des complications associées à ceux-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161494591P | 2011-06-08 | 2011-06-08 | |
US61/494,591 | 2011-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012170702A1 true WO2012170702A1 (fr) | 2012-12-13 |
Family
ID=46513825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/041375 WO2012170702A1 (fr) | 2011-06-08 | 2012-06-07 | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012170702A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014011926A1 (fr) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique |
US8933083B2 (en) | 2003-01-14 | 2015-01-13 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11279702B2 (en) | 2020-05-19 | 2022-03-22 | Kallyope, Inc. | AMPK activators |
US11407768B2 (en) | 2020-06-26 | 2022-08-09 | Kallyope, Inc. | AMPK activators |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
US11884626B2 (en) | 2015-06-22 | 2024-01-30 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
Citations (298)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016339A1 (fr) | 1990-04-14 | 1991-10-31 | New England Medical Center Hospitals, Inc. | Inhibiteurs de dipeptidyl-aminopeptidase de type iv |
DD296075A5 (de) | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
WO1993008259A2 (fr) | 1991-10-22 | 1993-04-29 | New England Medical Center Hospitals, Inc. | Inhibiteurs de dipeptidyl-aminopeptidase de type iv |
WO1993010127A1 (fr) | 1991-11-22 | 1993-05-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Procede de production d'un ester de prolineboronate |
WO1995015309A1 (fr) | 1993-12-03 | 1995-06-08 | Ferring B.V. | Inhibiteurs de la dp-iv-serine protease |
WO1995029691A1 (fr) | 1994-04-28 | 1995-11-09 | Georgia Tech Research Corporation | Derives de la proline phosphonate |
DE19616486A1 (de) | 1996-04-25 | 1997-10-30 | Knoell Hans Forschung Ev | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
JPH1081666A (ja) | 1996-06-12 | 1998-03-31 | Ishihara Sangyo Kaisha Ltd | フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
WO1998018763A1 (fr) | 1996-10-25 | 1998-05-07 | Tanabe Seiyaku Co., Ltd. | Derives de tetrahydroisoquinoline |
WO1998019998A2 (fr) | 1996-11-07 | 1998-05-14 | Novartis Ag | 2-cyanopyrrolidines a substitution n |
JPH10182613A (ja) | 1996-10-25 | 1998-07-07 | Tanabe Seiyaku Co Ltd | テトラヒドロイソキノリン誘導体 |
WO1998050066A1 (fr) | 1997-05-07 | 1998-11-12 | Trustees Of Tufts College | Potentialisation de la reponse immunitaire par production de composes se fixant a une dipeptidase cytoplasmique |
CA2289124A1 (fr) | 1997-05-07 | 1998-11-12 | Trustees Of Tufts College | Utilisation d'un inhibiteur du cd26 pour preparer un medicament traitant le vih |
WO1999016864A1 (fr) | 1997-09-29 | 1999-04-08 | Point Therapeutics, Inc. | Stimulation de cellules hematopoietiques in vitro |
WO1999025719A1 (fr) | 1997-11-18 | 1999-05-27 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation |
WO1999056753A1 (fr) | 1998-05-04 | 1999-11-11 | Point Therapeutics, Inc. | Stimulation hematopoietique |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
WO1999062914A1 (fr) | 1998-06-05 | 1999-12-09 | Point Therapeutics, Inc. | Composes cycliques de boroproline |
WO1999067278A1 (fr) | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Promedicaments d'inhibiteurs de la dipeptidylpeptidase iv |
DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
WO2000010549A1 (fr) | 1998-08-21 | 2000-03-02 | Point Therapeutics, Inc. | Regulation de l'activite de substrat |
WO2000023421A1 (fr) | 1998-10-22 | 2000-04-27 | Idun Pharmaceuticals, Inc. | INHIBITEURS ACYLE(SUBSTITUE) DIPEPTIDYLE DE LA FAMILLE ICE/ced-3 DES CYSTEINES PROTEASES |
WO2000031258A2 (fr) | 1998-11-20 | 2000-06-02 | Arena Pharmaceuticals, Inc. | Recepteurs humains couples a la proteine g orphan |
WO2000034241A1 (fr) | 1998-12-10 | 2000-06-15 | Novartis Ag | 2-cyanopyrrolidines n-substitues |
JP2000191616A (ja) | 1998-12-24 | 2000-07-11 | Senju Pharmaceut Co Ltd | 新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬 |
WO2000056296A2 (fr) | 1999-03-23 | 2000-09-28 | Ferring Bv | Compositions favorisant la fecondite |
WO2000056297A2 (fr) | 1999-03-23 | 2000-09-28 | Ferring B.V. | Compositions favorisant la croissance |
WO2000069868A1 (fr) | 1999-05-17 | 2000-11-23 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Analogues de la sulphostine et procede de preparation de la sulphostine et de ses analogues |
WO2000071135A1 (fr) | 1999-05-25 | 2000-11-30 | Point Therapeutics, Inc. | Agents anti-tumorales contenant des composes de boroproline |
WO2001034594A1 (fr) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs |
WO2001052825A2 (fr) | 2000-01-21 | 2001-07-26 | Novartis Ag | Combinaisons comprenant un inhibiteur de la dipeptidylpeptidase - iv |
WO2001055105A1 (fr) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | 2-cyanopyroles et -pyrrolines a substitution n inhibant l'enzyme dpp-iv |
WO2001068603A2 (fr) | 2000-03-10 | 2001-09-20 | Bristol-Myers Squibb Co. | Inhibiteurs de la dipeptidyl peptidase iv, a base de pyrrolidone fusionnee a du cyclopropyle, et procede |
US20010031780A1 (en) | 2000-01-24 | 2001-10-18 | Anders Kanstrup | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
WO2001081337A1 (fr) | 2000-04-26 | 2001-11-01 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv |
WO2001081304A1 (fr) | 2000-04-26 | 2001-11-01 | Ferring Bv | Inhibiteurs de dipeptidyl peptidase iv |
WO2001096295A2 (fr) | 2000-06-13 | 2001-12-20 | Novartis Ag | Composes organiques |
WO2001097808A1 (fr) | 2000-06-19 | 2001-12-27 | Smithkline Beecham Plc | Combinaisons d'inhibiteurs de peptidase iv de dipeptidyl et d'autres agents antidiabetiques pour traiter le diabete sucre |
WO2002001427A1 (fr) | 2000-06-29 | 2002-01-03 | Worldsmart Technology Pty Ltd | Protection contre les depenses impulsives |
WO2002002560A2 (fr) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Composes heterocycliques inhibiteurs de l'enzyme dpp-iv |
US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
WO2002014271A1 (fr) | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
WO2002030890A1 (fr) | 2000-10-06 | 2002-04-18 | Tanabe Seiyaku Co., Ltd. | Composes azotes a noyau a cinq elements |
WO2002034900A1 (fr) | 2000-10-27 | 2002-05-02 | The University Of Sydney | Dipeptidyl peptidases |
WO2002038541A1 (fr) | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Derives de cyanopyrrolidine |
US6410508B1 (en) | 1998-10-07 | 2002-06-25 | Med College Georgia Res Inst | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
WO2002051836A1 (fr) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de dipeptidyl peptidase iv |
WO2002055088A1 (fr) | 2001-01-16 | 2002-07-18 | Nippon Kayaku Kabushiki Kaisha | Remedes destines au traitement de la suppression de la moelle osseuse et de maladies infectieuses et agents permettant d'augmenter la concentration leucocytaire du sang |
US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO2002062764A1 (fr) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Composes heterocycliques condenses |
WO2002068420A1 (fr) | 2001-02-24 | 2002-09-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Derives xanthine, fabrication et utilisations en tant qu'agents pharmaceutiques |
JP2002265439A (ja) | 2001-03-08 | 2002-09-18 | Mitsubishi Pharma Corp | シアノピロリジン誘導体およびその医薬用途 |
EP1245568A1 (fr) | 2001-03-28 | 2002-10-02 | Les Laboratoires Servier | Dérives sulfonyles d'-aminoacides et leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV ( DPP IV) |
WO2002076450A1 (fr) | 2001-03-27 | 2002-10-03 | Merck & Co., Inc. | Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete |
WO2002083109A1 (fr) | 2001-04-11 | 2002-10-24 | Ferring Bv | Traitement du diabete de type 2 a l'aide d'inhibiteurs de dipeptidylpeptidase iv |
WO2002083128A1 (fr) | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | Inhibiteurs a base de 2,1-oxazoline et 1,2-pyrazoline de la dipeptidyl peptidase iv et methode associee |
EP1258476A1 (fr) | 2001-05-15 | 2002-11-20 | Les Laboratoires Servier | Dérivés d'alpha-amino-acides, leur procédé de préparation ainsi que leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV (DPP IV) |
JP2002356472A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 含窒素五員環化合物 |
JP2002356471A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
WO2003000250A1 (fr) | 2001-06-25 | 2003-01-03 | Ferring Bv | Agents antidiabetiques a base de 3-fluoro-pyrrolidines |
WO2003000181A2 (fr) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Inhibiteurs de dipeptidyl peptidase utilises dans le traitement du diabete |
WO2003000180A2 (fr) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete |
WO2003002530A2 (fr) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase |
WO2003002595A2 (fr) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Nouveaux inhibiteurs de dipeptidylpeptidase iv et leurs utilisations en tant qu'agents anti-cancereux |
WO2003002593A2 (fr) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv |
WO2003002531A2 (fr) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
WO2003002553A2 (fr) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
WO2003004496A1 (fr) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Derives de purine inhibiteurs de dpp-iv pour le traitement du diabete |
WO2003004498A1 (fr) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Pyrazines beta-amino tetrahydroimidazo (1, 2-a) et pyrazines tetrahydrotrioazolo (4, 3-a) utilisees en tant qu'inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete |
WO2003022871A2 (fr) | 2001-09-06 | 2003-03-20 | Probiodrug Ag | Nouveaux inhibiteurs de dipeptidylpeptidase i |
WO2003024965A2 (fr) | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Composes heterocycliques constituant des inhibiteurs de l'enzyme dpp-iv |
WO2003024942A1 (fr) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Derive thiazolidine et son utilisation medicamenteuse |
WO2003035067A1 (fr) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv (dp-iv) tenant lieu d'agents anti-diabetiques |
WO2003035057A1 (fr) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Inhibiteurs de la dipeptidyl peptidase iv |
WO2003037327A1 (fr) | 2001-10-26 | 2003-05-08 | F. Hoffmann-La-Roche Ag | Derives de pyrrolidine n-substitues en tant qu'inhibiteurs de la dipeptidyl peptidase iv |
WO2003038123A2 (fr) | 2001-10-31 | 2003-05-08 | Novartis Ag | Procede de traitement du diabete et conditions apparentees basees sur des polymorphismes dans le gene tcf1 |
WO2003040174A2 (fr) | 2001-11-09 | 2003-05-15 | Probiodrug Ag | Composes d'aminocetone substitues |
CA2466870A1 (fr) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Techniques de traitement de maladies auto-immunes et reactifs associes |
US20030105077A1 (en) | 2001-07-03 | 2003-06-05 | Kanstrup Anders Bendtz | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US20030119750A1 (en) | 2001-06-27 | 2003-06-26 | Hans-Ulrich Demuth | Use of dipeptidyl peptidase IV inhibitors |
US20030119738A1 (en) | 2001-09-06 | 2003-06-26 | Andre Niestroj | Novel inhibitors of dipeptidyl peptidase I |
US20030125304A1 (en) | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
WO2003055881A1 (fr) | 2001-12-27 | 2003-07-10 | F. Hoffmann-La Roche Ag | Derives de pyrido(2,1-a)isoquinoline comme inhibiteurs dpp-iv |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
WO2003057144A2 (fr) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Changement d'inhibiteurs de la dipeptidyl peptidase iv |
WO2003068748A1 (fr) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Nouveaux derives de pyridine et de quinoline |
WO2003068757A1 (fr) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Nouveaux derives de pyridine et de pyrimidine |
EP1338592A1 (fr) | 2002-02-22 | 2003-08-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Dérivés de 2-phénylpipérazine |
JP2003238566A (ja) | 2001-02-02 | 2003-08-27 | Takeda Chem Ind Ltd | 縮合複素環化合物 |
EP1338651A1 (fr) | 2000-12-01 | 2003-08-27 | Yamanouchi Pharmaceutical Co. Ltd. | Procede de depistage d'un remede |
EP1338595A2 (fr) | 2002-02-25 | 2003-08-27 | Eisai Co., Ltd. | Dérivés de Xanthines servant d'inhibiteurs de DPP-IV |
US20030162820A1 (en) | 2002-02-28 | 2003-08-28 | Hans-Ulrich Demuth | Glutaminyl based DPIV inhibitors |
WO2003072528A2 (fr) | 2002-02-08 | 2003-09-04 | Idun Pharmaceuticals, Inc. | Inhibiteurs de dipeptidyle d'acide substitue de la famille ice/ced-3 des proteases de cysteine |
US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO2003074500A2 (fr) | 2002-03-06 | 2003-09-12 | Sanofi-Aventis | Nouveaux composes |
WO2003080633A1 (fr) | 2002-03-25 | 2003-10-02 | Nippon Kayaku Kabushiki Kaisha | Nouveau derive d'$g(a)-amino-n-(diaminophosphinyl)lactame |
WO2003082817A2 (fr) | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete |
WO2003084940A1 (fr) | 2002-04-08 | 2003-10-16 | Alangudi Sankaranarayanan | Thiazolidine-4-carbonitriles et analogues et leur utilisation comme inhibiteurs de dipeptidyl-peptidas |
JP2003300977A (ja) | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | キサンチン誘導体 |
JP2003327532A (ja) | 2002-05-10 | 2003-11-19 | Takeda Chem Ind Ltd | ペプチダーゼ阻害剤 |
WO2003095425A1 (fr) | 2002-05-09 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Derives de cyanopyrrolidine |
WO2003099279A1 (fr) | 2002-05-29 | 2003-12-04 | Novartis Ag | Association d'un inhibiteur de dipeptidyl peptidase iv (dpp iv) et d'un compose cardio-vasculaire |
WO2003101958A2 (fr) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Amides cycliques fluores utilises comme inhibiteurs de la dipeptidyl peptidase iv |
WO2003101448A1 (fr) | 2002-06-03 | 2003-12-11 | Novartis Ag | Utilisation de cyanopyrrolidines substituees et de preparations de combinaison contenant celles-ci dans le traitement d'hyperlipidemie et de maladies associees |
WO2003104229A1 (fr) | 2002-06-06 | 2003-12-18 | エーザイ株式会社 | Nouveau derive d'imidazole fondu |
WO2003105763A2 (fr) | 2002-06-14 | 2003-12-24 | Amylin Pharmaceuticals, Inc. | Prevention et/ou traitement de maladie enterique inflammatoire au moyen de peptides yy ou d'antagonistes de peptides yy |
WO2003106456A2 (fr) | 2002-06-14 | 2003-12-24 | Sanofi-Synthelabo | Nouveaux composes |
WO2004000327A1 (fr) | 2002-06-24 | 2003-12-31 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Agent therapeutique pour des diabetes de type 2 |
JP2004002367A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JP2004002368A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2004004661A2 (fr) | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Polytherapie a base de composes de boroproline |
WO2004007446A1 (fr) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive de l'azetidine ou ses sels |
WO2004007468A1 (fr) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Inhibiteurs de piperidino pyrimidine dipeptidyl peptidase utilises dans le traitement du diabete |
WO2004007517A1 (fr) | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Nouveaux derives de thiophene-glycoside, procede permettant de les produire, medicaments contenant lesdits composes et leur utilisation |
WO2004009544A1 (fr) | 2002-07-23 | 2004-01-29 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de 2-cyano-4-fluoropyrrolidine ou de son sel |
JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
JP2004035574A (ja) | 2000-10-06 | 2004-02-05 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
JP2004043429A (ja) | 2002-02-25 | 2004-02-12 | Eisai Co Ltd | 新規キサンチン誘導体およびdppiv阻害剤 |
WO2004014860A2 (fr) | 2002-08-08 | 2004-02-19 | Takeda Pharmaceutical Company Limited | Composes heterocycliques fusionnes |
DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
WO2004018468A2 (fr) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, leur production et leur utilisation comme medicament |
DE10238243A1 (de) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
WO2004020407A1 (fr) | 2002-08-29 | 2004-03-11 | Taisho Pharmaceutical Co.,Ltd. | Benzenesulfonate d'un derive de 4-fluoro-2-cyanopyrrolidine |
US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
WO2004026822A2 (fr) | 2002-09-19 | 2004-04-01 | Abbott Laboratories | Compositions pharmaceutiques utiles comme inhibiteurs de la peptidase-iv dipeptidyl (dpp-iv) |
WO2004033455A2 (fr) | 2002-10-08 | 2004-04-22 | Novo Nordisk A/S | Sels succiniques d'inhibiteurs heterocycliques de dpp-iv |
WO2004032836A2 (fr) | 2002-10-07 | 2004-04-22 | Merck & Co., Inc. | Inhibiteurs de la dipeptidyl peptidase heterocyclique beta-amino utiles pour le traitement ou la prevention du diabete |
WO2004037181A2 (fr) | 2002-10-23 | 2004-05-06 | Bristol-Myers Squibb Company | Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants |
WO2004037169A2 (fr) | 2002-10-18 | 2004-05-06 | Merck & Co., Inc. | Inhibiteurs de dipeptidylpeptidase heterocyclique beta-amino destines au traitement ou a la prevention de diabetes |
DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US20040097510A1 (en) | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2004041795A1 (fr) | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Nouveaux inhibiteurs de dipeptidyl peptidase iv |
WO2004043940A1 (fr) | 2002-11-07 | 2004-05-27 | Merck & Co., Inc. | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete |
WO2004046106A1 (fr) | 2002-11-18 | 2004-06-03 | Pfizer Products Inc. | Amides cycliques fluorés inhibant la dipeptidyl peptidase iv |
WO2004048379A1 (fr) | 2002-11-01 | 2004-06-10 | Sumitomo Pharmaceuticals Co., Ltd. | Compose de xanthine |
WO2004048352A2 (fr) | 2002-11-27 | 2004-06-10 | Fujisawa Pharmaceutical Co., Ltd. | Inhibiteur de la dpp-iv |
WO2004050658A1 (fr) | 2002-12-03 | 2004-06-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouvelles imidazo-pyridinones et imidazo-pyridazinones substituees, leur production et leur utilisation en tant que medicaments |
WO2004050022A2 (fr) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidylpeptisase pour le traitement ou la prevention de diabetes |
DE10256264A1 (de) | 2002-12-03 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2004052850A2 (fr) | 2002-12-09 | 2004-06-24 | Bristol-Myers Squibb Company | Procedes et composes pour produire des inhibiteurs de la dipeptidyle-peptidase et leurs intermediaires |
US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2004052362A1 (fr) | 2002-12-10 | 2004-06-24 | Novartis Ag | Combinaision d'un inhibiteur de dpp-iv et d'un compose ppar-alpha |
US20040138214A1 (en) | 2002-11-08 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
WO2004058266A1 (fr) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | Derives de 3-amino-4-phenylbutanoique acide utilises en tant qu'inhibiteurs de dipeptidyl peptidase pour le traitement ou la prevention du diabete |
WO2004065380A1 (fr) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme |
WO2004064778A2 (fr) | 2003-01-17 | 2004-08-05 | Merck & Co. Inc. | Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete |
WO2004067509A1 (fr) | 2003-01-31 | 2004-08-12 | Sanwa Kagaku Kenkyusho Co., Ltd. | Composé inhibant la dipeptidyl peptidase iv |
WO2004069162A2 (fr) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete |
WO2004071454A2 (fr) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Composes d'azetidine substitues servant d'inhibiteurs de dipeptidyl peptidase iv |
JP2004244412A (ja) | 2003-01-20 | 2004-09-02 | Kotobuki Seiyaku Kk | 4位に置換基を有する2−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤 |
WO2004076413A2 (fr) | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Derives d'aryle et heteroaryle susbtitues tenant lieu de modulateurs du metabolisme du glucose et prophylaxie et traitement de troubles associes |
WO2004076434A1 (fr) | 2003-02-28 | 2004-09-10 | Aic | Inhibiteurs de dipeptidyl peptidases |
WO2004076433A1 (fr) | 2003-02-28 | 2004-09-10 | Aic | Inhibiteurs de dipeptidyle peptidase |
WO2004080990A1 (fr) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | Derives de c-glycoside et sels correspondants |
WO2004085661A2 (fr) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc | Procede de synthese de derives d'acides amines beta chiraux |
WO2004085378A1 (fr) | 2003-03-19 | 2004-10-07 | Merck & Co. Inc. | Procede pour preparer des derives d'acide amine beta chiraux par hydrogenation asymetrique |
US6803357B1 (en) | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
WO2004087650A2 (fr) | 2003-03-27 | 2004-10-14 | Merck & Co. Inc. | Procede et intermediaires pour la preparation d'inhibiteurs d'amide d'acide beta-amino de dipeptidyle peptidase-iv |
WO2004087053A2 (fr) | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Inhibiteurs de dipeptidyle peptidase |
EP1469873A2 (fr) | 2001-11-26 | 2004-10-27 | Trustees of Tufts College | Inhibiteurs peptidomimetiques d'enzymes de clivage post-proline |
WO2004092128A1 (fr) | 2003-04-10 | 2004-10-28 | Smithkline Beecham Corporation | Formes cristallines anhydres de (2s, 4s)-1-{(2r)-2-amino-3-'4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile |
US6812350B2 (en) | 2002-06-04 | 2004-11-02 | Pfizer Inc. | Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds |
JP2004315496A (ja) | 2002-08-08 | 2004-11-11 | Takeda Chem Ind Ltd | 縮合複素環化合物 |
WO2004096806A1 (fr) | 2003-04-30 | 2004-11-11 | Sumitomo Pharmaceuticals Co. Ltd. | Derive d'imidazole condense |
WO2004099134A2 (fr) | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Inhibiteurs de la dp iv a base de glutaminyle |
WO2004099185A1 (fr) | 2003-05-09 | 2004-11-18 | Fujisawa Pharmaceutical Co. Ltd. | Derives 2-cyanopyrrolidine et leur utilisation comme inhibiteurs de la dpp-iv |
WO2004104215A2 (fr) | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7) |
WO2004103276A2 (fr) | 2003-05-14 | 2004-12-02 | Merck & Co., Inc. | Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete |
WO2004104216A2 (fr) | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4) |
WO2004103993A1 (fr) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Inhibiteurs de dipeptidyl peptidase |
WO2004108730A1 (fr) | 2003-06-05 | 2004-12-16 | Fujisawa Pharmaceutical Co., Ltd. | Inhibiteur de l'enzyme dpp-iv |
WO2004110436A1 (fr) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Indoles fusionnes en tant qu'inhibiteurs de dipeptidyle peptidase destines au traitement ou a la prevention des diabetes |
WO2004111051A1 (fr) | 2003-06-18 | 2004-12-23 | Boehringer Ingelheim International Gmbh | Derives d'imidazopyridazinones et d'imidazopyridones, leur preparation et leur utilisation comme medicaments |
US20040259902A1 (en) | 2003-06-20 | 2004-12-23 | Markus Boehringer | Pyrido [2,1-a] isoquinoline derivatives |
US20040259843A1 (en) | 2002-09-19 | 2004-12-23 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2004111041A1 (fr) | 2003-06-12 | 2004-12-23 | Fujisawa Pharmaceutical Co., Ltd. | Compose de pyrrolidine, de thiazolidine et d'oxazolidine inhibant la dipeptidyl-peptidase-iv (dpp-iv) |
WO2004110375A2 (fr) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Polytherapie permettant de traiter le diabete |
US20040259903A1 (en) | 2003-06-20 | 2004-12-23 | Markus Boehringer | Pyrido [2,1-a] isoquinoline derivatives |
WO2004112701A2 (fr) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete |
WO2005003135A1 (fr) | 2003-06-24 | 2005-01-13 | Merck & Co., Inc. | Sel d'acide phosphorique d'un inhibiteur de la dipeptidyl peptidase iv |
WO2005007647A1 (fr) | 2003-07-11 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents |
JP2005023038A (ja) | 2003-07-04 | 2005-01-27 | Taisho Pharmaceut Co Ltd | 慢性腎疾患治療薬 |
WO2005009956A1 (fr) | 2003-07-21 | 2005-02-03 | Smithkline Beecham Corporation | Sel d'acide (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes crristallines anhydres |
WO2005012249A2 (fr) | 2003-08-01 | 2005-02-10 | Bristol-Myers Squibb Company | Inhibiteurs a base d'adamantyglycine de la dipeptidyl peptidase iv et procedes associes |
WO2005011581A2 (fr) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv pour le traitement ou la prevention du diabete |
WO2005012326A1 (fr) | 2003-08-01 | 2005-02-10 | Tanabe Seiyaku Co., Ltd. | Nouveaux composes possedant une activite inhibitrice dirigee contre le transporteur dependant du sodium |
WO2005012312A1 (fr) | 2003-07-25 | 2005-02-10 | Sanofi-Aventis Deutschland Gmbh | Nouvelles cyanothiazolides, leur procede de production et leur utilisation comme medicament |
WO2005012308A1 (fr) | 2003-07-25 | 2005-02-10 | Sanofi-Aventis Deutschland Gmbh | Nouveaux cyanopyrrolidides, procedes pour leur production et leur utilisation comme medicament |
US20050043292A1 (en) | 2003-08-20 | 2005-02-24 | Pfizer Inc | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors |
WO2005020920A2 (fr) | 2003-09-02 | 2005-03-10 | Merck & Co., Inc. | Nouvelles formes cristallines d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyl peptidase-iv |
WO2005021536A2 (fr) | 2003-08-29 | 2005-03-10 | Sanofi-Aventis | Nouveaux composes |
US20050059724A1 (en) | 2003-07-25 | 2005-03-17 | Aventis Pharma Deutschland Gmbh | Novel cyanopyrrolidides, process for their preparation and their use as medicaments |
WO2005023762A1 (fr) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Derives de pyrrolidine-2-carbonitrile et leur utilisation comme inhibiteurs de la dipeptidyle peptidase-iv (dpp-iv) |
US20050059716A1 (en) | 2003-07-25 | 2005-03-17 | Aventis Pharma Deutschland Gmbh | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
WO2005026148A1 (fr) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidylpeptidase |
WO2005025554A2 (fr) | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Inhibiteur de la dipeptidylpeptidase iv |
WO2005030127A2 (fr) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Nouvelle forme cristalline d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyle peptase-iv |
WO2005030751A2 (fr) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Inhibiteurs de dipeptidyle peptidase |
WO2005033099A2 (fr) | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant |
WO2005032590A1 (fr) | 2003-10-03 | 2005-04-14 | Takeda Pharmaceutical Company Limited | Remede contre le diabete |
WO2005033106A1 (fr) | 2003-10-06 | 2005-04-14 | Alangudi Sankaranarayanan | Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv |
WO2005034940A2 (fr) | 2003-10-15 | 2005-04-21 | Imtm Gmbh | Inhibiteurs doubles d'alanyl-aminopeptidase et de dipeptidylpeptidase iv utilises pour influer de maniere fonctionnelle sur differentes cellules et pour traiter des affections immunologiques, inflammatoires, neuronales et autres |
WO2005037828A1 (fr) | 2003-10-20 | 2005-04-28 | Lg Life Sciences Ltd. | Inhibiteurs de dpp-iv, procedes d'elaboration correspondants, et compositions pharmaceutiques renfermant ces inhibiteurs comme principe actif |
WO2005037779A2 (fr) | 2003-10-15 | 2005-04-28 | Imtm Gmbh | Nouveaux inhibiteurs de dipeptidylpeptidases iv destines a influencer le fonctionnement de diverses cellules et a traiter des maladies immunologiques, inflammatoires, neuronales et autres |
WO2005040095A1 (fr) | 2003-10-16 | 2005-05-06 | Astrazeneca Ab | Inhibiteurs de la dipeptidyl-peptidase iv |
WO2005042488A1 (fr) | 2003-10-31 | 2005-05-12 | Takeda Pharmaceutical Company Limited | Composes pyridines utilises comme inhibiteurs de dipeptidyle peptidase iv |
WO2005044195A2 (fr) | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Derives de phenylalanine fusionnes utilises comme inhibiteurs de la dipeptidyl peptidase-iv dans le traitement ou la prevention du diabete |
WO2005047297A1 (fr) | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Composés heterocycliques d'acide boronique |
WO2005049022A2 (fr) | 2003-11-17 | 2005-06-02 | Novartis Ag | Utilisation de composes organiques |
WO2005051950A1 (fr) | 2003-11-27 | 2005-06-09 | Boehringer Ingelheim International Gmbh | Nouvelle xanthine 8-(piperazine-1-yl) et 8-([1,4]diazepan-1-yl), sa production et son utilisation comme medicament |
EP1541148A1 (fr) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Inhibiteurs de dpp-iv |
EP1541143A1 (fr) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Inhibiteurs de dpp-iv |
US20050131019A1 (en) | 2003-09-04 | 2005-06-16 | Zhonghua Pei | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2005058849A1 (fr) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant |
WO2005063750A1 (fr) | 2003-12-23 | 2005-07-14 | Boehringer Ingelheim International Gmbh | Composes imidazol bicycliques, leur fabrication et leur utilisation comme medicaments |
EP1561752A1 (fr) | 2000-07-04 | 2005-08-10 | Novo Nordisk A/S | Composés hétérocycliques en tant qu'inhibiteurs de l'enzyme DPP-IV |
WO2005072530A1 (fr) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Nouveau sel cristallin d'un inhibiteur de dipeptidyle peptidase-iv |
WO2005075426A1 (fr) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant |
WO2005079795A2 (fr) | 2004-02-20 | 2005-09-01 | Novartis Ag | Utilisation de composes organiques |
WO2005082348A2 (fr) | 2004-02-23 | 2005-09-09 | Trustees Of Tufts College | Inhibiteurs de la dipeptidylpeptidase iv |
WO2005082849A1 (fr) | 2004-02-23 | 2005-09-09 | Trustees Of Tufts College | Lactames utilisees comme inhibiteurs peptidomimetiques a contrainte conformationnelle |
WO2005087235A1 (fr) | 2004-03-09 | 2005-09-22 | National Health Research Institutes | Composes de pyrrolidine |
US20050209249A1 (en) | 2004-03-08 | 2005-09-22 | Irini Akritopoulou-Zanze | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20050215603A1 (en) | 2004-03-08 | 2005-09-29 | Irini Akritopoulou-Zanze | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20050215784A1 (en) | 2002-09-19 | 2005-09-29 | Madar David J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2005092877A1 (fr) | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Derives du benzol substitues par un glucopyranosyle,, medicaments renfermant ces composes, leur utilisation et leur procede de production |
WO2005095343A1 (fr) | 2004-03-05 | 2005-10-13 | Santhera Pharmaceuticals (Schweiz) Gmbh | Inhibiteurs de la dpp-iv |
WO2005095381A1 (fr) | 2004-03-15 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyle peptidase |
WO2005113510A1 (fr) | 2004-05-21 | 2005-12-01 | Santhera Pharmaceuticals (Schweiz) Ag | Inhibiteurs dpp-iv |
WO2005116014A1 (fr) | 2004-05-12 | 2005-12-08 | Pfizer Products Inc. | Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv |
EP1604989A1 (fr) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Inhibiteurs de DPP-IV |
EP1604980A1 (fr) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Inhibiteurs de DPP-IV |
EP1604662A1 (fr) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2 |
WO2005119526A1 (fr) | 2004-06-03 | 2005-12-15 | Pfizer Products Inc. | Structure cristalline de dipeptidyl peptidase iv (dpp-iv) et ses utilisations |
WO2005123685A1 (fr) | 2004-06-16 | 2005-12-29 | Astrazeneca Ab | Tetrahydroquinolones et aza-analogues associes utilises en tant qu'inhibiteurs de la dpp-iv dans le traitement du diabete |
EP1623983A1 (fr) | 2004-08-05 | 2006-02-08 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Composés hétérocycliques utilisables comme inhibiteurs de DPP-IV |
EP1633970A1 (fr) | 2003-06-03 | 2006-03-15 | MAN B & W Diesel Aktiengesellschaft | Injecteur de carburant |
WO2006040625A1 (fr) | 2004-10-12 | 2006-04-20 | Glenmark Pharmaceuticals S.A. | Nouveaux inhibiteurs de dipeptidyle peptidase iv, compositions pharmaceutiques en contenant, et leur procede de preparation |
WO2006058628A2 (fr) | 2004-11-30 | 2006-06-08 | F.Hoffmann-La Roche Ag | Derives benzoquinolizine substitues |
US20060135512A1 (en) | 2004-12-20 | 2006-06-22 | Markus Boehringer | Aminocycloalkanes as DPP-IV inhibitors |
WO2006068163A1 (fr) | 2004-12-24 | 2006-06-29 | Dainippon Sumitomo Pharma Co., Ltd. | Dérivés bicycliques de pyrrole |
WO2006076231A2 (fr) | 2005-01-10 | 2006-07-20 | Arena Pharmaceuticals, Inc. | Polytherapie destinee au traitement du diabete et de troubles lies au diabete et au traitement de troubles pouvant etre soignes par une augmentation du taux de glp-1 dans le sang |
WO2006080421A1 (fr) | 2005-01-28 | 2006-08-03 | Chugai Seiyaku Kabushiki Kaisha | Dérivé de spirocétal et emploi dudit dérivé au titre de médicament contre le diabète |
WO2006088129A1 (fr) | 2005-02-18 | 2006-08-24 | Mitsubishi Pharma Corporation | Sel d'un dérivé de proline, solvate dudit sel, et méthode de production dudit sel |
EP1702916A1 (fr) | 2005-03-18 | 2006-09-20 | Santhera Pharmaceuticals (Schweiz) GmbH | Inhibiteurs de DPP-IV |
WO2006100181A2 (fr) | 2005-03-22 | 2006-09-28 | F. Hoffmann-La Roche Ag | Nouveau sel et polymorphes de l'inhibiteur de dpp-iv |
WO2006104356A1 (fr) | 2005-04-01 | 2006-10-05 | Lg Life Sciences, Ltd. | Composés inhibiteurs de la dipeptidylpeptidase-iv, méthodes de synthèse desdits composés, et préparations pharmaceutiques contenant lesdits composés au titre de principe actif |
WO2006116157A2 (fr) | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs de la dipeptidyl peptidase iv |
US20060264433A1 (en) | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2006134613A2 (fr) | 2005-06-17 | 2006-12-21 | Aurigene Discovery Technologies Limited | Nouveaux derives d'indole substitues en 5 utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv (dpp-iv) |
WO2007003964A1 (fr) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Agonistes du récepteur couplé aux protéines g |
US20070015269A1 (en) | 2002-11-25 | 2007-01-18 | Michael Hennig | Crystals of DPP-IV |
US20070049596A1 (en) | 2005-08-30 | 2007-03-01 | Zhonghua Pei | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2007035372A2 (fr) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Formes polymorphes de sel benzoate de 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile, et leurs procedes d'utilisation |
US20070142436A1 (en) | 2005-12-21 | 2007-06-21 | Andre Bubendorf | New salt and polymorph of a DPP-IV inhibitor |
WO2007071738A1 (fr) | 2005-12-23 | 2007-06-28 | Novartis Ag | Composes heterocycliques condenses utiles en tant qu’inhibiteurs de dpp-iv |
US20070167468A1 (en) | 2004-08-06 | 2007-07-19 | Sanofi-Aventis Deutschland Gmbh | Substituted bicyclic 8-pyrr0lidinoxanthines, methods for their production, pharmaceutical formulations and their use |
US20070238753A1 (en) | 2004-02-27 | 2007-10-11 | Madar David J | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) |
WO2007120689A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu |
WO2007120702A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée |
EP1852108A1 (fr) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
WO2007128721A1 (fr) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim Internationalgmbh | Polymorphes |
WO2007128761A2 (fr) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Utilisations d'inhibiteurs de l'enzyme dpp iv |
WO2007148185A2 (fr) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | 3-amino-pyrrolidino-4-lactames substitués |
WO2008017670A1 (fr) | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-d]pyrimidines utilisées en tant qu'inhibiteurs de dpp-iv pour le traitement du diabète sucré |
WO2008027273A2 (fr) | 2006-08-30 | 2008-03-06 | Phenomix Corporation | Sels citrates et tartrates solides d'inhibiteurs de la dpp-iv |
WO2008028662A1 (fr) | 2006-09-07 | 2008-03-13 | Santhera Pharmaceuticals (Schweiz) Ag | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide et composés associés utilisés en tant qu'inhibiteurs dpp-iv pour le traitement du diabète sucré de type 2 |
EP1902730A1 (fr) | 2005-06-09 | 2008-03-26 | Banyu Pharmaceutical Co., Ltd. | Agoniste de npy y2 pour une utilisation en tant qu agent thérapeutique contre une maladie s accompagnant de diarrhée |
EP1905759A1 (fr) | 2006-09-07 | 2008-04-02 | Santhera Pharmaceuticals (Schweiz) AG | Derivés n-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide et composés similaires pour l'utilisation comme inhibiteurs dpp-iv pour le traitement de type 2 diabetes mellitus |
WO2008040995A1 (fr) | 2006-10-07 | 2008-04-10 | Peakdale Molecular Limited | Indoles destinés à être utilisés comme inhibiteurs de dpp-iv |
WO2008067465A1 (fr) | 2006-11-29 | 2008-06-05 | Takeda Pharmaceutical Company Limited | Polymorphes de sel de succinate de 2-[6-(3-amino-pipéridin-1-yl)-3-méthyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylméthy]-4-fluor-benzonitrile et leurs procédés d'utilisation |
US20080146818A1 (en) | 2004-02-05 | 2008-06-19 | Yasumichi Fukuda | Bicycloester Derivative |
WO2008109591A1 (fr) | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose |
WO2008114857A1 (fr) | 2007-03-22 | 2008-09-25 | Kyorin Pharmaceutical Co., Ltd. | Procédé de préparation d'un dérivé d'aminoacétylpyrrolidinecarbonitrile |
WO2008141021A1 (fr) | 2007-05-08 | 2008-11-20 | Concert Pharmaceuticals, Inc. | Dérivés deutérés de composés de tétrahydrotriazolopyrazine et leur utilisation en tant qu'inhibiteurs de la dpp-iv |
WO2008144730A2 (fr) | 2007-05-21 | 2008-11-27 | Phenomix Corporation | Formulation pharmaceutique stable pour un inhibiteur de dpp-iv |
WO2009003681A1 (fr) | 2007-07-02 | 2009-01-08 | Santhera Pharmaceuticals (Schweiz) Ag | Inhibiteurs de dpp-iv |
WO2009009751A1 (fr) | 2007-07-12 | 2009-01-15 | Phenomix Corporation | Intermédiaire synthétique cristallin utilisé dans la préparation d'un inhibiteur de la ddp-iv et son procédé de purification |
EP2019099A1 (fr) | 2007-07-02 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Inhibiteurs Dpp-IV |
WO2009037719A1 (fr) | 2007-09-21 | 2009-03-26 | Lupin Limited | Nouveaux composés en tant qu'inhibiteurs de dipeptidyle peptidase-iv (dpp-iv) |
WO2009084497A1 (fr) | 2007-12-28 | 2009-07-09 | Dainippon Sumitomo Pharma Co., Ltd. | Dérivé de pipéridine substituée par un méthyle |
WO2009113423A1 (fr) | 2008-03-10 | 2009-09-17 | 大日本住友製薬株式会社 | Composé de pyrrole bicyclique |
WO2009126535A1 (fr) * | 2008-04-07 | 2009-10-15 | Irm Llc | Composés et compositions servant de modulateurs de l’activité de gpr119 |
WO2009126245A1 (fr) | 2008-04-07 | 2009-10-15 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation d'un récepteur couplé à la protéine g pour identifier des sécrétagogues du peptide yy (pyy) et composés utiles dans le traitement de pathologies modulées par le pyy |
EP2119717A1 (fr) | 2004-02-18 | 2009-11-18 | Boehringer Ingelheim International GmbH | 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que complexe DDP IV |
US20100120790A1 (en) | 2007-04-19 | 2010-05-13 | Dong-A Pharm. Co., Ltd | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity |
WO2010086411A1 (fr) | 2009-01-29 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Traitement du diabète chez des patients pédiatriques |
WO2010146597A1 (fr) | 2009-06-18 | 2010-12-23 | Lupin Limited | Dérivés de 2-amino-2-[8-(diméthylcarbamoyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-exo-éthanoyle comme puissants inhibiteurs de la dpp-iv |
WO2011008663A1 (fr) * | 2009-07-15 | 2011-01-20 | Eli Lilly And Company | Agonistes du gpr119 |
EP2292589A1 (fr) | 2009-09-02 | 2011-03-09 | IMTM GmbH | Nouveaux inhibiteurs multifonctionnels de la peptidase, en particulier pour une utilisation en médecine |
WO2011028455A1 (fr) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotétrahydropanes utilisés comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prévenir le diabète |
WO2011037793A1 (fr) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Aminopipéridines substituées utilisées en tant qu'inhibiteurs de la dipeptidyl peptidase-iv dans le cadre du traitement du diabète |
WO2011079778A1 (fr) | 2009-12-30 | 2011-07-07 | China Shanghai Fochon Pharmaceutical Co Ltd | Dérivés de 3-(3-aminopipéridin-1-yl)-5-oxo-1,2,4-triazine à titre d'inhibiteurs de dipeptidyl peptidase iv (dpp-iv) |
WO2011127051A1 (fr) * | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
WO2011147207A1 (fr) | 2010-05-24 | 2011-12-01 | 上海阳帆医药科技有限公司 | Dérivés d'hexahydropyrrolo[3,4-b]pyrrole, leurs procédés de préparation et leurs utilisations pharmaceutiques |
WO2012017391A2 (fr) | 2010-08-03 | 2012-02-09 | Cadila Pharmaceuticals Limited | Nouveaux composés en tant qu'inhibiteurs de la dpp-iv et procédé de préparation associé |
WO2012060590A2 (fr) | 2010-11-01 | 2012-05-10 | Lg Life Sciences Ltd. | Hydrate de tartrate de 1-{(2s)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoropipéridin-2-one |
-
2012
- 2012-06-07 WO PCT/US2012/041375 patent/WO2012170702A1/fr active Application Filing
Patent Citations (530)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD296075A5 (de) | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
EP0528858A1 (fr) | 1990-04-14 | 1993-03-03 | New England Medical Center Inc | Inhibiteurs de dipeptidyl-aminopeptidase de type iv. |
JPH05508624A (ja) | 1990-04-14 | 1993-12-02 | ニュー イングランド メデカル センター ホスピタルズ インク | ジペプチジル―アミノベプチダーゼ・4型の阻害剤 |
WO1991016339A1 (fr) | 1990-04-14 | 1991-10-31 | New England Medical Center Hospitals, Inc. | Inhibiteurs de dipeptidyl-aminopeptidase de type iv |
EP1050540A2 (fr) | 1991-10-22 | 2000-11-08 | New England Medical Center Hospitals, Inc. | Inhibiteurs de dipeptidyl-aminopeptidase de type IV |
WO1993008259A2 (fr) | 1991-10-22 | 1993-04-29 | New England Medical Center Hospitals, Inc. | Inhibiteurs de dipeptidyl-aminopeptidase de type iv |
EP0610317A1 (fr) | 1991-10-22 | 1994-08-17 | New England Medical Center | Inhibiteurs de dipeptidyl-aminopeptidase de type iv |
WO1993010127A1 (fr) | 1991-11-22 | 1993-05-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Procede de production d'un ester de prolineboronate |
CA2123128A1 (fr) | 1991-11-22 | 1993-05-27 | Roger Snow | Methode de fabrication d'un ester de prolineboronate |
JPH07501078A (ja) | 1991-11-22 | 1995-02-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | プロリンボロネートエステルの製法 |
EP0641347A1 (fr) | 1991-11-22 | 1995-03-08 | Boehringer Ingelheim Pharmaceuticals Inc. | Procede de production d'un ester de prolineboronate |
WO1995015309A1 (fr) | 1993-12-03 | 1995-06-08 | Ferring B.V. | Inhibiteurs de la dp-iv-serine protease |
EP0731789A1 (fr) | 1993-12-03 | 1996-09-18 | Ferring B.V. | Inhibiteurs de la dp-iv-serine protease |
JPH09509921A (ja) | 1993-12-03 | 1997-10-07 | フェーリング ベスローテン フェンノートシャップ | 酵素インヒビター |
WO1995029691A1 (fr) | 1994-04-28 | 1995-11-09 | Georgia Tech Research Corporation | Derives de la proline phosphonate |
DE19616486A1 (de) | 1996-04-25 | 1997-10-30 | Knoell Hans Forschung Ev | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
WO1997040832A1 (fr) | 1996-04-25 | 1997-11-06 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Utilisation d'effecteurs de la dipeptidyl peptidase iv pour abaisser la teneur en glucose dans le sang chez les mammiferes |
JP2001510442A (ja) | 1996-04-25 | 2001-07-31 | プロビオドラッグ ゲゼルシャフト フュル アルツナイミッテルフォルシュング エムベーハー | 哺乳動物の血糖値低下のためのジペプチジルペプチダーゼ▲iv▼エフェクターの使用 |
US6303661B1 (en) | 1996-04-25 | 2001-10-16 | Probiodrug | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
JPH1081666A (ja) | 1996-06-12 | 1998-03-31 | Ishihara Sangyo Kaisha Ltd | フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物 |
WO1998018763A1 (fr) | 1996-10-25 | 1998-05-07 | Tanabe Seiyaku Co., Ltd. | Derives de tetrahydroisoquinoline |
JPH10182613A (ja) | 1996-10-25 | 1998-07-07 | Tanabe Seiyaku Co Ltd | テトラヒドロイソキノリン誘導体 |
JP2000511559A (ja) | 1996-11-07 | 2000-09-05 | ノバルティス アクチエンゲゼルシャフト | N―置換2―シアノピロリジン |
WO1998019998A2 (fr) | 1996-11-07 | 1998-05-14 | Novartis Ag | 2-cyanopyrrolidines a substitution n |
EP0975359A1 (fr) | 1997-05-07 | 2000-02-02 | Trustees Of Tufts College | Potentialisation de la reponse immunitaire par production de composes se fixant a une dipeptidase cytoplasmique |
CA2289125A1 (fr) | 1997-05-07 | 1998-11-12 | Trustees Of Tufts College | Potentialisation de la reponse immunitaire par production de composes se fixant a une dipeptidase cytoplasmique |
CA2289124A1 (fr) | 1997-05-07 | 1998-11-12 | Trustees Of Tufts College | Utilisation d'un inhibiteur du cd26 pour preparer un medicament traitant le vih |
US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
WO1998050046A1 (fr) | 1997-05-07 | 1998-11-12 | Trustees Of Tufts College | Utilisation d'un inhibiteur du cd26 pour preparer un medicament traitant le vih |
US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
EP0980249A1 (fr) | 1997-05-07 | 2000-02-23 | Trustees Of Tufts College | Utilisation d'un inhibiteur du cd26 pour preparer un medicament traitant le vih |
WO1998050066A1 (fr) | 1997-05-07 | 1998-11-12 | Trustees Of Tufts College | Potentialisation de la reponse immunitaire par production de composes se fixant a une dipeptidase cytoplasmique |
WO1999016864A1 (fr) | 1997-09-29 | 1999-04-08 | Point Therapeutics, Inc. | Stimulation de cellules hematopoietiques in vitro |
WO1999025719A1 (fr) | 1997-11-18 | 1999-05-27 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation |
EP1043328A1 (fr) | 1997-11-18 | 2000-10-11 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation |
US6803357B1 (en) | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
WO1999056753A1 (fr) | 1998-05-04 | 1999-11-11 | Point Therapeutics, Inc. | Stimulation hematopoietique |
WO1999061431A1 (fr) | 1998-05-28 | 1999-12-02 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Nouveaux effecteurs de dipeptidylpeptidase iv |
EP1215207A2 (fr) | 1998-05-28 | 2002-06-19 | Probiodrug AG | Sels d'isoleucyl-thiazolidine et -pyrrolidine et leur utilisation comme inhibiteurs de dipeptidylpeptidase |
EP1082314A1 (fr) | 1998-05-28 | 2001-03-14 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Nouveaux effecteurs de dipeptidylpeptidase iv |
JP2002516318A (ja) | 1998-05-28 | 2002-06-04 | プロバイオドラッグ ゲゼルシャフト フュア アルツナイミッテルフォルシュンク エムベーハー | ジペプチジル・ペプチダーゼivの新規エフェクター |
US20030134802A1 (en) | 1998-05-28 | 2003-07-17 | Hans-Ulrich Demuth | Novel effectors of dipepetidyl peptidase IV |
EP1304327A2 (fr) | 1998-05-28 | 2003-04-23 | Probiodrug AG | Thiazolide et pyrrolide de glutamine ainsi que leur utilisation comme inhibiteurs de dipeptidylpeptidase IV |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
JP2002517401A (ja) | 1998-06-05 | 2002-06-18 | ポイント セラピューティクス, インコーポレイテッド | 環状ボロプロリン化合物 |
WO1999062914A1 (fr) | 1998-06-05 | 1999-12-09 | Point Therapeutics, Inc. | Composes cycliques de boroproline |
JP2003524591A (ja) | 1998-06-24 | 2003-08-19 | プロバイオドラッグ ゲゼルシャフト フュア アルツナイミッテルフォルシュンク エムベーハー | Dpiv阻害剤のプロドラッグ |
US20020049164A1 (en) | 1998-06-24 | 2002-04-25 | Hans-Ulrich Demuth | Prodrugs of DP IV-inhibitors |
WO1999067278A1 (fr) | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Promedicaments d'inhibiteurs de la dipeptidylpeptidase iv |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
EP0995440A1 (fr) | 1998-07-31 | 2000-04-26 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Procédé pour augmenter le taux de glucose dans le sang des mammifères |
EP1104293A1 (fr) | 1998-08-21 | 2001-06-06 | Point Therapeutics, Inc. | Regulation de l'activite de substrat |
WO2000010549A1 (fr) | 1998-08-21 | 2000-03-02 | Point Therapeutics, Inc. | Regulation de l'activite de substrat |
CA2339537A1 (fr) | 1998-08-21 | 2000-03-02 | Barbara Wallner | Regulation de l'activite de substrat |
US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
US6410508B1 (en) | 1998-10-07 | 2002-06-25 | Med College Georgia Res Inst | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
JP2002527504A (ja) | 1998-10-22 | 2002-08-27 | アイドゥン ファーマシューティカルズ, インコーポレイテッド | システインプロテアーゼのICE/ced−3系の置換アシルジペプチジル抑制剤 |
WO2000023421A1 (fr) | 1998-10-22 | 2000-04-27 | Idun Pharmaceuticals, Inc. | INHIBITEURS ACYLE(SUBSTITUE) DIPEPTIDYLE DE LA FAMILLE ICE/ced-3 DES CYSTEINES PROTEASES |
EP1123272A1 (fr) | 1998-10-22 | 2001-08-16 | Idun Pharmaceuticals, Inc. | Inhibiteurs acyle(substitue) dipeptidyle de la famille ice/ced-3 des cysteines proteases |
WO2000031258A2 (fr) | 1998-11-20 | 2000-06-02 | Arena Pharmaceuticals, Inc. | Recepteurs humains couples a la proteine g orphan |
WO2000034241A1 (fr) | 1998-12-10 | 2000-06-15 | Novartis Ag | 2-cyanopyrrolidines n-substitues |
US6166063A (en) | 1998-12-10 | 2000-12-26 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
EP1137635A1 (fr) | 1998-12-10 | 2001-10-04 | Novartis AG | 2-cyanopyrrolidines n-substitues |
JP2002531547A (ja) | 1998-12-10 | 2002-09-24 | ノバルティス アクチエンゲゼルシャフト | N置換されている2−シアノピロリジン |
JP2000191616A (ja) | 1998-12-24 | 2000-07-11 | Senju Pharmaceut Co Ltd | 新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬 |
WO2000056297A2 (fr) | 1999-03-23 | 2000-09-28 | Ferring B.V. | Compositions favorisant la croissance |
WO2000056296A2 (fr) | 1999-03-23 | 2000-09-28 | Ferring Bv | Compositions favorisant la fecondite |
WO2000069868A1 (fr) | 1999-05-17 | 2000-11-23 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Analogues de la sulphostine et procede de preparation de la sulphostine et de ses analogues |
JP2000327689A (ja) | 1999-05-17 | 2000-11-28 | Microbial Chem Res Found | スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法 |
WO2000071135A1 (fr) | 1999-05-25 | 2000-11-30 | Point Therapeutics, Inc. | Agents anti-tumorales contenant des composes de boroproline |
US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO2001034594A1 (fr) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs |
JP2003535034A (ja) | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法 |
EP1228061A1 (fr) | 1999-11-12 | 2002-08-07 | Guilford Pharmaceuticals Inc. | Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs |
US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
EP1248604A2 (fr) | 2000-01-21 | 2002-10-16 | Novartis AG | Combinaisons comprenant un inhibiteur de la dipeptidylpeptidase - iv |
WO2001052825A2 (fr) | 2000-01-21 | 2001-07-26 | Novartis Ag | Combinaisons comprenant un inhibiteur de la dipeptidylpeptidase - iv |
US6645995B2 (en) | 2000-01-24 | 2003-11-11 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
WO2001055105A1 (fr) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | 2-cyanopyroles et -pyrrolines a substitution n inhibant l'enzyme dpp-iv |
US20010031780A1 (en) | 2000-01-24 | 2001-10-18 | Anders Kanstrup | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
EP1254113A1 (fr) | 2000-01-24 | 2002-11-06 | Novo Nordisk A/S | 2-cyanopyroles et -pyrrolines a substitution n inhibant l'enzyme dpp-iv |
JP2003520849A (ja) | 2000-01-24 | 2003-07-08 | ノボ ノルディスク アクティーゼルスカブ | 酵素dpp−ivの阻害剤であるn−置換2−シアノピロールおよび−ピロリン |
US20020103384A1 (en) | 2000-01-24 | 2002-08-01 | Anders Kanstrup | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
JP2003531118A (ja) | 2000-03-10 | 2003-10-21 | ブリストル−マイヤーズ スクイブ カンパニー | シクロプロピル縮合ピロリジン骨格を有するジペプチジルペプチダーゼivの阻害剤及び方法 |
EP1261586A2 (fr) | 2000-03-10 | 2002-12-04 | Bristol-Myers Squibb Company | Inhibiteurs de la dipeptidyl peptidase iv, a base de pyrrolidone fusionnee a du cyclopropyle, et procede |
WO2001068603A2 (fr) | 2000-03-10 | 2001-09-20 | Bristol-Myers Squibb Co. | Inhibiteurs de la dipeptidyl peptidase iv, a base de pyrrolidone fusionnee a du cyclopropyle, et procede |
WO2001081337A1 (fr) | 2000-04-26 | 2001-11-01 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv |
JP2003531204A (ja) | 2000-04-26 | 2003-10-21 | フェリング ベスローテン フェンノートシャップ | ジペプチジルペプチダーゼivの阻害剤 |
US20030216450A1 (en) | 2000-04-26 | 2003-11-20 | Evans David Michael | Inhibitors of dipeptidyl peptidase IV |
EP1280797A1 (fr) | 2000-04-26 | 2003-02-05 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv |
EP1282600A1 (fr) | 2000-04-26 | 2003-02-12 | Ferring BV | Inhibiteurs de dipeptidyl peptidase iv |
JP2003531191A (ja) | 2000-04-26 | 2003-10-21 | フェリング ベスローテン フェンノートシャップ | ジペプチジル・ペプチダーゼivの阻害剤 |
WO2001081304A1 (fr) | 2000-04-26 | 2001-11-01 | Ferring Bv | Inhibiteurs de dipeptidyl peptidase iv |
JP2004503531A (ja) | 2000-06-13 | 2004-02-05 | ノバルティス アクチエンゲゼルシャフト | 2−シアノピロリジン誘導体および薬剤としてのそれらの使用 |
EP1296974A2 (fr) | 2000-06-13 | 2003-04-02 | Novartis AG | Composes organiques |
WO2001096295A2 (fr) | 2000-06-13 | 2001-12-20 | Novartis Ag | Composes organiques |
US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
WO2001097808A1 (fr) | 2000-06-19 | 2001-12-27 | Smithkline Beecham Plc | Combinaisons d'inhibiteurs de peptidase iv de dipeptidyl et d'autres agents antidiabetiques pour traiter le diabete sucre |
JP2003535898A (ja) | 2000-06-19 | 2003-12-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 真性糖尿病の治療用のジペプチジルペプチダーゼiv阻害剤および他の抗糖尿病剤の組み合わせ |
WO2002001427A1 (fr) | 2000-06-29 | 2002-01-03 | Worldsmart Technology Pty Ltd | Protection contre les depenses impulsives |
EP1561752A1 (fr) | 2000-07-04 | 2005-08-10 | Novo Nordisk A/S | Composés hétérocycliques en tant qu'inhibiteurs de l'enzyme DPP-IV |
EP1301187A2 (fr) | 2000-07-04 | 2003-04-16 | Novo Nordisk A/S | Composes heterocycliques inhibiteurs de l'enzyme dpp-iv |
WO2002002560A2 (fr) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Composes heterocycliques inhibiteurs de l'enzyme dpp-iv |
US20040034014A1 (en) | 2000-07-04 | 2004-02-19 | Kanstrup Anders Bendtz | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
US20020161001A1 (en) | 2000-07-04 | 2002-10-31 | Kanstrup Anders Bendtz | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
US7235538B2 (en) | 2000-07-04 | 2007-06-26 | Novo Nordisk A/S | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV |
WO2002014271A1 (fr) | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
JP2004035574A (ja) | 2000-10-06 | 2004-02-05 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
WO2002030891A1 (fr) | 2000-10-06 | 2002-04-18 | Tanabe Seiyaku Co., Ltd. | Composes aliphatiques azotes a noyau a cinq elements |
US20040063935A1 (en) | 2000-10-06 | 2004-04-01 | Kosuke Yasuda | Aliphatic nitrogenous five-membered ring compounds |
WO2002030890A1 (fr) | 2000-10-06 | 2002-04-18 | Tanabe Seiyaku Co., Ltd. | Composes azotes a noyau a cinq elements |
US20040229926A1 (en) | 2000-10-06 | 2004-11-18 | Tanabe Seiyaku Co., Ltd. | Aliphatic nitrogen - containing 5 - membered ring compound |
JP2002356471A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
US6849622B2 (en) | 2000-10-06 | 2005-02-01 | Tanabe Seiyaku Co., Ltd. | Aliphatic nitrogenous five-membered ring compounds |
JP2002356472A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 含窒素五員環化合物 |
WO2002034900A1 (fr) | 2000-10-27 | 2002-05-02 | The University Of Sydney | Dipeptidyl peptidases |
US20040072892A1 (en) | 2000-11-10 | 2004-04-15 | Hiroshi Fukushima | Cyanopyrrolidine derivatives |
US20070112059A1 (en) | 2000-11-10 | 2007-05-17 | Taisho Pharmaceutical Co., Ltd. | Cyanopyrrolidine derivatives |
WO2002038541A1 (fr) | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Derives de cyanopyrrolidine |
EP1333025A1 (fr) | 2000-11-10 | 2003-08-06 | Taisho Pharmaceutical Co., Ltd | Derives de cyanopyrrolidine |
EP1338651A1 (fr) | 2000-12-01 | 2003-08-27 | Yamanouchi Pharmaceutical Co. Ltd. | Procede de depistage d'un remede |
WO2002051836A1 (fr) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de dipeptidyl peptidase iv |
CA2433090A1 (fr) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de dipeptidyl peptidase iv |
US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
EP1354882A1 (fr) | 2000-12-27 | 2003-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteur de dipeptidyl peptidase iv |
WO2002055088A1 (fr) | 2001-01-16 | 2002-07-18 | Nippon Kayaku Kabushiki Kaisha | Remedes destines au traitement de la suppression de la moelle osseuse et de maladies infectieuses et agents permettant d'augmenter la concentration leucocytaire du sang |
EP1355886A1 (fr) | 2001-02-02 | 2003-10-29 | Takeda Chemical Industries, Ltd. | Composes heterocycliques condenses |
WO2002062764A1 (fr) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Composes heterocycliques condenses |
JP2003238566A (ja) | 2001-02-02 | 2003-08-27 | Takeda Chem Ind Ltd | 縮合複素環化合物 |
WO2002068420A1 (fr) | 2001-02-24 | 2002-09-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Derives xanthine, fabrication et utilisations en tant qu'agents pharmaceutiques |
JP2004522786A (ja) | 2001-02-24 | 2004-07-29 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | キサンチン誘導体、それらの調製及び医薬組成物としてのそれらの使用 |
US20040087587A1 (en) | 2001-02-24 | 2004-05-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20020198205A1 (en) | 2001-02-24 | 2002-12-26 | Frank Himmelsbach | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040077645A1 (en) | 2001-02-24 | 2004-04-22 | Frank Himmelsbach | Xanthine derivatives,production and use thereof as medicament |
JP2002265439A (ja) | 2001-03-08 | 2002-09-18 | Mitsubishi Pharma Corp | シアノピロリジン誘導体およびその医薬用途 |
WO2002076450A1 (fr) | 2001-03-27 | 2002-10-03 | Merck & Co., Inc. | Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete |
US20040106656A1 (en) | 2001-03-27 | 2004-06-03 | Ashton Wallace T | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2004525929A (ja) | 2001-03-27 | 2004-08-26 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療または予防用のジペプチジルペプチダーゼ阻害薬 |
EP1385508A1 (fr) | 2001-03-27 | 2004-02-04 | Merck & Co., Inc. | Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete |
US6716843B2 (en) | 2001-03-28 | 2004-04-06 | Les Laboratoires Servier | Alpha-amino acid sulphonyl compounds |
EP1245568A1 (fr) | 2001-03-28 | 2002-10-02 | Les Laboratoires Servier | Dérives sulfonyles d'-aminoacides et leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV ( DPP IV) |
FR2822826A1 (fr) | 2001-03-28 | 2002-10-04 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20030087950A1 (en) | 2001-03-28 | 2003-05-08 | Denanteuil Guillaume | New alpha-amino acid sulphonyl compounds |
WO2002083109A1 (fr) | 2001-04-11 | 2002-10-24 | Ferring Bv | Traitement du diabete de type 2 a l'aide d'inhibiteurs de dipeptidylpeptidase iv |
JP2004525179A (ja) | 2001-04-11 | 2004-08-19 | フェリング ベスローテン フェンノートシャップ | ジペプチジルペプチダーゼiv阻害剤でのii型糖尿病の処置 |
EP1377288A1 (fr) | 2001-04-12 | 2004-01-07 | Bristol-Myers Squibb Company | Inhibiteurs a base de 2,1-oxazoline et 1,2-pyrazoline de la dipeptidyl peptidase iv et methode associee |
US20020183367A1 (en) | 2001-04-12 | 2002-12-05 | Sulsky Richard B. | 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
JP2004532220A (ja) | 2001-04-12 | 2004-10-21 | ブリストル−マイヤーズ スクイブ カンパニー | ジペプチジル・ペプチダーゼivの2,1−オキサゾリンおよび1,2−ピラゾリンに基づくインヒビターおよび方法 |
WO2002083128A1 (fr) | 2001-04-12 | 2002-10-24 | Bristol-Myers Squibb Company | Inhibiteurs a base de 2,1-oxazoline et 1,2-pyrazoline de la dipeptidyl peptidase iv et methode associee |
US20030078247A1 (en) | 2001-05-15 | 2003-04-24 | De Nanteuil Guillaume | Alpha-amino-acid compounds |
EP1258476A1 (fr) | 2001-05-15 | 2002-11-20 | Les Laboratoires Servier | Dérivés d'alpha-amino-acides, leur procédé de préparation ainsi que leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV (DPP IV) |
US6706742B2 (en) | 2001-05-15 | 2004-03-16 | Les Laboratories Servier | Alpha-amino-acid compounds |
JP2002363157A (ja) | 2001-05-15 | 2002-12-18 | Lab Servier | 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物 |
FR2824825A1 (fr) | 2001-05-15 | 2002-11-22 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2004535433A (ja) | 2001-06-20 | 2004-11-25 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療用のジペプチジルペプチダーゼ阻害薬 |
JP2005500308A (ja) | 2001-06-20 | 2005-01-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療するためのジペプチジルペプチダーゼ阻害剤 |
WO2003000180A2 (fr) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete |
WO2003000181A2 (fr) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Inhibiteurs de dipeptidyl peptidase utilises dans le traitement du diabete |
EP1406622A2 (fr) | 2001-06-20 | 2004-04-14 | Merck & Co., Inc. | Inhibiteurs de dipeptidyl peptidase utilises dans le traitement du diabete |
EP1406872A2 (fr) | 2001-06-20 | 2004-04-14 | Merck & Co., Inc. | Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete |
JP2004534815A (ja) | 2001-06-25 | 2004-11-18 | フェリング ベスローテン フェンノートシャップ | 抗糖尿病薬としての3−フルオロ−ピロリジン |
WO2003000250A1 (fr) | 2001-06-25 | 2003-01-03 | Ferring Bv | Agents antidiabetiques a base de 3-fluoro-pyrrolidines |
EP1399154A1 (fr) | 2001-06-25 | 2004-03-24 | Ferring BV | Agents antidiabetiques a base de 3-fluoro-pyrrolidines |
JP2004521149A (ja) | 2001-06-27 | 2004-07-15 | プロバイオドラッグ アーゲー | 新規なジペプチジルぺプチダ−ゼiv阻害剤およびそれらの抗癌剤としての使用 |
WO2003002596A2 (fr) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Nouvelle utilisation d'inhibiteurs de la dipeptidyl peptidase iv |
WO2003002531A2 (fr) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
EP1399471A2 (fr) | 2001-06-27 | 2004-03-24 | Probiodrug AG | Utilisation d'inhibiteurs de la dipeptidyl peptidase iv comme agents pour la therapie des maladies neurologiques |
JP2004530729A (ja) | 2001-06-27 | 2004-10-07 | プロバイオドラッグ アーゲー | ジペプチジルペプチダーゼiv触媒作用の拮抗調節に有用なペプチド構造 |
EP1399433A2 (fr) | 2001-06-27 | 2004-03-24 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
WO2003002593A2 (fr) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv |
WO2003002530A2 (fr) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase |
WO2003072556A1 (fr) | 2001-06-27 | 2003-09-04 | Prosidion Ltd. | Inhibiteurs de dpiv a base de groupes glutaminyl |
WO2003002595A2 (fr) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Nouveaux inhibiteurs de dipeptidylpeptidase iv et leurs utilisations en tant qu'agents anti-cancereux |
EP1399420A2 (fr) | 2001-06-27 | 2004-03-24 | SmithKline Beecham Corporation | Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase |
JP2005500321A (ja) | 2001-06-27 | 2005-01-06 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
JP2004534836A (ja) | 2001-06-27 | 2004-11-18 | プロバイオドラッグ アーゲー | ジペプチジルぺプチダ−ゼiv阻害剤の新規な使用 |
US20030119750A1 (en) | 2001-06-27 | 2003-06-26 | Hans-Ulrich Demuth | Use of dipeptidyl peptidase IV inhibitors |
EP1399469A2 (fr) | 2001-06-27 | 2004-03-24 | Probiodrug AG | Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv |
WO2003002553A2 (fr) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
JP2004535445A (ja) | 2001-06-27 | 2004-11-25 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
EP1406873A2 (fr) | 2001-06-27 | 2004-04-14 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
EP1399470A2 (fr) | 2001-06-27 | 2004-03-24 | Probiodrug AG | Nouveaux inhibiteurs de dipeptidylpeptidase iv et leurs utilisations en tant qu'agents anti-cancereux |
EP1404675A1 (fr) | 2001-07-03 | 2004-04-07 | Novo Nordisk A/S | Derives de purine inhibiteurs de dpp-iv pour le traitement du diabete |
WO2003004496A1 (fr) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Derives de purine inhibiteurs de dpp-iv pour le traitement du diabete |
US20030105077A1 (en) | 2001-07-03 | 2003-06-05 | Kanstrup Anders Bendtz | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US7192952B2 (en) | 2001-07-03 | 2007-03-20 | Novo Nordisk, A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
US20050148606A1 (en) | 2001-07-03 | 2005-07-07 | Kanstrup Anders B. | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
JP2005502624A (ja) | 2001-07-03 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病を治療するための、dpp−ivを阻害するプリン誘導体 |
WO2003004498A1 (fr) | 2001-07-06 | 2003-01-16 | Merck & Co., Inc. | Pyrazines beta-amino tetrahydroimidazo (1, 2-a) et pyrazines tetrahydrotrioazolo (4, 3-a) utilisees en tant qu'inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete |
US20030100563A1 (en) | 2001-07-06 | 2003-05-29 | Edmondson Scott D. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2004536115A (ja) | 2001-07-06 | 2004-12-02 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害薬としてのβ−アミノテトラヒドロイミダゾ(1,2−A)ピラジン類及びテトラヒドロトリアゾロ(4,3−A)ピラジン類 |
EP1412357A1 (fr) | 2001-07-06 | 2004-04-28 | Merck & Co., Inc. | Pyrazines beta-amino tetrahydroimidazo (1, 2-a) et pyrazines tetrahydrotrioazolo (4, 3-a) utilisees en tant qu'inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete |
US6699871B2 (en) | 2001-07-06 | 2004-03-02 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2005505531A (ja) | 2001-08-17 | 2005-02-24 | プロビオドルグ アーゲー | 新規ジペプチジルペプチダーゼiv阻害剤および血圧レベルを低下させるためのそれらの使用 |
WO2003015775A1 (fr) | 2001-08-17 | 2003-02-27 | Probiodrug Ag | Inhibiteurs de dipeptidyl peptidase iv et leurs utilisations pour diminuer la pression sanguine |
US20030119738A1 (en) | 2001-09-06 | 2003-06-26 | Andre Niestroj | Novel inhibitors of dipeptidyl peptidase I |
WO2003022871A2 (fr) | 2001-09-06 | 2003-03-20 | Probiodrug Ag | Nouveaux inhibiteurs de dipeptidylpeptidase i |
DE10143840A1 (de) | 2001-09-06 | 2003-03-27 | Probiodrug Ag | Neue Inhibitoren der Dipeptidylpeptidase I |
WO2003024942A1 (fr) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Derive thiazolidine et son utilisation medicamenteuse |
US20040259883A1 (en) | 2001-09-14 | 2004-12-23 | Hiroshi Sakashita | Thiazolidine derivative and medicinal use thereof |
EP1426366A1 (fr) | 2001-09-14 | 2004-06-09 | Mitsubishi Pharma Corporation | Derive thiazolidine et son utilisation medicamenteuse |
WO2003024965A2 (fr) | 2001-09-19 | 2003-03-27 | Novo Nordisk A/S | Composes heterocycliques constituant des inhibiteurs de l'enzyme dpp-iv |
EP1463727A2 (fr) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Composes heterocycliques constituant des inhibiteurs de l'enzyme dpp-iv |
US20030199528A1 (en) | 2001-09-19 | 2003-10-23 | Kanstrup Anders B. | Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV |
WO2003035067A1 (fr) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv (dp-iv) tenant lieu d'agents anti-diabetiques |
WO2003035057A1 (fr) | 2001-10-23 | 2003-05-01 | Ferring B.V. | Inhibiteurs de la dipeptidyl peptidase iv |
US20050004205A1 (en) | 2001-10-23 | 2005-01-06 | Evans David M | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
EP1450794A1 (fr) | 2001-10-23 | 2004-09-01 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv (dp-iv) tenant lieu d'agents anti-diabetiques |
EP1446116A1 (fr) | 2001-10-23 | 2004-08-18 | Ferring B.V. | Inhibiteurs de la dipeptidyl peptidase iv |
US20030130281A1 (en) | 2001-10-26 | 2003-07-10 | Markus Boehringer | DPP IV inhibitors |
WO2003037327A1 (fr) | 2001-10-26 | 2003-05-08 | F. Hoffmann-La-Roche Ag | Derives de pyrrolidine n-substitues en tant qu'inhibiteurs de la dipeptidyl peptidase iv |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
EP1441719A1 (fr) | 2001-10-26 | 2004-08-04 | F. Hoffmann-La Roche Ag | Derives de pyrrolidine n-substitues en tant qu'inhibiteurs de la dipeptidyl peptidase iv |
WO2003038123A2 (fr) | 2001-10-31 | 2003-05-08 | Novartis Ag | Procede de traitement du diabete et conditions apparentees basees sur des polymorphismes dans le gene tcf1 |
JP2005507261A (ja) | 2001-10-31 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Tcf1遺伝子における多型に基づく糖尿病および関連状態の治療方法 |
EP1442049A2 (fr) | 2001-11-09 | 2004-08-04 | Probiodrug AG | Composes d'aminocetone substitues |
US20030125304A1 (en) | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
WO2003040174A2 (fr) | 2001-11-09 | 2003-05-15 | Probiodrug Ag | Composes d'aminocetone substitues |
EP1469873A2 (fr) | 2001-11-26 | 2004-10-27 | Trustees of Tufts College | Inhibiteurs peptidomimetiques d'enzymes de clivage post-proline |
CA2466870A1 (fr) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Techniques de traitement de maladies auto-immunes et reactifs associes |
WO2003045228A2 (fr) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Techniques de traitement de maladies auto-immunes et reactifs associes |
WO2003057666A2 (fr) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Inhibiteurs de la dipeptidyl peptidase iv |
EP1465891A2 (fr) | 2001-12-26 | 2004-10-13 | Guilford Pharmaceuticals Inc. | Inhibiteurs de la dipeptidyl peptidase iv |
WO2003057144A2 (fr) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Changement d'inhibiteurs de la dipeptidyl peptidase iv |
EP1461337A1 (fr) | 2001-12-27 | 2004-09-29 | F. Hoffmann-La Roche Ag | Derives de pyrido(2,1-a)isoquinoline comme inhibiteurs dpp-iv |
US20030149071A1 (en) | 2001-12-27 | 2003-08-07 | Gobbi Luca Claudio | Pyrido [2,1-a] isoquinoline derivatives |
WO2003055881A1 (fr) | 2001-12-27 | 2003-07-10 | F. Hoffmann-La Roche Ag | Derives de pyrido(2,1-a)isoquinoline comme inhibiteurs dpp-iv |
US20040176406A1 (en) | 2001-12-27 | 2004-09-09 | Gobbi Luca Claudio | Pyrido [2,1-a] isoquinoline derivatives |
US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
WO2003072528A2 (fr) | 2002-02-08 | 2003-09-04 | Idun Pharmaceuticals, Inc. | Inhibiteurs de dipeptidyle d'acide substitue de la famille ice/ced-3 des proteases de cysteine |
US20030232788A1 (en) | 2002-02-08 | 2003-12-18 | Idun Pharmaceuticals, Inc. | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases |
US6867205B2 (en) | 2002-02-13 | 2005-03-15 | Hoffman-La Roche Inc. | Pyridine and pyrimidine derivatives |
EP1476435A1 (fr) | 2002-02-13 | 2004-11-17 | F. Hoffmann-La Roche Ag | Nouveaux derives de pyridine et de pyrimidine |
WO2003068757A1 (fr) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Nouveaux derives de pyridine et de pyrimidine |
EP1476429A1 (fr) | 2002-02-13 | 2004-11-17 | F. Hoffmann-La Roche Ag | Nouveaux derives de pyridine et de quinoline |
WO2003068748A1 (fr) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Nouveaux derives de pyridine et de quinoline |
US6800650B2 (en) | 2002-02-13 | 2004-10-05 | Hoffmann-La Roche Inc. | Pyridine and quinoline derivatives |
US20030216382A1 (en) | 2002-02-13 | 2003-11-20 | Markus Boehringer | Pyridine and pyrimidine derivatives |
US20030195188A1 (en) | 2002-02-13 | 2003-10-16 | Markus Boehringer | Pyridine and quinoline derivatives |
EP1338592A1 (fr) | 2002-02-22 | 2003-08-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Dérivés de 2-phénylpipérazine |
EP1338595A2 (fr) | 2002-02-25 | 2003-08-27 | Eisai Co., Ltd. | Dérivés de Xanthines servant d'inhibiteurs de DPP-IV |
US20040082570A1 (en) | 2002-02-25 | 2004-04-29 | Eisai Co., Ltd. | Xanthine derivative and DPPIV inhibitor |
JP2004043429A (ja) | 2002-02-25 | 2004-02-12 | Eisai Co Ltd | 新規キサンチン誘導体およびdppiv阻害剤 |
US20030162820A1 (en) | 2002-02-28 | 2003-08-28 | Hans-Ulrich Demuth | Glutaminyl based DPIV inhibitors |
EP1480961A1 (fr) | 2002-02-28 | 2004-12-01 | Prosidion Limited | Inhibiteurs de dpiv a base de groupes glutaminyl |
EP1487807A2 (fr) | 2002-03-06 | 2004-12-22 | Sanofi-Aventis | Nouveaux composes |
WO2003074500A2 (fr) | 2002-03-06 | 2003-09-12 | Sanofi-Aventis | Nouveaux composes |
EP1489088A1 (fr) | 2002-03-25 | 2004-12-22 | Nippon Kayaku Kabushiki Kaisha | Nouveau derive d'alpha-amino-n-(diaminophosphinyl)lactame |
WO2003082817A2 (fr) | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete |
EP1490335A2 (fr) | 2002-03-25 | 2004-12-29 | Merck & Co., Inc. | Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete |
WO2003080633A1 (fr) | 2002-03-25 | 2003-10-02 | Nippon Kayaku Kabushiki Kaisha | Nouveau derive d'$g(a)-amino-n-(diaminophosphinyl)lactame |
JP2004002367A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JP2004002368A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2003084940A1 (fr) | 2002-04-08 | 2003-10-16 | Alangudi Sankaranarayanan | Thiazolidine-4-carbonitriles et analogues et leur utilisation comme inhibiteurs de dipeptidyl-peptidas |
US20030225102A1 (en) | 2002-04-08 | 2003-12-04 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
EP1492777A1 (fr) | 2002-04-08 | 2005-01-05 | Torrent Pharmaceuticals Ltd | Thiazolidine-4-carbonitriles et analogues et leur utilisation comme inhibiteurs de dipeptidyl-peptidas |
JP2003300977A (ja) | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | キサンチン誘導体 |
WO2003095425A1 (fr) | 2002-05-09 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Derives de cyanopyrrolidine |
JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
JP2003327532A (ja) | 2002-05-10 | 2003-11-19 | Takeda Chem Ind Ltd | ペプチダーゼ阻害剤 |
WO2003099279A1 (fr) | 2002-05-29 | 2003-12-04 | Novartis Ag | Association d'un inhibiteur de dipeptidyl peptidase iv (dpp iv) et d'un compose cardio-vasculaire |
WO2003101448A1 (fr) | 2002-06-03 | 2003-12-11 | Novartis Ag | Utilisation de cyanopyrrolidines substituees et de preparations de combinaison contenant celles-ci dans le traitement d'hyperlipidemie et de maladies associees |
US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
US20040242898A1 (en) | 2002-06-04 | 2004-12-02 | Pfizer Inc | Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds |
WO2003101958A2 (fr) | 2002-06-04 | 2003-12-11 | Pfizer Products Inc. | Amides cycliques fluores utilises comme inhibiteurs de la dipeptidyl peptidase iv |
US6812350B2 (en) | 2002-06-04 | 2004-11-02 | Pfizer Inc. | Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds |
EP1513808A2 (fr) | 2002-06-04 | 2005-03-16 | Pfizer Products Inc. | Amides cycliques fluores utilises comme inhibiteurs de la dipeptidyl peptidase iv |
WO2003104229A1 (fr) | 2002-06-06 | 2003-12-18 | エーザイ株式会社 | Nouveau derive d'imidazole fondu |
US20040116328A1 (en) | 2002-06-06 | 2004-06-17 | Eisai Co., Ltd. | Condensed imidazole derivatives |
EP1517907A2 (fr) | 2002-06-14 | 2005-03-30 | Sanofi-Aventis | Derives d'azabicyclo-octane et nonane ayant une activite inhibitrice de ddp-iv |
WO2003106456A2 (fr) | 2002-06-14 | 2003-12-24 | Sanofi-Synthelabo | Nouveaux composes |
WO2003105763A2 (fr) | 2002-06-14 | 2003-12-24 | Amylin Pharmaceuticals, Inc. | Prevention et/ou traitement de maladie enterique inflammatoire au moyen de peptides yy ou d'antagonistes de peptides yy |
JP2004026678A (ja) | 2002-06-24 | 2004-01-29 | Microbial Chem Res Found | 2型糖尿病治療剤 |
WO2004000327A1 (fr) | 2002-06-24 | 2003-12-31 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Agent therapeutique pour des diabetes de type 2 |
WO2004004661A2 (fr) | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Polytherapie a base de composes de boroproline |
WO2004007446A1 (fr) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive de l'azetidine ou ses sels |
WO2004007517A1 (fr) | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Nouveaux derives de thiophene-glycoside, procede permettant de les produire, medicaments contenant lesdits composes et leur utilisation |
WO2004007468A1 (fr) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Inhibiteurs de piperidino pyrimidine dipeptidyl peptidase utilises dans le traitement du diabete |
WO2004009544A1 (fr) | 2002-07-23 | 2004-01-29 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de 2-cyano-4-fluoropyrrolidine ou de son sel |
JP2004315496A (ja) | 2002-08-08 | 2004-11-11 | Takeda Chem Ind Ltd | 縮合複素環化合物 |
WO2004014860A2 (fr) | 2002-08-08 | 2004-02-19 | Takeda Pharmaceutical Company Limited | Composes heterocycliques fusionnes |
US20040097510A1 (en) | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2004018468A2 (fr) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, leur production et leur utilisation comme medicament |
DE10238243A1 (de) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
WO2004018467A2 (fr) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Derives de xanthine, leur production et leur utilisation comme medicaments |
DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
WO2004018469A1 (fr) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouveaux derives de purine, leur procede de production et leur utilisation en tant que medicament |
WO2004020407A1 (fr) | 2002-08-29 | 2004-03-11 | Taisho Pharmaceutical Co.,Ltd. | Benzenesulfonate d'un derive de 4-fluoro-2-cyanopyrrolidine |
US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2004026822A2 (fr) | 2002-09-19 | 2004-04-01 | Abbott Laboratories | Compositions pharmaceutiques utiles comme inhibiteurs de la peptidase-iv dipeptidyl (dpp-iv) |
US20050215784A1 (en) | 2002-09-19 | 2005-09-29 | Madar David J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20040259843A1 (en) | 2002-09-19 | 2004-12-23 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7238724B2 (en) | 2002-09-19 | 2007-07-03 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2004032836A2 (fr) | 2002-10-07 | 2004-04-22 | Merck & Co., Inc. | Inhibiteurs de la dipeptidyl peptidase heterocyclique beta-amino utiles pour le traitement ou la prevention du diabete |
WO2004033455A2 (fr) | 2002-10-08 | 2004-04-22 | Novo Nordisk A/S | Sels succiniques d'inhibiteurs heterocycliques de dpp-iv |
WO2004037169A2 (fr) | 2002-10-18 | 2004-05-06 | Merck & Co., Inc. | Inhibiteurs de dipeptidylpeptidase heterocyclique beta-amino destines au traitement ou a la prevention de diabetes |
WO2004037181A2 (fr) | 2002-10-23 | 2004-05-06 | Bristol-Myers Squibb Company | Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants |
WO2004041795A1 (fr) | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Nouveaux inhibiteurs de dipeptidyl peptidase iv |
WO2004048379A1 (fr) | 2002-11-01 | 2004-06-10 | Sumitomo Pharmaceuticals Co., Ltd. | Compose de xanthine |
WO2004043940A1 (fr) | 2002-11-07 | 2004-05-27 | Merck & Co., Inc. | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete |
WO2004041820A1 (fr) | 2002-11-08 | 2004-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouveaux derives de xanthine, leur production et leur utilisation comme medicaments |
DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US20040138214A1 (en) | 2002-11-08 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040110817A1 (en) | 2002-11-18 | 2004-06-10 | Pfizer Inc | Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides |
WO2004046106A1 (fr) | 2002-11-18 | 2004-06-03 | Pfizer Products Inc. | Amides cycliques fluorés inhibant la dipeptidyl peptidase iv |
US20070100561A1 (en) | 2002-11-25 | 2007-05-03 | Michael Hennig | Crystals of DPP-IV |
US20070015269A1 (en) | 2002-11-25 | 2007-01-18 | Michael Hennig | Crystals of DPP-IV |
WO2004048352A2 (fr) | 2002-11-27 | 2004-06-10 | Fujisawa Pharmaceutical Co., Ltd. | Inhibiteur de la dpp-iv |
DE10256264A1 (de) | 2002-12-03 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2004050658A1 (fr) | 2002-12-03 | 2004-06-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouvelles imidazo-pyridinones et imidazo-pyridazinones substituees, leur production et leur utilisation en tant que medicaments |
WO2004050022A2 (fr) | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidylpeptisase pour le traitement ou la prevention de diabetes |
WO2004052850A2 (fr) | 2002-12-09 | 2004-06-24 | Bristol-Myers Squibb Company | Procedes et composes pour produire des inhibiteurs de la dipeptidyle-peptidase et leurs intermediaires |
WO2004052362A1 (fr) | 2002-12-10 | 2004-06-24 | Novartis Ag | Combinaision d'un inhibiteur de dpp-iv et d'un compose ppar-alpha |
WO2004058266A1 (fr) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | Derives de 3-amino-4-phenylbutanoique acide utilises en tant qu'inhibiteurs de dipeptidyl peptidase pour le traitement ou la prevention du diabete |
WO2004065380A1 (fr) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme |
WO2004064778A2 (fr) | 2003-01-17 | 2004-08-05 | Merck & Co. Inc. | Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete |
JP2004244412A (ja) | 2003-01-20 | 2004-09-02 | Kotobuki Seiyaku Kk | 4位に置換基を有する2−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤 |
WO2004067509A1 (fr) | 2003-01-31 | 2004-08-12 | Sanwa Kagaku Kenkyusho Co., Ltd. | Composé inhibant la dipeptidyl peptidase iv |
WO2004069162A2 (fr) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete |
WO2004071454A2 (fr) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Composes d'azetidine substitues servant d'inhibiteurs de dipeptidyl peptidase iv |
WO2004076413A2 (fr) | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Derives d'aryle et heteroaryle susbtitues tenant lieu de modulateurs du metabolisme du glucose et prophylaxie et traitement de troubles associes |
WO2004076433A1 (fr) | 2003-02-28 | 2004-09-10 | Aic | Inhibiteurs de dipeptidyle peptidase |
WO2004076434A1 (fr) | 2003-02-28 | 2004-09-10 | Aic | Inhibiteurs de dipeptidyl peptidases |
WO2004080990A1 (fr) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | Derives de c-glycoside et sels correspondants |
WO2004085378A1 (fr) | 2003-03-19 | 2004-10-07 | Merck & Co. Inc. | Procede pour preparer des derives d'acide amine beta chiraux par hydrogenation asymetrique |
WO2004085661A2 (fr) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc | Procede de synthese de derives d'acides amines beta chiraux |
WO2004087053A2 (fr) | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Inhibiteurs de dipeptidyle peptidase |
WO2004087650A2 (fr) | 2003-03-27 | 2004-10-14 | Merck & Co. Inc. | Procede et intermediaires pour la preparation d'inhibiteurs d'amide d'acide beta-amino de dipeptidyle peptidase-iv |
WO2004092128A1 (fr) | 2003-04-10 | 2004-10-28 | Smithkline Beecham Corporation | Formes cristallines anhydres de (2s, 4s)-1-{(2r)-2-amino-3-'4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile |
WO2004096806A1 (fr) | 2003-04-30 | 2004-11-11 | Sumitomo Pharmaceuticals Co. Ltd. | Derive d'imidazole condense |
WO2004099134A2 (fr) | 2003-05-05 | 2004-11-18 | Prosidion Ltd. | Inhibiteurs de la dp iv a base de glutaminyle |
WO2004099185A1 (fr) | 2003-05-09 | 2004-11-18 | Fujisawa Pharmaceutical Co. Ltd. | Derives 2-cyanopyrrolidine et leur utilisation comme inhibiteurs de la dpp-iv |
WO2004103276A2 (fr) | 2003-05-14 | 2004-12-02 | Merck & Co., Inc. | Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete |
US20040254226A1 (en) | 2003-05-14 | 2004-12-16 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2004103993A1 (fr) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Inhibiteurs de dipeptidyl peptidase |
WO2004104216A2 (fr) | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4) |
WO2004104215A2 (fr) | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7) |
EP1633970A1 (fr) | 2003-06-03 | 2006-03-15 | MAN B & W Diesel Aktiengesellschaft | Injecteur de carburant |
WO2004108730A1 (fr) | 2003-06-05 | 2004-12-16 | Fujisawa Pharmaceutical Co., Ltd. | Inhibiteur de l'enzyme dpp-iv |
WO2004110375A2 (fr) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Polytherapie permettant de traiter le diabete |
WO2004110436A1 (fr) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Indoles fusionnes en tant qu'inhibiteurs de dipeptidyle peptidase destines au traitement ou a la prevention des diabetes |
WO2004111041A1 (fr) | 2003-06-12 | 2004-12-23 | Fujisawa Pharmaceutical Co., Ltd. | Compose de pyrrolidine, de thiazolidine et d'oxazolidine inhibant la dipeptidyl-peptidase-iv (dpp-iv) |
WO2004112701A2 (fr) | 2003-06-17 | 2004-12-29 | Merck & Co., Inc. | Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete |
WO2004111051A1 (fr) | 2003-06-18 | 2004-12-23 | Boehringer Ingelheim International Gmbh | Derives d'imidazopyridazinones et d'imidazopyridones, leur preparation et leur utilisation comme medicaments |
DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US20040259902A1 (en) | 2003-06-20 | 2004-12-23 | Markus Boehringer | Pyrido [2,1-a] isoquinoline derivatives |
EP1638968A1 (fr) | 2003-06-20 | 2006-03-29 | F.Hoffmann-La Roche Ag | Hexahydropyrido-isoquinolines utilises comme inhibiteurs de dpp-iv |
WO2005000848A1 (fr) | 2003-06-20 | 2005-01-06 | F. Hoffmann-La Roche Ag | Derives de pyrido[2,1-a]isoquinoline utilises comme inhibiteurs de dpp-iv |
WO2005000846A1 (fr) | 2003-06-20 | 2005-01-06 | F.Hoffmann-La Roche Ag | Hexahydropyrido-isoquinolines utilises comme inhibiteurs de dpp-iv |
US20040259903A1 (en) | 2003-06-20 | 2004-12-23 | Markus Boehringer | Pyrido [2,1-a] isoquinoline derivatives |
WO2005003135A1 (fr) | 2003-06-24 | 2005-01-13 | Merck & Co., Inc. | Sel d'acide phosphorique d'un inhibiteur de la dipeptidyl peptidase iv |
US20050032804A1 (en) | 2003-06-24 | 2005-02-10 | Cypes Stephen Howard | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
JP2005023038A (ja) | 2003-07-04 | 2005-01-27 | Taisho Pharmaceut Co Ltd | 慢性腎疾患治療薬 |
WO2005007647A1 (fr) | 2003-07-11 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents |
WO2005009956A1 (fr) | 2003-07-21 | 2005-02-03 | Smithkline Beecham Corporation | Sel d'acide (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes crristallines anhydres |
WO2005012308A1 (fr) | 2003-07-25 | 2005-02-10 | Sanofi-Aventis Deutschland Gmbh | Nouveaux cyanopyrrolidides, procedes pour leur production et leur utilisation comme medicament |
DE10333935A1 (de) | 2003-07-25 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20050059716A1 (en) | 2003-07-25 | 2005-03-17 | Aventis Pharma Deutschland Gmbh | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
WO2005012312A1 (fr) | 2003-07-25 | 2005-02-10 | Sanofi-Aventis Deutschland Gmbh | Nouvelles cyanothiazolides, leur procede de production et leur utilisation comme medicament |
US20050059724A1 (en) | 2003-07-25 | 2005-03-17 | Aventis Pharma Deutschland Gmbh | Novel cyanopyrrolidides, process for their preparation and their use as medicaments |
WO2005011581A2 (fr) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv pour le traitement ou la prevention du diabete |
WO2005012326A1 (fr) | 2003-08-01 | 2005-02-10 | Tanabe Seiyaku Co., Ltd. | Nouveaux composes possedant une activite inhibitrice dirigee contre le transporteur dependant du sodium |
WO2005012249A2 (fr) | 2003-08-01 | 2005-02-10 | Bristol-Myers Squibb Company | Inhibiteurs a base d'adamantyglycine de la dipeptidyl peptidase iv et procedes associes |
US20050038020A1 (en) | 2003-08-01 | 2005-02-17 | Hamann Lawrence G. | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
WO2005019168A2 (fr) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Derives fluores de lysine en tant qu'inhibiteurs de la dipeptidylpeptidase iv |
US20050043292A1 (en) | 2003-08-20 | 2005-02-24 | Pfizer Inc | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors |
WO2005021536A2 (fr) | 2003-08-29 | 2005-03-10 | Sanofi-Aventis | Nouveaux composes |
US20100160328A1 (en) | 2003-08-29 | 2010-06-24 | Sanofi-Aventis | New compounds useful for dpp-iv enzyme inhibition |
US7652021B2 (en) | 2003-08-29 | 2010-01-26 | Sanofi-Aventis | Compounds useful for DPP-IV enzyme inhibition |
EP1664031A2 (fr) | 2003-08-29 | 2006-06-07 | Sanofi-Aventis | Dérivés d'adamantane et d'azabicyclo-octane et -nonane, procédé pour leur préparation et leur utilisation comme inhibiteurs de dpp-iv |
US20060276487A1 (en) | 2003-08-29 | 2006-12-07 | Sanofi-Aventis | New compounds useful for DPP-IV enzyme inhibition |
WO2005020920A2 (fr) | 2003-09-02 | 2005-03-10 | Merck & Co., Inc. | Nouvelles formes cristallines d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyl peptidase-iv |
WO2005023762A1 (fr) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Derives de pyrrolidine-2-carbonitrile et leur utilisation comme inhibiteurs de la dipeptidyle peptidase-iv (dpp-iv) |
US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20050131019A1 (en) | 2003-09-04 | 2005-06-16 | Zhonghua Pei | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2005026148A1 (fr) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidylpeptidase |
WO2005030751A2 (fr) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Inhibiteurs de dipeptidyle peptidase |
WO2005025554A2 (fr) | 2003-09-09 | 2005-03-24 | Japan Tobacco Inc. | Inhibiteur de la dipeptidylpeptidase iv |
WO2005030127A2 (fr) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Nouvelle forme cristalline d'un sel d'acide phosphorique d'un inhibiteur de dipeptidyle peptase-iv |
WO2005032590A1 (fr) | 2003-10-03 | 2005-04-14 | Takeda Pharmaceutical Company Limited | Remede contre le diabete |
WO2005033099A2 (fr) | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant |
EP1682540A1 (fr) | 2003-10-06 | 2006-07-26 | Alangudi Sankaranarayanan | Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv |
WO2005033106A1 (fr) | 2003-10-06 | 2005-04-14 | Alangudi Sankaranarayanan | Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv |
WO2005037779A2 (fr) | 2003-10-15 | 2005-04-28 | Imtm Gmbh | Nouveaux inhibiteurs de dipeptidylpeptidases iv destines a influencer le fonctionnement de diverses cellules et a traiter des maladies immunologiques, inflammatoires, neuronales et autres |
WO2005034940A2 (fr) | 2003-10-15 | 2005-04-21 | Imtm Gmbh | Inhibiteurs doubles d'alanyl-aminopeptidase et de dipeptidylpeptidase iv utilises pour influer de maniere fonctionnelle sur differentes cellules et pour traiter des affections immunologiques, inflammatoires, neuronales et autres |
WO2005040095A1 (fr) | 2003-10-16 | 2005-05-06 | Astrazeneca Ab | Inhibiteurs de la dipeptidyl-peptidase iv |
WO2005037828A1 (fr) | 2003-10-20 | 2005-04-28 | Lg Life Sciences Ltd. | Inhibiteurs de dpp-iv, procedes d'elaboration correspondants, et compositions pharmaceutiques renfermant ces inhibiteurs comme principe actif |
WO2005042488A1 (fr) | 2003-10-31 | 2005-05-12 | Takeda Pharmaceutical Company Limited | Composes pyridines utilises comme inhibiteurs de dipeptidyle peptidase iv |
WO2005044195A2 (fr) | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Derives de phenylalanine fusionnes utilises comme inhibiteurs de la dipeptidyl peptidase-iv dans le traitement ou la prevention du diabete |
WO2005047297A1 (fr) | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Composés heterocycliques d'acide boronique |
WO2005049022A2 (fr) | 2003-11-17 | 2005-06-02 | Novartis Ag | Utilisation de composes organiques |
WO2005051950A1 (fr) | 2003-11-27 | 2005-06-09 | Boehringer Ingelheim International Gmbh | Nouvelle xanthine 8-(piperazine-1-yl) et 8-([1,4]diazepan-1-yl), sa production et son utilisation comme medicament |
EP1541143A1 (fr) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Inhibiteurs de dpp-iv |
US20080027035A1 (en) | 2003-12-09 | 2008-01-31 | Graffinity Pharmaceuticals Ag | Dpp-Iv Inhibitors |
EP1541148A1 (fr) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Inhibiteurs de dpp-iv |
WO2005056013A1 (fr) | 2003-12-09 | 2005-06-23 | Santhera Pharmaceuticals (Schweiz) Gmbh | Inhibiteurs dpp-iv |
WO2005056003A1 (fr) | 2003-12-09 | 2005-06-23 | Santhera Pharmaceuticals (Schweiz) Gmbh | Inhibiteurs dpp-iv |
WO2005058849A1 (fr) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant |
WO2005063750A1 (fr) | 2003-12-23 | 2005-07-14 | Boehringer Ingelheim International Gmbh | Composes imidazol bicycliques, leur fabrication et leur utilisation comme medicaments |
WO2005072530A1 (fr) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Nouveau sel cristallin d'un inhibiteur de dipeptidyle peptidase-iv |
WO2005075426A1 (fr) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant |
US20080146818A1 (en) | 2004-02-05 | 2008-06-19 | Yasumichi Fukuda | Bicycloester Derivative |
EP2119717A1 (fr) | 2004-02-18 | 2009-11-18 | Boehringer Ingelheim International GmbH | 8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que complexe DDP IV |
WO2005079795A2 (fr) | 2004-02-20 | 2005-09-01 | Novartis Ag | Utilisation de composes organiques |
WO2005082849A1 (fr) | 2004-02-23 | 2005-09-09 | Trustees Of Tufts College | Lactames utilisees comme inhibiteurs peptidomimetiques a contrainte conformationnelle |
WO2005082348A2 (fr) | 2004-02-23 | 2005-09-09 | Trustees Of Tufts College | Inhibiteurs de la dipeptidylpeptidase iv |
US20070238753A1 (en) | 2004-02-27 | 2007-10-11 | Madar David J | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) |
EP1593671A1 (fr) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | Inhibiteurs de la DPP-IV |
US20070197522A1 (en) | 2004-03-05 | 2007-08-23 | Edwards Paul J | Dpp-iv inhibitors |
WO2005095343A1 (fr) | 2004-03-05 | 2005-10-13 | Santhera Pharmaceuticals (Schweiz) Gmbh | Inhibiteurs de la dpp-iv |
US20050215603A1 (en) | 2004-03-08 | 2005-09-29 | Irini Akritopoulou-Zanze | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7348346B2 (en) | 2004-03-08 | 2008-03-25 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20080119464A1 (en) | 2004-03-08 | 2008-05-22 | Irini Akritopoulou-Zanze | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
US7671076B2 (en) | 2004-03-08 | 2010-03-02 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US20050209249A1 (en) | 2004-03-08 | 2005-09-22 | Irini Akritopoulou-Zanze | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2005087235A1 (fr) | 2004-03-09 | 2005-09-22 | National Health Research Institutes | Composes de pyrrolidine |
WO2005095381A1 (fr) | 2004-03-15 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyle peptidase |
WO2005092877A1 (fr) | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Derives du benzol substitues par un glucopyranosyle,, medicaments renfermant ces composes, leur utilisation et leur procede de production |
WO2005116014A1 (fr) | 2004-05-12 | 2005-12-08 | Pfizer Products Inc. | Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv |
US20070265301A1 (en) | 2004-05-21 | 2007-11-15 | Edwards Paul J | Dpp-IV Inhibitors |
WO2005113510A1 (fr) | 2004-05-21 | 2005-12-01 | Santhera Pharmaceuticals (Schweiz) Ag | Inhibiteurs dpp-iv |
WO2005119526A1 (fr) | 2004-06-03 | 2005-12-15 | Pfizer Products Inc. | Structure cristalline de dipeptidyl peptidase iv (dpp-iv) et ses utilisations |
EP1756740A1 (fr) | 2004-06-03 | 2007-02-28 | Pfizer Products Inc. | Structure cristalline de dipeptidyl peptidase iv (dpp-iv) et ses utilisations |
EP1791536A1 (fr) | 2004-06-08 | 2007-06-06 | Santhera Pharmaceuticals (Schweiz) AG | Derives de 1-[(3r)-amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2r)-acide carboxilique-benzylamine et composes apparentes utilises comme inhibiteurs de la dipeptidyl-peptidase iv (dpp-iv) destines au traitement du diabete non insulino-dependant |
US20080015146A1 (en) | 2004-06-08 | 2008-01-17 | Santhera Pharmaceuticals (Deutschland) Ag | Dpp-IV Inhibitors |
US20080176838A1 (en) | 2004-06-08 | 2008-07-24 | Santhera Pharmaceuticals (Deutschland) Ag | Dpp-IV Inhibitors |
WO2005120494A1 (fr) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | Derives de 1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-acide carboxilique-benzylamine et composes apparentes utilises comme inhibiteurs de la dipeptidyl-peptidase iv (dpp-iv) destines au traitement du diabete non insulino-dependant |
WO2005121089A1 (fr) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | Inhibiteurs de la dpp-iv |
EP1604989A1 (fr) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Inhibiteurs de DPP-IV |
US20070265261A1 (en) | 2004-06-08 | 2007-11-15 | Edwards Paul J | Dpp-IV Inhibitors |
EP1604980A1 (fr) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Inhibiteurs de DPP-IV |
EP1604662A1 (fr) | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2 |
WO2005121131A1 (fr) | 2004-06-08 | 2005-12-22 | Santhera Pharmaceuticals (Schweiz) Ag | Inhibiteurs de la dpp-iv |
US20080009512A1 (en) | 2004-06-16 | 2008-01-10 | Astrazeneca Ab | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes |
WO2005123685A1 (fr) | 2004-06-16 | 2005-12-29 | Astrazeneca Ab | Tetrahydroquinolones et aza-analogues associes utilises en tant qu'inhibiteurs de la dpp-iv dans le traitement du diabete |
EP1758863A1 (fr) | 2004-06-16 | 2007-03-07 | AstraZeneca AB | Tetrahydroquinolones et aza-analogues associes utilises en tant qu'inhibiteurs de la dpp-iv dans le traitement du diabete |
WO2006013104A1 (fr) | 2004-08-05 | 2006-02-09 | Santhera Pharmaceuticals (Schweiz) Ag | Composés hétérocycliques utiles comme inhibiteurs de la dpp-iv |
EP1778682A1 (fr) | 2004-08-05 | 2007-05-02 | Santhera Pharmaceuticals (Schweiz) AG | Composés hétérocycliques utiles comme inhibiteurs de la dpp-iv |
US20080064728A1 (en) | 2004-08-05 | 2008-03-13 | Santhera Pharmaceuticals (Schweiz) Ag | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors |
EP1623983A1 (fr) | 2004-08-05 | 2006-02-08 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Composés hétérocycliques utilisables comme inhibiteurs de DPP-IV |
US20070167468A1 (en) | 2004-08-06 | 2007-07-19 | Sanofi-Aventis Deutschland Gmbh | Substituted bicyclic 8-pyrr0lidinoxanthines, methods for their production, pharmaceutical formulations and their use |
WO2006040625A1 (fr) | 2004-10-12 | 2006-04-20 | Glenmark Pharmaceuticals S.A. | Nouveaux inhibiteurs de dipeptidyle peptidase iv, compositions pharmaceutiques en contenant, et leur procede de preparation |
WO2006058628A2 (fr) | 2004-11-30 | 2006-06-08 | F.Hoffmann-La Roche Ag | Derives benzoquinolizine substitues |
EP1851216A2 (fr) | 2004-11-30 | 2007-11-07 | F.Hoffmann-La Roche Ag | Derives benzoquinolizine substitues en tant qu'inhibiteurs de dpp-iv pour le traitement du diabete |
US20090192129A1 (en) | 2004-12-12 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. | Bicyclic pyrrole derivatives |
US20060135512A1 (en) | 2004-12-20 | 2006-06-22 | Markus Boehringer | Aminocycloalkanes as DPP-IV inhibitors |
US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
WO2006068163A1 (fr) | 2004-12-24 | 2006-06-29 | Dainippon Sumitomo Pharma Co., Ltd. | Dérivés bicycliques de pyrrole |
WO2006076231A2 (fr) | 2005-01-10 | 2006-07-20 | Arena Pharmaceuticals, Inc. | Polytherapie destinee au traitement du diabete et de troubles lies au diabete et au traitement de troubles pouvant etre soignes par une augmentation du taux de glp-1 dans le sang |
WO2006080421A1 (fr) | 2005-01-28 | 2006-08-03 | Chugai Seiyaku Kabushiki Kaisha | Dérivé de spirocétal et emploi dudit dérivé au titre de médicament contre le diabète |
WO2006088129A1 (fr) | 2005-02-18 | 2006-08-24 | Mitsubishi Pharma Corporation | Sel d'un dérivé de proline, solvate dudit sel, et méthode de production dudit sel |
US20090216016A1 (en) | 2005-02-18 | 2009-08-27 | Mitsubishi Pharma Corporation | Salt of proline derivative, solvate thereof, and production method thereof |
EP1702916A1 (fr) | 2005-03-18 | 2006-09-20 | Santhera Pharmaceuticals (Schweiz) GmbH | Inhibiteurs de DPP-IV |
US20080275086A1 (en) | 2005-03-18 | 2008-11-06 | Paul John Edwards | Dpp-Iv Inhibitors |
WO2006097175A1 (fr) | 2005-03-18 | 2006-09-21 | Santhera Pharmaceuticals (Schweiz) Ag | Inhibiteurs de la dpp-iv |
WO2006100181A2 (fr) | 2005-03-22 | 2006-09-28 | F. Hoffmann-La Roche Ag | Nouveau sel et polymorphes de l'inhibiteur de dpp-iv |
EP1888571A2 (fr) | 2005-03-22 | 2008-02-20 | F. Hoffmann-Roche AG | Nouveau sel et polymorphes de l'inhibiteur de dpp-iv |
WO2006104356A1 (fr) | 2005-04-01 | 2006-10-05 | Lg Life Sciences, Ltd. | Composés inhibiteurs de la dipeptidylpeptidase-iv, méthodes de synthèse desdits composés, et préparations pharmaceutiques contenant lesdits composés au titre de principe actif |
WO2006116157A2 (fr) | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs de la dipeptidyl peptidase iv |
US20060264433A1 (en) | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
EP1902730A1 (fr) | 2005-06-09 | 2008-03-26 | Banyu Pharmaceutical Co., Ltd. | Agoniste de npy y2 pour une utilisation en tant qu agent thérapeutique contre une maladie s accompagnant de diarrhée |
EP1912706A2 (fr) | 2005-06-17 | 2008-04-23 | Aurigene Discovery Technologies Limited | Nouveaux derives d'indole substitues en 5 utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv (dpp-iv) |
WO2006134613A2 (fr) | 2005-06-17 | 2006-12-21 | Aurigene Discovery Technologies Limited | Nouveaux derives d'indole substitues en 5 utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv (dpp-iv) |
US20090149504A1 (en) | 2005-06-17 | 2009-06-11 | Aurigene Discovery Technologies Limited | Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors |
WO2007003964A1 (fr) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Agonistes du récepteur couplé aux protéines g |
WO2007027651A2 (fr) | 2005-08-30 | 2007-03-08 | Abbott Laboratories | Compositions pharmaceutiques utilisees comme inhibiteurs de la dipeptidyl peptidase iv (dpp-iv) |
US20070049596A1 (en) | 2005-08-30 | 2007-03-01 | Zhonghua Pei | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7834012B2 (en) | 2005-08-30 | 2010-11-16 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2007035372A2 (fr) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Formes polymorphes de sel benzoate de 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile, et leurs procedes d'utilisation |
US20070142436A1 (en) | 2005-12-21 | 2007-06-21 | Andre Bubendorf | New salt and polymorph of a DPP-IV inhibitor |
EP1966193A1 (fr) | 2005-12-21 | 2008-09-10 | F. Hoffmann-la Roche AG | Nouveau sel et polymorphe d un inhibiteur de dpp-iv |
US20100093808A1 (en) | 2005-12-21 | 2010-04-15 | Bubendorf Andre | Salt and polymorph of a dpp-iv inhibitor |
WO2007071576A1 (fr) | 2005-12-21 | 2007-06-28 | F. Hoffmann-La Roche Ag | Nouveau sel et polymorphe d’un inhibiteur de dpp-iv |
EP1966215A1 (fr) | 2005-12-23 | 2008-09-10 | Novartis AG | Composes heterocycliques condenses utiles en tant qu'inhibiteurs de dpp-iv |
WO2007071738A1 (fr) | 2005-12-23 | 2007-06-28 | Novartis Ag | Composes heterocycliques condenses utiles en tant qu’inhibiteurs de dpp-iv |
WO2007120689A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu |
WO2007120702A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée |
EP2023902A1 (fr) | 2006-05-04 | 2009-02-18 | Boehringer Ingelheim International Gmbh | Formulations de l'inhibiteur de dpp iv |
EP2277509A1 (fr) | 2006-05-04 | 2011-01-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Compositions d'inhibiteurs de la DPP IV |
EP1852108A1 (fr) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
WO2007128721A1 (fr) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim Internationalgmbh | Polymorphes |
WO2007128761A2 (fr) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Utilisations d'inhibiteurs de l'enzyme dpp iv |
WO2007148185A2 (fr) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | 3-amino-pyrrolidino-4-lactames substitués |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
WO2008017670A1 (fr) | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-d]pyrimidines utilisées en tant qu'inhibiteurs de dpp-iv pour le traitement du diabète sucré |
EP2057160A1 (fr) | 2006-08-08 | 2009-05-13 | Boehringer Ingelheim International GmbH | Pyrrolo [3,2-d]pyrimidines utilisees en tant qu'inhibiteurs de dpp-iv pour le traitement du diabete sucre |
US20100323988A1 (en) | 2006-08-30 | 2010-12-23 | Phenomix Corporation | Solid citrate and tartrate salts of dpp-iv inhibitors |
EP2061474A2 (fr) | 2006-08-30 | 2009-05-27 | Phenomix Corporation | Sels citrates et tartrates solides d'inhibiteurs de la dpp-iv |
WO2008027273A2 (fr) | 2006-08-30 | 2008-03-06 | Phenomix Corporation | Sels citrates et tartrates solides d'inhibiteurs de la dpp-iv |
EP1905759A1 (fr) | 2006-09-07 | 2008-04-02 | Santhera Pharmaceuticals (Schweiz) AG | Derivés n-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide et composés similaires pour l'utilisation comme inhibiteurs dpp-iv pour le traitement de type 2 diabetes mellitus |
WO2008028662A1 (fr) | 2006-09-07 | 2008-03-13 | Santhera Pharmaceuticals (Schweiz) Ag | N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide et composés associés utilisés en tant qu'inhibiteurs dpp-iv pour le traitement du diabète sucré de type 2 |
WO2008040995A1 (fr) | 2006-10-07 | 2008-04-10 | Peakdale Molecular Limited | Indoles destinés à être utilisés comme inhibiteurs de dpp-iv |
WO2008040974A1 (fr) | 2006-10-07 | 2008-04-10 | Peakdale Molecular Limited | Indoles utiles en tant qu'inhibiteurs de la dpp-iv |
WO2008067465A1 (fr) | 2006-11-29 | 2008-06-05 | Takeda Pharmaceutical Company Limited | Polymorphes de sel de succinate de 2-[6-(3-amino-pipéridin-1-yl)-3-méthyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylméthy]-4-fluor-benzonitrile et leurs procédés d'utilisation |
WO2008109591A1 (fr) | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose |
WO2008114857A1 (fr) | 2007-03-22 | 2008-09-25 | Kyorin Pharmaceutical Co., Ltd. | Procédé de préparation d'un dérivé d'aminoacétylpyrrolidinecarbonitrile |
US20100120790A1 (en) | 2007-04-19 | 2010-05-13 | Dong-A Pharm. Co., Ltd | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity |
US8030315B2 (en) | 2007-04-19 | 2011-10-04 | Dong-A Pharm. Co., Ltd. | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity |
WO2008141021A1 (fr) | 2007-05-08 | 2008-11-20 | Concert Pharmaceuticals, Inc. | Dérivés deutérés de composés de tétrahydrotriazolopyrazine et leur utilisation en tant qu'inhibiteurs de la dpp-iv |
WO2008144730A2 (fr) | 2007-05-21 | 2008-11-27 | Phenomix Corporation | Formulation pharmaceutique stable pour un inhibiteur de dpp-iv |
EP2019099A1 (fr) | 2007-07-02 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Inhibiteurs Dpp-IV |
WO2009003681A1 (fr) | 2007-07-02 | 2009-01-08 | Santhera Pharmaceuticals (Schweiz) Ag | Inhibiteurs de dpp-iv |
EP2175727A1 (fr) | 2007-07-12 | 2010-04-21 | Phenomix Corporation | Intermédiaire synthétique cristallin utilisé dans la préparation d'un inhibiteur de la ddp-iv et son procédé de purification |
WO2009009751A1 (fr) | 2007-07-12 | 2009-01-15 | Phenomix Corporation | Intermédiaire synthétique cristallin utilisé dans la préparation d'un inhibiteur de la ddp-iv et son procédé de purification |
WO2009037719A1 (fr) | 2007-09-21 | 2009-03-26 | Lupin Limited | Nouveaux composés en tant qu'inhibiteurs de dipeptidyle peptidase-iv (dpp-iv) |
WO2009084497A1 (fr) | 2007-12-28 | 2009-07-09 | Dainippon Sumitomo Pharma Co., Ltd. | Dérivé de pipéridine substituée par un méthyle |
WO2009113423A1 (fr) | 2008-03-10 | 2009-09-17 | 大日本住友製薬株式会社 | Composé de pyrrole bicyclique |
WO2009126535A1 (fr) * | 2008-04-07 | 2009-10-15 | Irm Llc | Composés et compositions servant de modulateurs de l’activité de gpr119 |
WO2009126245A1 (fr) | 2008-04-07 | 2009-10-15 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation d'un récepteur couplé à la protéine g pour identifier des sécrétagogues du peptide yy (pyy) et composés utiles dans le traitement de pathologies modulées par le pyy |
WO2010086411A1 (fr) | 2009-01-29 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Traitement du diabète chez des patients pédiatriques |
WO2010146597A1 (fr) | 2009-06-18 | 2010-12-23 | Lupin Limited | Dérivés de 2-amino-2-[8-(diméthylcarbamoyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-exo-éthanoyle comme puissants inhibiteurs de la dpp-iv |
US20120082635A1 (en) | 2009-06-18 | 2012-04-05 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
WO2011008663A1 (fr) * | 2009-07-15 | 2011-01-20 | Eli Lilly And Company | Agonistes du gpr119 |
WO2011028455A1 (fr) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotétrahydropanes utilisés comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prévenir le diabète |
WO2011026781A1 (fr) | 2009-09-02 | 2011-03-10 | Imtm Gmbh | Nouveaux inhibiteurs de peptidase multifonctionnels, particulièrement destinés à un usage médical |
EP2292589A1 (fr) | 2009-09-02 | 2011-03-09 | IMTM GmbH | Nouveaux inhibiteurs multifonctionnels de la peptidase, en particulier pour une utilisation en médecine |
WO2011037793A1 (fr) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Aminopipéridines substituées utilisées en tant qu'inhibiteurs de la dipeptidyl peptidase-iv dans le cadre du traitement du diabète |
WO2011079778A1 (fr) | 2009-12-30 | 2011-07-07 | China Shanghai Fochon Pharmaceutical Co Ltd | Dérivés de 3-(3-aminopipéridin-1-yl)-5-oxo-1,2,4-triazine à titre d'inhibiteurs de dipeptidyl peptidase iv (dpp-iv) |
WO2011127051A1 (fr) * | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
WO2011147207A1 (fr) | 2010-05-24 | 2011-12-01 | 上海阳帆医药科技有限公司 | Dérivés d'hexahydropyrrolo[3,4-b]pyrrole, leurs procédés de préparation et leurs utilisations pharmaceutiques |
WO2012017391A2 (fr) | 2010-08-03 | 2012-02-09 | Cadila Pharmaceuticals Limited | Nouveaux composés en tant qu'inhibiteurs de la dpp-iv et procédé de préparation associé |
WO2012060590A2 (fr) | 2010-11-01 | 2012-05-10 | Lg Life Sciences Ltd. | Hydrate de tartrate de 1-{(2s)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoropipéridin-2-one |
Non-Patent Citations (123)
Title |
---|
ABBOTT ET AL., BRAIN RES, vol. 1043, 2005, pages 139 - 144 |
ABE ET AL., J. NA.T PROD., vol. 67, 2004, pages 999 - 1004 |
ADRIAN, GASTROENTEROL., vol. 89, 1985, pages 1070 - 1077 |
AHREN ET AL., DIABETES CARE, vol. 25, 2002, pages 869 - 875 |
AHREN ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 89, 2004, pages 2078 - 2084 |
AHREN, ENDOCRINOLOGY, vol. 146, 2005, pages 2055 - 2059 |
AREHART ET AL., CIRC RES, CIRC. RES., vol. 102, 2008, pages 986 - 993 |
ATIK ET AL., CLIN ORTHOP RELAT RES, vol. 443, 2006, pages 19 - 24 |
BALASUBRAMANIAM ET AL., J. MED. CHEM., vol. 43, 2000, pages 3420 - 3427 |
BALASUBRAMANIAM ET AL., PEPTIDES, vol. 28, 2007, pages 235 - 240 |
BATTERHAM ET AL., NATURE, vol. 418, 2002, pages 650 - 654 |
BEHRE, SCAND J CLIN LAB INVEST, vol. 67, 2007, pages 449 - 458 |
BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
BILCHIK ET AL., GASTROENTEROL., vol. 105, 1993, pages 1441 - 1448 |
BOEY ET AL., DIABETOLOGIA, vol. 49, 2006, pages 1360 - 1370 |
BOEY ET AL., NEUROPEPTIDES, vol. 42, 2008, pages 19 - 30 |
BOLLAG ET AL., ENDOCRINOLOGY, vol. 141, 2000, pages 1228 - 1235 |
BOLLAG ET AL., MOL CELL ENDOCRINOL, vol. 177, 2001, pages 35 - 41 |
BOSE ET AL., DIABETES, vol. 54, 2005, pages 146 - 151 |
BRADLEY, J PATHOL, vol. 214, 2008, pages 149 - 160 |
BRANCATI, F. L., ARCH. INTERN. MED., vol. 159, 1999, pages 957 - 963 |
CALDWELL ET AL., BIOORG. MED.CHEM. LETT., vol. 14, 2004, pages 1265 - 1268 |
CHAUDHRI ET AL., ANNU REV PHYSIOL, vol. 70, 2008, pages 239 - 255 |
COLLIER, T. L., J. LABELLED COMPD. RADIOPHARM., vol. 42, 1999, pages S264 - S266 |
COX, PEPTIDES, vol. 28, 2007, pages 345 - 351 |
CRUZE ET AL., PEPTIDES, vol. 28, 2007, pages 269 - 280 |
DEACON ET AL., J CLIN ENDOCRINOL METAB, vol. 85, 2000, pages 3575 - 3581 |
DEACON, REGUL PEPT, vol. 128, pages 117 - 124 |
DRUCKER, CELL METAB, vol. 3, 2006, pages 153 - 165 |
DURING ET AL., NAT. MED., vol. 9, 2003, pages 1173 - 1179 |
EBERLEIN ET AL., PEPTIDES, vol. 10, 1989, pages 797 - 803 |
EBERLEIN, PEPTIDES, vol. 10, 1989, pages 797 - 803 |
EDMONDSON ET AL., BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 5151 - 5155 |
EDWARD B. ROCHE: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS |
EKBLAD ET AL., PEPTIDES, vol. 23, 2002, pages 251 - 261 |
EKSTRAND ET AL., PNAS USA, vol. 100, 2003, pages 6033 - 6038 |
EL BAHH ET AL., EUR. J. NEUROSCI., vol. 22, 2005, pages 1417 - 1430 |
GENNARO ET AL.: "Remington, The Science and Practice of Pharmacy, 20th Edition,", 2000, LIPPINCOTT WILLIAMS & WILKINS |
GOMEZ ET AL., AM. J. PHYSIOL., vol. 268, 1995, pages G71 - G81 |
GONON, CARDIOVASC RES., vol. 78, 2008, pages 116 - 122 |
GRANDT ET AL., REGUL. PEPT., vol. 51, 1994, pages 151 - 159 |
GREENE, T. W.; WUTS, P. G. M.: "Protecting Groups in Organic Synthesis, 3rd Edition,", 1999, WILEY |
GREIG ET AL., ANN N YACAD SCI, vol. 1035, 2004, pages 290 - 315 |
GRISE ET AL., J. SURG. RES., vol. 82, 1999, pages 151 - 155 |
GUERRE-MILLO, DIABETES & METAHOLISM, vol. 34, 2008, pages 12 - 1R |
H.-U. DEMUTH ET AL.: "Type 2 diabetes-therapy with DPP-IV inhibitors", BIOCHIM. BIOPHYS. ACTA, vol. 1751, 2005, pages 33 - 44 |
HANSMANN ET AL., CIRCULATION, vol. 115, 2007, pages 1275 - 1284 |
HARA ET AL., DIABETES CARE, vol. 29, 2006, pages 1357 - 1362 |
HAY ET AL., J CLIN GASTROENTEROL, vol. 14, 1992, pages 309 - 317 |
HILL, J. O. ET AL., SCIENCE, vol. 280, 1998, pages 1371 - 1374 |
JONES ET AL., ANN. REP. MED. CHEM., vol. 44, 2009, pages 149 - 170 |
JONES, ANN. REP. MED. CHEM., vol. 44, 2009, pages 149 - 170 |
JONES, EXPERT OPIN. THER. PATENTS, vol. 19, no. 10, 2009, pages 1339 - 1359 |
K. AUGUSTYNS: "Inhibitors of proline-specific dipeptidyl peptidases: DPP-IV inhibitors as a novel approach for the treatment of type 2 diabetes", EXPERT OPIN. THER. PATENTS, vol. 15, 2005, pages 1387 - 1407, XP002453370, DOI: doi:10.1517/13543776.15.10.1387 |
K.J. GUILLORY: "Polymorphism in Pharmaceutical Solids", vol. 95, 1999, MARCEL DEKKER, INC., article "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", pages: 202 - 209 |
KEIGHLEY ET AL., AILMENT PHARMACOL THER, vol. 18, 2003, pages 66 - 70 |
KEIRE ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 279, 2000, pages G126 - G131 |
KUBOTA ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 25863 - 25866 |
LAMB ET AL., J. MED. CHEM., vol. 50, 2007, pages 2264 - 2268 |
LE BAS, M.-D., J. LABELLED COMPD. RADIOPHARM., vol. 44, 2001, pages S280 - S282 |
LE STUNFF, DIABETES, vol. 43, 1989, pages 696 - 702 |
LEE ET AL., J. CLIN. INVEST., vol. 111, 2003, pages 1853 - 1862 |
LEE ET AL., PEPTIDES, vol. 24, 2003, pages 99 - 106 |
LIU ET AL., J. SURG. RES., vol. 58, 1995, pages 6 - 11 |
LIU ET AL., J. SURG. RES., vol. 58, 1995, pages 707 - 712 |
LIU ET AL., SURGERY, vol. 118, 1995, pages 229 - 236 |
LIU, AM SURG, vol. 62, 1996, pages 232 - 236 |
LUNDBERG, PNAS USA, vol. 79, 1982, pages 4471 - 4475 |
MAEDA ET AL., NAT. MED., vol. 8, 2002, pages 731 - 737 |
MATSUDA ET AL., J BIOL CHEM, vol. 277, 2002, pages 37487 - 37491 |
MCFADDEN ET AL., AM. J. SURG., vol. 188, 2004, pages 516 - 519 |
MCINTOSH ET AL., REGUL PEPT, vol. 128, 2005, pages 159 - 165 |
MENTLEIN, EXPERT OPIN INVESTIG DRUGS, vol. 14, 2005, pages 57 - 64 |
MORLEY ET AL., LIFE SCIENCES, vol. 41, 1987, pages 2157 - 2165 |
NAUCK ET AL., DIABETES, vol. 53, no. 3, 2004, pages 190 - 196 |
NAUCK ET AL., DRUG NEWS PERSPECT, vol. 16, 2003, pages 413 - 422 |
NIGHTINGALE ET AL., GUT, vol. 39, 1996, pages 267 - 272 |
NISHIMURA ET AL., CIRCULATION, vol. 117, 2008, pages 216 - 223 |
O'BRIEN, M.; DAILY, B.; SCHURRIA, M.: "Assay for DPPIV activity using a homogeneous, luminescent method", CELL NOTES, 2005 |
OHASHI, HYPERTENSION, vol. 47, 2006, pages 1108 - 1116 |
OKADA ET AL., ENDOCRINOLOGY, 1993, pages 180 |
OKU ET AL., FEBS LETTERS, vol. 581, 2007, pages 5029 - 5033 |
ORTIZ ET AL., JPET, vol. 323, 2007, pages 692 - 700 |
OUCHI ET AL., CIRCULATION, vol. 100, 1999, pages 2473 - 2476 |
OUCHI ET AL., CLIN CHIM ACTA, vol. 380, 2007, pages 24 - 30 |
PARKER ET AL., BR. J. PHARMACOL., vol. 153, 2008, pages 420 - 431 |
PEARSON, NURSING TIMES, vol. 100, 2004, pages 86 - 90 |
PEDERSON, P., DIAB. METAB. REV., vol. 5, 1989, pages 505 - 509 |
PERRY, I. J., BMJ, vol. 310, 1995, pages 560 - 564 |
PETERS, BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 1491 - 1493 |
PITTNER ET AL., INT. J. OBES. RELAT. METAB. DISORD., vol. 28, 2004, pages 963 - 971 |
RAISZ, J CLIN INVEST, vol. 115, 2005, pages 3318 - 3325 |
RENSHAW, CURRENT DRUG TARGETS, vol. 6, 2005, pages 171 - 179 |
RIMOIN, D. L.: "Emery and Rimoin's Principles and Practice of Medical Genetics 3 Ed.", vol. 1, 1996, pages: 1401 - 1402 |
ROTWEIN, R. ET AL., N. ENGL. J. MED., vol. 308, 1983, pages 65 - 71 |
RUGGERI, NAT MED, vol. 8, 2002, pages 1227 - 1234 |
SCHWARTZ, CELL METABOLISM, vol. 11, 2010, pages 445 - 447 |
SCHWARTZ, CELL METAHOLISM, vol. 11, 2010, pages 445 - 447 |
SHAH, CURRENT OPINION IN DRUG DIS-COVERY & DEVELOPMENT, vol. 12, 2009, pages 519 - 532 |
SHAH, CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 12, 2009, pages 519 - 532 |
SHIBATA ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 28670 - 28674 |
SHIBATA ET AL., J. MOL. CELL CURDIOL., vol. 42, 2007, pages 1065 - 1074 |
SHIBATA ET AL., NAT MED, vol. 11, 2005, pages 1096 - 1103 |
SHORE ET AL., J. ALLERGY CLIN. IMMUNOL, vol. 118, 2006, pages 389 - 395 |
SUMMER ET AL., AM J. PHYSIOL. LUNG CELL MOL. PHYSIOL, 7 March 2008 (2008-03-07) |
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14 |
TAO ET AL., CIRCULATION, vol. 115, 2007, pages 1408 - 1416 |
TATEMOTO, NATURE, vol. 285, 1980, pages 417 - 418 |
TILG ET AL., NAT. REV. IMMUNOL., vol. 6, 2006, pages 772 - 783 |
TSENG ET AL., PEPTIDES, vol. 23, 2002, pages 389 - 395 |
TSUKIYAMA, MOL ENDOCRINOL, vol. 20, 2006, pages 1644 - 1651 |
UENO ET AL., REGUL PEPT, vol. 145, 2008, pages 12 - 16 |
VILLHAUER ET AL., J. MED. CHEM., vol. 45, 2002, pages 2362 - 2365 |
VILLHAUER ET AL., J. MED. CHEM., vol. 46, 2003, pages 2774 - 2789 |
VONA-DAVIS ET AL., PEPTIDES, vol. 28, 2007, pages 334 - 338 |
WOLDBYE ET AL., NEUROBIOLOGY OF DISEASE, vol. 20, 2005, pages 760 - 772 |
WORTLEY ET AL., GASTROENTEROL., vol. 133, 2007, pages 1534 - 1543 |
XIE ET AL., BONE, vol. 37, 2005, pages 759 - 769 |
YAMAMOTO ET AL., CLINICAL SCIENCE, vol. 103, 2002, pages 137 - 142 |
YOKOTA ET AL., BLOOD, vol. 96, 2000, pages 1723 - 1732 |
ZANDER ET AL., LANCET, vol. 359, 2002, pages 824 - 830 |
ZHONG, AM J PHYSIOL ENDOCRINOL METAB, vol. 292, 2007, pages E543 - E548 |
ZHU, G-D., 1. ORG. CHEM., vol. 67, 2002, pages 943 - 948 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933083B2 (en) | 2003-01-14 | 2015-01-13 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US10894787B2 (en) | 2010-09-22 | 2021-01-19 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
WO2014011926A1 (fr) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique |
US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US11884626B2 (en) | 2015-06-22 | 2024-01-30 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
US11279702B2 (en) | 2020-05-19 | 2022-03-22 | Kallyope, Inc. | AMPK activators |
US11851429B2 (en) | 2020-05-19 | 2023-12-26 | Kallyope, Inc. | AMPK activators |
US11407768B2 (en) | 2020-06-26 | 2022-08-09 | Kallyope, Inc. | AMPK activators |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130023494A1 (en) | Modulators of the gpr119 receptor and the treatment of disorders related thereto | |
US20210340133A1 (en) | Modulators of the gpr119 receptor and the treatment of disorders related thereto | |
WO2012170702A1 (fr) | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci | |
US20140066369A1 (en) | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | |
US20140038889A1 (en) | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | |
US20140051714A1 (en) | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | |
US20140018371A1 (en) | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | |
WO2013055910A1 (fr) | Modulateurs du récepteur gpr119 et traitement de troubles associés | |
WO2011005929A1 (fr) | Dérivé de pipéridine et son utilisation pour le traitement du diabète et de l'obésité | |
EA018703B1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
TW201035077A (en) | Soluble guanylate cyclase activators | |
JP2009542702A (ja) | 代謝の調節因子および代謝に関連する障害の処置 | |
JP2013507366A (ja) | Gpr119活性モジュレーターとしての化合物および組成物 | |
JP7106623B2 (ja) | 核内受容体に対して活性の化合物 | |
TW202304891A (zh) | 苯并[d][1,3]二呃衍生物 | |
WO2014074668A1 (fr) | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci | |
EA040124B1 (ru) | Модуляторы рецептора gpr119 и лечение связанных с ним нарушений | |
KR20230170034A (ko) | 비만 치료를 위한 glp1 수용체의 활성화제로서의 2-((4-((s)-2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]디옥솔-4-일)피페리딘-1-일)메틸)-1-(((s)-옥세탄-2-일)메틸)-1h-이미다졸 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12735361 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12735361 Country of ref document: EP Kind code of ref document: A1 |